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Abstract 
 A number of fungal species, particularly Candida species, are 
opportunistic pathogens capable of causing disease in humans.  These range 
from relatively mild infections in healthy individuals (e.g. thrush) to life 
threatening systemic infections and colonisation of major organs in 
immunocompromised individuals.  Existing methods of identifying Candida 
species in clinical samples are time and resource intensive and are not always 
specific enough to differentiate between drug-susceptible and drug-resistant 
species.    
  
Atlas Genetics have developed a novel electrochemical assay for the 
detection of nucleic acid from target pathogens using PCR followed by 
hybridisation by labelled probes.  The work describes the development of a 
suite of probes and optimisation of reaction conditions for the rapid detection 
of fungal pathogens using this assay.  A suite of five species-specific probes 
was developed to detect the five most clinically relevant Candida species as 
well as a pan-fungal probe capable of detection of DNA from any fungal 
species.  Additionally, since the assay was novel, the work investigated other 
aspects such as probe and primer design which led to the development of a 
quick bioinformatics approach for design of species-specific probes which is 
also described.  The results demonstrated that species-specific detection of C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei was possible, 
and that there was no cross reactivity exhibited by any probe with isolates 
from a test panel of other Candida species.  The limit of detection of the assay 
was shown to be approximately one genome in 1ml of blood or 10 whole cells 
in 1ml of blood.   
 
The use of solid-state electrodes for detection provides an opportunity for 
miniaturisation of the assay into a robust, easily operated, portable system 
capable of rapid detection of pathogenic DNA in clinical samples either at 
point of care or in the microbiological laboratory. 
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Chapter 1. Introduction. 
1.1 Fungal infections 
 Fungal species are capable of causing myriad human diseases which 
range from relatively trivial topical infections such as athlete’s foot and thrush, 
to life threatening invasive conditions such as fungaemia (fungal cells present 
in the blood) which can lead to infection of major organs.  A wide range of 
fungi are capable of causing invasive fungal infections and these include, but 
are not limited to, species of the genera Candida, Aspergillus, Cryptococcus 
and Saccharomyces.  Invasive fungal infections (IFI) are a considerable 
burden on healthcare resources.  A study by Wilson et al. (2002) estimated 
that in the US, for the year 1998, the cost of the first year of treatment for 
fungal infections came to $2.6 billion nationally, which represented 0.24% of 
the total US health expenditure. The average cost per person with a fungal 
infection was estimated at $31,200, which was nearly eight times higher than 
the average amount spent on healthcare by the rest of the population.  At 
least some of the considerable cost of hospitalisation and inpatient care which 
made up this figure was likely to have been due to treatment of the underlying 
disease which predisposed the patient to IFI.  Nonetheless, it cannot be 
ignored that IFI necessitates continued hospital care and treatment at no 
small cost.  A more recent study performed by Zaoutis et al. (2005) estimated 
that in the United States cases of candidaemia in adults accounted for 
increased hospital costs of between $33,604 and $45,602 per episode for the 
year of 2000.  For the same period the increased costs for paediatric patients 
were estimated at between $65,058 and $119,474.   
  
Invasive fungal infections, although rare, are most commonly associated with 
individuals with a weakened immune system due to underlying disease, either 
because of the progression of the disease itself or the treatment that is 
administered to the patient.  They are particularly associated with patients 
suffering from cancer, HIV infections and patients who have received organ 
transplants (Jarvis, 1995; Wenzel, 1995) - HIV patients because of the action 
of the virus on lymphocytes, cancer patients due to the cytotoxic treatment 
they receive, and transplantation patients due to immunosuppressant drugs 
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with which they are treated.  As a result these patients require lengthy care in 
hospitals and invasive fungal infections are frequently nosocomially acquired 
(Wisplinghoff et al., 2004; Costa-de-Oliveira et al., 2008).  Over the last few 
decades the immunocompromised patient population has increased due to 
advances in medical treatment and it is no coincidence that the incidence of 
invasive fungal infections has also increased.  For example, in the United 
States the incidence of sepsis caused by fungal organisms increased by 
207% from 5,231 cases in 1979 to 16,042 cases in 2000 (Martin et al. 2003); 
Arendrup et al. (2008) reported an increase in fungaemia in Denmark of 17% 
over the two years between 2004 and 2006, and Abelson et al. (2005) 
reported a significant increase in episodes of fungaemia in a children’s 
hospital in the United States over the 11-year period from 1991 through 2001.  
  
Of the fungi implicated in invasive infections, species of the genus Candida 
are by far the most prevalent in the clinical setting.  They are members of the 
hemiascomycetes group of fungi and reproduce vegetatively by multipolar 
budding, forming blastoconidia which may form branching chains.  They are 
also capable of forming well developed pseudohyphae (McGinnis, 1980).  
Some species (C. albicans and C. dubliniensis) are capable of producing a 
structure called a germ tube which is an immature hypha and as such is a 
known virulence factor (Calderone & Fonzi, 2001) though it can be used for 
identification of these species from clinical samples. Candida species, though 
frequently associated with mucosal membranes of humans and other animals 
are ubiquitous in the environment, with isolates from the five clinically relevant 
species having been found in a range of environments, according to the 
Centraalbureau voor Schimmelcultures (CBS) yeast database: on plants, in 
tree bark, in soil, in the gut of insects, in fermentations of various substrates, 
in foods such as yoghurt and on rotting fruit and vegetation.  They are capable 
of causing invasive disease by endogenous colonisation following damage to 
the skin or mucosa or by direct access to the circulation by, for example, 
surgery or introduction of a central venous catheter (Davey, 2010). 
 
Candida species are responsible for 70-80% of diagnosed fungal bloodstream 
infections in the United States (Beck-Sague and Jarvis, 1993; Fridkin and 
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Jarvis, 1996; Trick et al., 2002) and they are a leading cause of nosocomial 
infections in patients undergoing lengthy hospital treatments (Pfaller, 1996) 
accounting for 7.6% of nosocomially acquired bloodstream infections in the 
United States and ranking them as the fourth most commonly encountered 
microbe isolated from blood (Edmond et al., 1999).  They are frequently 
encountered in patients with other complications who develop IFI, e.g. 
following solid organ transplant (Neofytos et al., 2010) and those who are 
critically ill (Vazquez, 2010).  Throughout the majority of the world C. albicans 
is the most commonly isolated species from patients with candidaemia, 
accounting for approximately 45-65% of cases while four other species - C. 
glabrata, C. parapsilosis, C. tropicalis and C. krusei – collectively account for 
a further 35-50% of infections (Hajjeh et al., 2004; Tortorano et al., 2004; 
Pfaller et al., 2010).  The incidences of the species can vary with patient 
factors such as age - infections caused by C. glabrata are more common in 
adult patients while C. parapsilosis is considerably more common in the 
paediatric patient population (Pfaller & Diekema, 2002).  This is due to the 
frequent handling of premature neonates by healthcare workers which allows 
the spread of the yeast.  Additionally, C. parapsilosis has been associated 
with biofilm production linked to indwelling lines (Shin et al., 2002) which are 
used to provide parenteral nutrition to premature neonates.  Geographical 
location can also affect the incidence of species.  In countries with a warmer 
climate, such as in Asia and S. America, the proportions of the above species 
frequently differ (Tan et al., 2009) and some studies have reported that the 
incidence of C. tropicalis in these countries was higher than that of C. albicans 
making C. tropicalis the leading causative agent of invasive infections 
(Chakrabarti et al., 2009; Pereira et al., 2010) although this was not a general 
trend in these areas (Bruder-Nascimento et al., 2010).  The remaining small 
percentage of candidaemia cases are caused by a number of less frequently 
encountered Candida species such as C. lusitaniae and C. guilliermondii (Kao 
et al., 1999; Health Protection Agency, 2006).   
  
The incidence of candidaemia reported in the population is relatively small 
with estimates of between 1.9 - 11 cases per 100,000 inhabitants being 
reported for European countries (Tortorano et al., 2006).  The upper limit of 
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this range was recorded in Denmark and was anomalously high, being three-
fold higher than the next highest incidence.  In the United States the incidence 
of candidaemia is generally higher than that of European countries: the study 
by Hajjeh et al. (2004) found an incidence of 24 cases per 100,000 inhabitants 
in Baltimore and a study by Kao et al. (1999) reported incidences of 8.7 and 
7.1 cases per 100,000 inhabitants in Atlanta and San Francisco respectively.  
The incidence of invasive Candida infections (which includes candidaemia), 
was estimated at between 22 to 29 cases per 100,000 inhabitants recorded 
over an 8-year period (Pfaller & Diekema, 2007).  The disease, therefore, is 
not very common.  However, the immunocompromised status associated with 
the majority of patients who develop candidaemia reduce the chances of 
survival and the mortality of candidaemia is high with estimates of crude 
mortality ranging between 30% - 50% (Tortorano et al., 2004; Horn et al., 
2007) and so the problem, whilst relatively rare, is deadly serious. 
 
1.2 Treatment of invasive fungal infections 
There are a number of antifungal drugs available for treatment of fungaemia 
and some of the most clinically relevant are discussed here.  Fluconazole is a 
triazole drug which became available in the early 1990’s and is now 
commonly used as the frontline drug for invasive fungal infections.  Like the 
other azole drugs, it exercises its antifungal effects by preventing synthesis of 
the predominant fungal cell membrane component ergosterol by inhibiting 
cytochrome P-450-dependent 14a-sterol demethylase (Hitchcock et al., 
1990).  Fluconazole has broad activity across yeasts and is less toxic and less 
expensive than some other antifungals.  Its main disadvantage is that several 
Candida species, most importantly C. krusei and C. glabrata exhibit resistance 
to it.  C. krusei is inherently resistant to fluconazole due to possession of a 
modified 14a-sterol demethylase enzyme which is less susceptible to 
inhibition by fluconazole (Orozco et al., 1998) while resistance in C. glabrata is 
mediated by an upregulation of the ATP-binding cassette transporters Cdr1p 
and Pdh1p which actively efflux fluconazole from the fungal cells (Vermitsky & 
Edlind, 2004). The drug is also ineffective against infections due to 
filamentous fungi. 
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Other triazole compounds have been developed which overcome some of the 
limitations exhibited by fluconazole.  These include voriconazole, itraconazole 
and the more recently derived posaconazole.   Voriconazole is recommended 
as alternative therapy for the treatment of invasive infections caused by C. 
krusei and fluconazole-resistant, voriconazole susceptible C. glabrata 
(Pappas et al., 2009; Pfaller et al., 2010b).  It also has a wider range of 
targets, being active against dimorphic fungi and filamentous fungi as well as 
yeasts (Fera et al., 2009) and is cheaper than the alternative antifungals 
amphotericin B and the echinocandins, caspofungin and anidulafungin, 
making it a more favourable treatment option.  Itraconazole is a choice 
antifungal agent for use against mucosal Candida infections and as antifungal 
prophylaxis for patients at risk of developing invasive fungal infections 
(Korting & Schöllmann, 2009; Pappas et al., 2009).  However, reduced 
susceptibility to this drug in vitro has been exhibited by isolates of C. glabrata 
and C. krusei (Messer et al., 2009).  Posaconazole, like voriconazole, exhibits 
improved efficacy against C. glabrata and C. krusei isolates compared to 
fluconazole in vitro, (Messer et al., 2009) and has shown promise in 
prophylactic therapy for patients at risk from invasive fungal infections 
(Cornely et al., 2007, Ullmann et al., 2007) and as salvage therapy for 
patients with invasive fungal infections which were refractory to conventional 
treatment (Walsh et al., 2007).  
 
Amphotericin B (AmB) was the mainstay drug for fungal infections for several 
decades and it is still a useful drug today, with a broad range of activity, which 
includes both yeasts and filamentous fungi.  Although it is relatively cheap its 
use is limited by its side effects which include nephrotoxicity, fevers and 
hypertension (Enoch et al., 2006).  A less toxic liposomal formulation is 
available although it is considerably more expensive.  Its antifungal action is 
due to molecules of the drug interacting directly with fungal cell membrane 
sterols to form pores (Holz, 1974) which alter the membrane’s permeability, 
allowing the leakage of vital cytoplasmic components from the fungal cell 
leading to its demise (Ghannoum & Rice, 1999).  Resistance to AmB is not 
common and C. lusitaniae is the most clinically relevant species in this 
respect.  As a result AmB is recommended to treat patients with Candida 
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infections caused by species such as C. glabrata or C. krusei which are 
frequently resistant to fluconazole, or for the treatment of infections caused by 
filamentous fungi.    
 
Flucytosine, or 5-fluorocytosine, is one of the oldest antifungals and is still 
used in combination therapy, frequently with amphotericin B, in certain 
instances of IFI (Bennett et al., 1979).  It does not possess antifungal 
properties until it is taken up into the fungal cell where its conversion into 5-
fluorouracil and 5-fluorodeoxyuridine inhibits synthesis of RNA and DNA 
(Waldorf & Polak, 1983).  It is of particular use when meningeal involvement is 
suspected as it readily crosses the blood/brain barrier into the cerebrospinal 
fluid (CSF) (Vermes et al., 2000).  
 
The echinocandins are a group of antifungal agents which include 
caspofungin and micafungin, and work by inhibiting the cell-wall enzyme 
complex β-1,3-D-glucan synthase which causes damage to the fungal cell 
wall leading to a fungicidal effect in Candida (Denning, 2003).  Echinocandins 
are not associated with serious side effects as mammalian cells lack any 
orthologous target molecule, they have few drug interactions and species-
specific resistance has not been widely reported.  As it is a more aggressive 
antifungal than fluconazole its use is recommended in cases involving fungal 
infections in neutropenic patients or as an alternative treatment for non-
neutropenic patients presenting with fluconazole-resistant Candida species 
(Pappas et al., 2009).  Table 1.1 summarises the antifungal resistance profiles 
of the most clinically relevant Candida species to the compounds described 
above.  
 
There are many considerations that must be made when choosing the 
appropriate treatment for invasive fungal infection.  The most important of 
these regard the health and safety of the patient but the cost of treatment 
must be considered also.  If inadequate therapy is administered, such as 
inadequate dosing of an antifungal or use of an inappropriate antifungal 
compound, it will increase the chance of failure of therapy and in the worst 
case the patient may die.  Even if the patient survives the time to recovery will  
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Table 1.1.  Resistance/susceptibility patterns observed in common Candida species to a 
range of antifungal agents (taken from Pappas et al., 2009). 
Candida species Fluconazole Voriconazole Amphotericin B Candins 
C. albicans S S S S 
C. tropicalis S S S S 
C. parapsilosis S S S S to R* 
C. glabrata S-DD to R S-DD to R S to I S 
C. krusei R S S to I S 
S – susceptible, S-DD – susceptible dose dependent, I – intermediately resistant, R – resistant 
*Echinocandin resistance among C. parapsilosis isolates is uncommon 
 
be greatly increased as long as they are treated inadequately and so the cost 
of treatment and hospital care will increase correspondingly.  Inadequate 
therapy is often due to treatment of an invasive fungal infection with an 
antifungal drug to which the infecting fungus is resistant (Garey et al., 2007).  
As mentioned above this is generally a species-specific phenomena and rapid 
identification of the causative organism to the species level is essential to 
ensure that effective treatment is administered as soon as possible. 
 
1.3. Detection of fungal pathogens 
 Rapid diagnosis and identification of fungal pathogens to the species 
level is essential for successful treatment of invasive fungal infections.  The 
difficulty in diagnosing fungal infections lies in the fact that there are rarely 
symptoms that definitively point to an invasive fungal infection and diagnoses 
are frequently made on clinical suspicion based on risk factors which increase 
the likelihood that a patient will develop an invasive Candida infection, such 
as immunosuppression, presence of an intravenous catheter, use of broad-
spectrum antibiotics and trauma to the gastrointestinal tract (Ostrosky-
Zeichner et al., 2007; Hsueh et al., 2009).  Pre-emptive diagnosis, therefore, 
is ultimately based on a judgement call which may still be incorrect even with 
the weight of evidence supporting the decision.   
 
1.3.1 Culture-based diagnostic methods 
 A definitive diagnosis of invasive fungal disease can be made following 
isolation of fungal colonies from clinical samples such as blood cultures or 
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biopsy specimens.  Following isolation, further tests must be performed on the 
fungus to confirm its identity, at which point any changes to provide the 
patient a more appropriate antifungal treatment regime can be made.  There 
are two major problems with this ‘gold standard’ approach.  The first is the 
time to diagnosis; a study by Morris et al. (1996) found that it took between 2-
3 days for 50% of the cultures tested to become positive and some required 
two weeks before recovery of fungal cultures.  The time to species 
identification is further increased by the need to perform biochemical and/or 
morphological tests to accurately identify the organism.  Germ tube testing is 
a relatively quick test which can be performed immediately after recovery of a 
positive yeast blood culture (Sheppard et al., 2008).  It requires a reasonable 
degree of expertise to perform accurately, however, and can only positively 
identify C. albicans.  Chromogenic media such as CHROMagar and 
Chromogenic Candida agar are available to differentiate yeast species based 
on the colour of the colonies.  This method has high sensitivity and specificity 
for the target species, is relatively inexpensive and requires little additional 
expertise but still requires at least 48hrs to achieve accurate identification and 
only a few species can be differentiated in this manner (Odds & Bernaerts, 
1994; Ghelardi et al., 2008).  Additionally, misidentification is possible due to 
the existence of a large number of yeast species, some of which can produce 
colonies of similar colours and morphologies to the target species 
(Hospenthal et al., 2006).  More advanced biochemical tests can be 
performed on cultured yeasts, such as the API Candida and AUXACOLOR 
systems.  These tests can distinguish a much greater range of species but 
require a degree of expertise to perform and require a further 24 - 48hrs to 
make species identifications (Campbell et al., 1999). The second problem is 
the issue of sensitivity – estimates have suggested that ~50% of blood 
cultures from patients with candidaemia prove negative for Candida species 
(Pemán & Zaragoza, 2009).  The outcome of these limitations is that effective 
therapy is likely to be delayed and this can have a significant impact on 
mortality (Morrell et al., 2005; Garey et al., 2006).    
  
In light of these limitations the moniker of ‘gold standard’ is perhaps not well 
deserved by culture based methods of fungal detection and identification in 
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the clinical setting.  To address this issue, numerous non-culture based tests 
have been developed for detection and identification of fungal species.  They 
can offer improved specificity and sensitivity and, crucially, decreased time to 
diagnosis.  The tests are, broadly speaking, of two types: those that identify 
fungi based on serological means such as antibody or antigen detection and 
those that detect nucleic acid. 
 
1.3.2 Serological methods 
 Serological tests for detection of invasive fungal infections based on 
antibody or antigen detection have been in existence for decades.  Antigen 
detection has utilised cell wall components such as mannan in the case of 
Candida species and galactomannan for Aspergillus species.  Some of the 
earliest tests, such as Pastorex-Candida and Cand-Tec, used latex 
agglutination for detection of mannan but such tests exhibited very poor 
sensitivity (Herent et al., 1992; White et al., 2005).  Newer serological 
methods have made use of enzyme immunoassays for detection of both the 
mannan antigen and anti-mannan antibodies e.g. Platelia Candida Antibody 
and Platelia Candida Antigen tests.  These are an improvement over latex 
agglutination with high specificity and improved, though still relatively low, 
sensitivity.  It was shown that the sensitivity could be increased by combining 
the results of both antibody and antigen tests together (Sendid et al., 1999) 
but the requirement for two tests complicates the process and increases the 
cost.  
  
A major drawback to these methods is the inability to directly make a specific 
identification to species level.  Therefore, while serological techniques allow 
some time to be saved due to their ability to detect fungi directly from 
prepared blood samples this saving is somewhat offset by the need to 
perform further biochemical and morphological tests to make species level 
identification to ensure appropriate treatment is being administered. 
 
1.3.3 Nucleic acid detection methods 
 Detection of nucleic acid offers significant advantages over other 
methods.  The polymerase chain reaction (PCR) allows amplification of the 
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smallest amounts of target nucleic acid to quantities which can be easily 
detected either directly (e.g. qPCR, real-time PCR) or by a number of 
downstream techniques (e.g. ELISA, pyrosequencing) in a matter of hours.  
Most importantly, however, is the presence of species-specific regions of 
nucleic acid which allows for the design of assays capable of identification to 
the species level.  The simplest methods involve using PCR for direct 
identification of fungi by amplifying products of different sizes which are 
specific for the species of interest (e.g. Kanbe et al., 2002; Arancia et al., 
2009) or generating a species-specific pattern of products as in random 
amplification of polymorphic DNA (Bautista-Muñoz et al., 2003).  More 
complex methods have involved using radiolabelled species-specific probes 
to detect fungal DNA following Southern blotting of PCR products (van 
Deventer et al., 1995), digoxigenin-labelled probes in enzyme immunoassays 
(Fujita et al., 1995; Shin et al., 1997).  The above methods require post-PCR 
sample handling but due to the rapidity of PCR-based methods rapid 
detection and identification of fungi can still be achieved.  However, such 
handling increases the potential for contamination of the samples leading to 
false positive results.   
 
More recently a large number of techniques using fluorescent probes in real-
time and qPCR assays (e.g. Maaroufi et al., 2003; Metwally et al., 2007; Hata 
et al., 2008; Lau et al., 2008) have been described.  These methods all share 
the advantage that detection occurs during the PCR amplification itself 
removing the need for post-PCR handling and so allowing even more rapid 
identification.  The methods which make use of fluorescently labelled probes, 
e.g. Taqman, can achieve specific detection at the level of PCR primers and 
also the probe molecules and this allows for the detection of a greater range 
of species.  Furthermore, some of these tests are capable of detection of 
fungal DNA from prepared blood samples without enrichment.  When 
combined with the species-level identification which is possible during real-
time PCR it allows for considerable reduction in time to diagnosis.  Several 
methods capable of direct fungal detection from blood have been described 
(e.g. McMullan et al., 2008; Zhao et al., 2009) and in combination with real-
time PCR it allows for the design of extremely rapid assays (<3 hours).   
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DNA sequencing is the most reliable molecular technique for definitive 
identification of fungal species.  Traditional sequencing using di-deoxy 
termination has been used to identify clinically relevant yeasts (Ciardo et al., 
2006; Linton et al., 2007) and is advantageous as it usually produces an 
unambiguous output which can quickly be compared to public or in house 
sequence databases to identify a species.  This characteristic is particularly 
useful when attempting to identify species exhibiting characteristics which are 
not covered by a biochemical test panel or a species which has not been 
implicated in human disease before (Borman et al., 2008).  The method is 
relatively expensive to perform, however, and relies on the presence of 
matching sequence data in databases to make identifications.  
Pyrosequencing is an advance on di-deoxy termination sequencing and is 
cheaper to perform but produces much shorter reads.  As a result the target 
for DNA sequencing must be carefully chosen to ensure sufficient variability 
for identification of fungal species.  Montero et al. (2008) compared 
pyrosequencing to di-deoxy sequencing and found that pyrosequencing 
correctly identified 69.1% of 133 isolates compared to 78.9% identified by di-
deoxy sequencing.  All isolates of the most clinically relevant fungi were 
successfully identified by pyrosequencing.  The method has been shown to be 
capable of identification of very closely related isolates by use of an 
appropriate target sequence, Borman et al. (2009) reported the successful 
differentiation of the three species of the C. parapsilosis species complex, C. 
parapsilosis, C. metapsilosis and C. orthopsilosis, using target sequence 
within the second internal transcribed spacer (ITS2) region. 
 
Molecular detection of fungi is undoubtedly quicker, particularly the PCR-
based tests, and requires less expertise to interpret compared with 
conventional tests based on morphology and biochemical testing but they still 
require a well resourced laboratory with trained personnel.  In the absence of 
this, patient samples must be sent to such facilities for testing and the results 
communicated back to the hospital, and so valuable time is wasted even with 
the rapid nucleic acid detection methods.  A solution would be the 
incorporation of a nucleic acid based test into an automated system that could 
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be used at or near the point of care with minimal need for training or 
interpretation by the user.  However, fluorescence-based techniques require 
sophisticated optical components that are difficult to miniaturise so alternative 
methods for detection would have to be found to allow the development of 
such a device. 
 
1.4. Nucleic acid detection using electrochemically labelled probes.  
 Hillier et al. (2004a) demonstrated electrochemical detection of DNA 
using oligonucleotide probes labelled at the terminal 5′ nucleotide with the 
electroactive compound ferrocene.   This ferrocene-labelled oligonucleotide 
molecule was shown to be digested by S1 nuclease to liberate labelled 
mononucleotides and short oligonucleotides which could be detected at the 
surface of a solid state electrode using differential pulse voltammetry (DPV).  
Briefly, a sweep of increasing voltage from -100mV to +500mV is performed 
and, at a voltage determined by the composition of the ferrocene molecule, 
electron transfer from the ferrocene to the electrode occurs, producing a 
measurable current.  DPV is used as it allows greater sensitivity due to the 
separation of the capacitive current (caused by charged molecules aligned at 
the surface of the electrode and the electrolyte solution) from the Faradaic 
current (caused by electron transfer due to chemical reactions taking place).  
The larger the amount of ferrocene-nucleotide that is present at the electrode 
surface, the higher the current produced.   Undigested probe was found to 
produce a substantially lower current compared to the digested ferrocene-
mononucleotide possibly due to a difference in the diffusion coefficient of 
undigested oligonucleotide, hindering its diffusion to the electrode surface, or 
by inhibition of electron transfer due to the presence of the additional atoms 
present in an intact oligonucleotide molecule.  The work was extended by 
Hillier et al. (2004b) to demonstrate detection of target DNA using a ferrocene-
labelled probe.  A short, synthetic target molecule was allowed to hybridise to 
a complementary ferrocene-labelled probe molecule and digestion of the 
probe:target heteroduplex was achieved by using the double-strand DNA 
(dsDNA)-specific gene 6 exonuclease from bacteriophage T7 (T7 
exonuclease; Kerr & Sadowski, 1972) resulting in the release of ferrocene-
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mononucleotides which were detected on solid electrodes using DPV, as 
above.   
 
The procedure was developed further by Atlas Genetics for the purpose of 
designing a rapid assay for the detection of DNA from pathogenic organisms.  
A PCR step was incorporated to amplify target DNA followed by post-PCR 
addition of a ferrocene-labelled oligonucleotide probe targeted to the region 
which was amplified.  The single strand DNA (ssDNA) probe could then bind 
to the amplified target site either by displacement of the non-target strand of 
the dsDNA amplicon or by binding to asymmetrically produced ssDNA 
ampicon and digestion of the hybrid molecule was achieved using T7 
exonuclease as above.  The products of the exonuclease digestion could then 
be assayed using DPV measurements on screen-printed carbon electrodes 
and the current produced by the oxidation of released ferrocene-
mononucleotides measured.   
 
Using this approach, preliminary assays demonstrated successful detection of 
DNA from Neisseria meningitidis while non-target DNA or DNA-free samples 
gave a consistently low, background level of current (S. Boundy, unpublished 
data).  The test demonstrated proof of concept of the electrochemical assay 
for the detection of DNA from target species.  The use of solid-state 
electrodes was a key feature as it would allow miniaturisation of the assay 
and Atlas Genetics have proposed the idea of designing a portable system 
incorporating components which would allow an assay to be automated and 
performed at or near the point of care with minimal input and interpretation by 
the user. 
 
1.4.1 Electrochemical detection of fungi 
 The at-or-near point of care electrochemical method of DNA detection 
proposed by Atlas Genetics has a number of potential advantages which 
make it particularly suitable for detection of fungal pathogens.  As with other 
PCR-based methods it is potentially capable of identification to species level 
and multiplex detection of several pathogens at once is possible.  The use of 
short target sequences for amplification (<500bp) combined with a low 
  - 14 - 
reaction volume suitable for manipulation by microfluidics decreases the time 
required to complete PCR and, if combined with an appropriate platform 
capable of rapid temperature ramping, would permit extremely rapid PCR.  
The reagents for DNA extraction, PCR amplification, probe hybridisation and 
exonuclease digestion would be present on disposable, single-use test cards.  
This would reduce the possibility of sample contamination and, combined with 
the use of solid electrodes for detection, would allow the detection and 
interpretation steps of the assay to be completely automated and require 
minimal expertise on the part of the user.  Hence the assay could allow a 
species-specific identification of a fungal pathogen potentially within an hour 
and appropriate treatment could be administered at once.  The main difficulty 
associated with such a device is the consistent recovery of fungal DNA from 
the assayed clinical sample, since fungal titres can be very low (Loeffler et al., 
2000). 
  
Before any assay can be miniaturised and performed on Atlas Genetics’ 
proposed Velox™ instrument it must first be developed on the benchtop and 
demonstrated to be capable of detection of DNA from target organisms as 
well as having a satisfactory degree of specificity and sensitivity. 
  
1.5 Aim 
 The aim of the project was to develop a benchtop assay to allow 
electrochemical detection of DNA from Candida species on solid electrodes 
utilising Atlas Genetics ferrocene-labelled oligonucleotide approach.  For the 
initial probe design the questions of which species to identify and the region of 
the genome to be targeted had to be considered, as well as the possibility of 
including probes for more generalised detection (i.e. species specific vs. 
genus specific vs. panfungal).  Once suitable probes had been identified and 
synthesised they had to be shown to be specific to the target species and also 
to possess the required sensitivity to detect small amounts of target DNA in a 
50µl reaction volume and finally in a blood sample. 
  
Additionally, since the methodology was novel the project was an opportunity 
to investigate some of the issues which surround the mechanism behind 
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detection of target DNA.  While pursuit of the primary aim of the project 
prevented a thorough examination of the issues in question, some of the more 
common or problematic issues that were encountered were explored to a 
degree and any findings of relevance were reported (see chapters 3 & 7).  
 
1.6 Strategy 
 As discussed above the number of fungal pathogens implicated in 
human disease is large and the design of probes capable of species-level 
identification for all of them would be extremely difficult and exhibit diminishing 
returns on the effort that would have to be invested in such a task.  Instead it 
would be sensible to have a smaller suite of probes that covered the most 
commonly occurring fungal pathogens as well as those most frequently 
implicated in antifungal resistance.  The majority of infections are caused by 
five species of the genus Candida and two of these, C. glabrata and C. krusei 
are commonly associated with antifungal resistance.  It was therefore decided 
that the assay should be developed to detect and identify these five species.  
Further to the design of the species-specific probes it was decided to try and 
design of a pan-fungal probe as well.  This approach would allow the early 
detection of an invasive fungal infection caused by uncommon species and 
would be a valuable early warning which would allow empiric antifungal 
treatment to be administered while further tests can be performed on the 
patient with the knowledge that fungal involvement has been demonstrated.  
  
The strategy of probe design that was therefore employed was to have a suite 
of 6 probes: 5 species specific probes targeted to C. albicans, C. parapsilosis, 
C. glabrata, C. tropicalis and C. krusei to detect the most common species of 
Candida implicated in invasive fungal infections, and a single pan-fungal 
probe that would detect DNA from any fungal species present in a sample.  
Fig 1.1 shows how the results of a multiplex reaction with the 5 + 1 probe 
suite could help inform treatment of a patient with suspected IFI.  As 
mentioned before, no approach could cover all eventualities of diagnosing a 
fungal infection but this strategy represents a useful advance in identification 
of fungal pathogens that aids in guiding treatment.    
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Figure 1.1  Decision tree which demonstrates how the 5 Candida species specific probes and the pan-
fungal probe would enable clinicians to make a more informed decision of how to treat an invasive 
fungal infection. 
 
The next question was the choice of DNA target for the probes.  PCR-based 
assays can be developed to detect any target DNA for which PCR primers 
and a specific probe can be designed.  Pathogenic organisms, including fungi, 
are particularly amenable in this respect as numerous DNA sequences from 
such organisms are available in public databases.  Areas of particular interest 
are the internal transcribed spacer (ITS) regions of the rRNA cistrons (fig 1.2).  
The ITS regions and have been targeted in a number of methodologies (Fujita 
et al., 1995; Turenne et al., 1999; Guiver et al. 2001; Leaw et al., 2007; Lau et 
al., 2008) and are very useful for design of species-specific primers and 
probes for identification as they are present in multiple copies between ~40 
and ~150 copies per haploid genome in fungi (Ganley & Kobayashi, 2007), 
they exhibit considerable variability between species and are flanked by the 
highly conserved rRNA genes which facilitate the design of more universal 
ALL FUNGAL probe gives positive signal 
Fungal pathogen not involved. 
No 
Yes 
One or more of the Candida species 
specific probes gives positive signal. 
No 
Infection caused by either a rare 
Candida species or another fungal 
pathogen e.g. Aspergillus, 
Malassezia, Cryptococcus species. 
Appropriate empiric antifungal treatment 
should be administered. If Aspergillus 
infection is suspected it is not treatable using 
fluconazole; ~50% of A. terreus isolates are 
resistant to amphotericin B. 
Begin treatment using an appropriate dosage of 
antifungal depending on the identity of the strain and 
status of the patient e.g. C.krusei must NOT be 
treated with fluconazole. 
Yes 
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primers and probes (Iwen et al., 2002).  It was decided to target the ITS2 
region for the design of the probes for species-specific identification and use 
fungal universal primers targeted to the flanking 5.8S and 26S rRNA genes to 
amplify the ITS2 region.  For design of the panfungal primers and probe the 
rRNA genes were used and eventually the 18S rRNA gene was settled on as 
the most favourable target.  The use of fungal universal primers has the 
disadvantage that any fungal species which contaminates the PCR mix will 
present a target for the primers.  Provided the species-specific probes have 
been well designed the probability of a false positive result is low; however, 
the probability of a false negative result is increased as the contaminant DNA 
will act as a target for the generic primers and so compete with target DNA for 
amplification.  This would be more likely to affect reactions where very low 
amounts of target DNA are present as the contaminant DNA will be able to 
sequester the primers and become the dominant amplicon early in the 
reaction.  It would be possible to design species-specific primers, however this 
was not attempted as it would make development of the assay for multiplex 
detection more difficult, due to potential primer-primer interactions and would 
make addition of further species-specific probes to the suite more difficult to 
achieve. 
  
Type strains of each of the five Candida species of interest were used to show 
that detection is possible using the appropriate probe while their specificity 
was tested experimentally against a panel of nine non-target Candida species 
that are implicated in human disease as well as against human DNA.  The 
robustness of the probes was tested against wild isolates of the appropriate 
species and clinical isolates were used where possible.  The robustness of 
the pan-fungal probe was tested experimentally against as wide a range of 
fungi as possible.  The limit of detection (LOD) of the probes was ascertained 
firstly in assays with extracted DNA 
 
Figure 1.2.  Schematic overview of the rRNA cistron showing the conserved rRNA genes flanking the 
variable ITS regions. 
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diluted to the level of 1 genome present in a 50µl PCR reaction.  If this is 
achieved successfully the LOD of extracted DNA spiked into healthy blood 
samples will be investigated.  Finally detection of small numbers of whole cells 
spiked into healthy blood samples will be attempted. 
  
If the assay can achieve all of the above goals satisfactorily then it will have 
demonstrated the utility of Atlas Genetics’ method and placed the fungal 
detection assay in good stead for further clinical testing and potential 
adaptation for use on the automated point of care system proposed by Atlas 
Genetics. 
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Chapter 2 - Materials and Methods. 
2.1 Culture acquisition 
Type strains of 10 Candida species were obtained from the Centraal Bureau 
voor Schimmelcultures (CBS) and wild strains were acquired from the culture 
collection at the University of Bath and from other donors – table 2.1 lists the 
strains that were used and includes information concerning their geographical 
origin and site of isolation, where available.  All species used had their identity 
confirmed by sequencing of the ITS2 region. All yeasts were cultured on 
yeast-peptone-dextrose (YPD) agar (1% yeast extract (Oxoid), 2% Bacto 
peptone (Oxoid), 2% glucose (Sigma), 2% Bacto agar (Difco)) at 28°C for 48 
hours.   
  
Samples of type strain cultures were prepared for long term storage using the 
following method: a growing colony was picked from YPD agar using a sterile 
loop, transferred to 5ml liquid YPD and incubated overnight at 28°C with 
shaking.  1ml samples of each culture were then aliquoted into 2ml 
microcentrifuge tubes and 1ml of 20% glycerol added as a cryoprotectant 
before transfer to -20°C storage.   
 
Filamentous fungi were cultured on potato dextrose agar (PDA) (Oxoid) and 
stored at 4°C until DNA extraction. 
 
 
2.2 Steps to limit contamination 
 In order to prevent contamination the setup of PCR reactions and the 
processing of blood samples was performed in a safety cabinet or flow hood 
which was regularly disinfected with 70% ethanol and sterilized using ultra 
violet (UV) irradiation.  The air flow remained switched off while the mix was 
prepared to avoid contamination of samples by airborne PCR amplicon.  All 
stock reagents were aliquoted into working stock solutions to limit potential 
contamination and problems associated with freeze-thawing. 
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Table 2.1.  List of fungal strains used.  Type strains are designated with 
(T)
. 
Species name 
University of 
Bath code 
Culture 
collection 
number Origin Species name 
University of 
Bath code 
Culture 
collection 
number Origin 
C. albicans (T) LN1568 CBS 562 Uruguay, interdigital candidiasis in human C. krusei (T) LN1562 CBS 573 
Sri Lanka, bronchomycosis, 
human sputum 
C. albicans LN2327 - U.K., blood C. krusei LN1606 - Uganda, human 
C. albicans LN1640 NCPF 3281 U.K., patient sample C. krusei LN1613 - Uganda, human 
C. albicans LN4350 - Endocarditis C. krusei LN1653 - U.K. patient sample 
C. albicans LN3664 - Human urine sample C. krusei LN1654 - U.K. patient sample 
C. glabrata (T) LN1563 CBS 138 Human faeces C. lusitaniae (T) LN1601 CBS 4413 Portugal, caecum of pig 
C. glabrata LN2231 - U.K., blood culture C. famata 
(T)
 LN1566 CBS 767 Carlsberg lab 
C. glabrata LN2230 - U.K., blood culture C. kefyr
 (T)
 LN1564 CBS 834 Netherlands, kefyr grain 
C. glabrata LN2228 - U.K., blood culture C. dubliniensis 
(T)
 LN1565 CBS 7987 Ireland, oral candidiasis in human 
C. glabrata LN2244 - U.K., blood culture C. guilliermondii 
(T)
 LN1602 CBS 566 Bronchomycosis, human 
C. parapsilosis (T) LN1567 CBS 604 Puerto Rico, case of sprue in human C. zeylanoides LN1666 NCPF 8426 Human 
C. parapsilosis LN2450 - Turkey C. pelliculosa LN1662 - Human 
C. parapsilosis LN2451 - U.K. S. cerevisiae LN2208 - High vaginal swab 
C. parapsilosis LN2235 - U.K., blood culture P. fermentans LN2308 - - 
C. parapsilosis LN2462 - U.K., blood culture C. inconspicua LN1649 NCPF 8625 Sputum, human 
C. tropicalis 
(T)
 LN1569 CBS 94 Bronchomycosis patient, human C. lipolytica LN1655 NCPF 8630 Human 
C. tropicalis LN3133 - Inclusions in vesicles Cr. gatii* N/A - Meningo-encephalitic lesion 
C. tropicalis LN1608 - Uganda, human Cr. victoriae LN3422 - - 
C. tropicalis LN1611 - Uganda, human A. nidulans LN2325 - - 
C. tropicalis LN1614 - Uganda, human F. oxysporum LN1107 - U.S.A. 
* Cr. gatii extracted DNA was used rather than cultures. 
CBS: Centraal Bureau voor Schimmelcultures, Netherlands. 
NCPF: National Collection of Pathogenic Fungi, U.K. 
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2.3 Whole blood acquisition and treatment 
 Blood from a healthy donor was collected by a trained individual into 
6ml vacutainer tubes.  For samples which were to be kept as whole blood or 
be processed to yield plasma, K2EDTA-coated vacutainers (BD Biosciences) 
were used to prevent clotting and upon collection of blood the vacutainer was 
inverted 8 – 10 times to ensure adequate mixing of the anti-coagulant with 
blood.  For samples which were to be processed to yield serum, untreated 
vacutainers were used for collection and the blood was incubated at 28°C for 
1 hour to allow clot formation.  The vacutainer was then centrifuged at 1400 
relative centrifugal force (rcf) for 10mins at 4°C.  1ml aliquots of the serum 
fraction were then pipetted into 2ml sterile cryovials.  For preparation of 
plasma samples the anti-coagulated blood sample was centrifuged at 1400rcf 
for 10mins at 4°C and then 1ml aliquots of the plasma fraction were aliquoted 
into 2ml sterile cryovials.  All of the plasma, serum and whole blood samples 
were stored at -80°C until used. 
 
2.4 DNA extraction 
2.4.1 Extraction from liquid cultures 
 The QIAgen DNeasy extraction kit was used for all extractions and the 
manufacturer’s protocol was followed with some modifications that were 
appropriate for treatment of fungal material.  The yeast cell count in a stock 
cell suspension was estimated by spectrometry according to the method 
described in Amberg et al. (2005) and a solution of approximately 5x106 yeast 
cells was prepared by appropriate dilution of the stock and centrifuged at 
10,000 rpm for 10mins to pellet the cells.  The supernatant was removed and 
the cell pellet resuspended in 500ul of a lyticase lysis buffer which comprised 
10U ml-1 lyticase from Arthrobacter luteus (Sigma), 50mM Tris, pH 7.5, 10mM 
EDTA and 28mM β-mercaptoethanol; the lyticase digestion was performed at 
37°C for 30mins.  For filamentous fungi, the PDA was flooded with 1ml of a 
sterile solution of 0.9% saline and agitated to transfer fungal material to the 
solution.  The saline was then collected, centrifuged, resuspended in lyticase 
buffer and incubated as above.  Following treatment by lyticase the 
sphaeroplasts were collected by centrifugation at 10,000rpm for 10mins, the 
supernatant removed and the sphaeroplasts resuspended in 180 µl buffer 
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ATL to which 20µl of a proteinase K solution provided in the kit was added 
and the mixture vortexed and incubated for 45mins at 55°C.  After proteinase 
treatment, 200µl of buffer AL and 200µl of absolute ethanol were added to the 
samples, mixed thoroughly and the samples left on ice for 30mins to increase 
precipitation of DNA and enhance final yield.  The samples were then placed 
in silica-based spin columns and wash steps with 500µl of buffer AW1 and 
AW2 were applied as per the manufacturer’s instructions.  DNA was then 
eluted twice from each column using 50µl of the elution buffer for each elution 
and a single 1.5ml tube was used to collect both eluates.  The concentration 
of eluted DNA was estimated by spectrometry.  All DNA was stored at -20oC. 
 
2.4.2 Extraction from blood samples spiked with C. albicans genomic 
DNA. 
 The required number of 1ml blood samples (whole blood or plasma) 
were removed from storage at -80°C and allowed to thaw.  C. albicans DNA 
was removed from -20C storage and allowed to thaw.  A 5ml sterile bijou tube 
had the required amount of C. albicans genomic DNA added and 1ml of the 
blood sample was then added to the bijou.  The solution was agitated gently 
to allow mixing of the DNA in the blood.  Extraction of the C. albicans DNA 
from blood was performed using GenElute Bacterial Genomic DNA extraction 
kit (Sigma) with considerable modification.   
 
The spiked blood samples had 2ml of a proprietary lysis buffer added and 
were incubated for 5mins at room temperature with occasional gentle 
agitation to allow mixing and complete lysis of blood cells.  Meanwhile the 
required number of extraction columns was prepared using Column 
Preparation Solution as per manufacturer’s instructions.  After the 5min 
incubation of blood samples 700µl of the lysate was applied to the spin 
column and centrifuged at 12,000g for 1min to allow DNA to bind to the 
column.  The flow-through was discarded.  The above step was repeated until 
all of the lysed blood sampled had been spun through the column.  After the 
final centrifugation the collection tube was discarded and replaced with a fresh 
one.  500µl of Wash Solution 1 was applied to the column and centrifuged at 
12,000g for 1min.  The collection tube was discarded and replaced.  500µl of 
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the wash solution with added ethanol was applied to the column and 
centrifuged at 12,000g for 1min.  This time the flow through was discarded, 
the column placed back in the same collection tube and centrifuged for a 
further 1min.  The collection tube was then discarded and replaced with a 
fresh one.  Elution of DNA was initially performed by adding 100µl of elution 
buffer to the column, incubating at room temperature for 30s and centrifuging 
at 12,000g for 1min.  30µl of this eluate was used as template in PCR 
reactions.  However, to improve the yield when very small amounts of C. 
albicans DNA were spiked into blood the elution buffer was prewarmed to 
60°C and 34.25µl was applied to the spin column, incubated for 30s at room 
temperature and centrifuged at 12,000g for 1min.  The eluate was then 
reapplied to the spin column, incubated and centrifuged for a second time.  
This entire eluate was then used as template in PCR amplifications. 
 
2.4.3 Extraction from blood samples spiked with C. albicans cells. 
 To obtain cell suspensions of the appropriate number of cells to spike 
into blood samples, growing colonies of C. albicans were picked with a sterile 
loop and resuspended in 500µl sterile H2O.  This stock solution was diluted 
10-fold and 50-fold and cell-density estimates of the three solutions were 
made using an improved Neubauer counting chamber.  After confirming that 
the estimates were in good agreement with one another, the cells were further 
diluted to yield solutions of 1cell µl-1 and 0.1cell µl-1.  The cell densities were 
confirmed retrospectively by performing plate counts.   
 
The extraction procedure was very similar to the method outlined in section 
2.4.2 but differed in the pretreatment step.  After thawing the blood samples, 
10µl of the appropriate C. albicans cell suspension was added to a 7ml sterile 
bijou and then the 1ml blood sample was added and the solution mixed.  
250µl of a lysis buffer containing 200U ml-1 lyticase (see section 2.4.1) was 
added and the reaction mix incubated at room temperature for 5min with 
gentle agitation.  After this step the extraction continued with the addition of 
1ml of the proprietary lysis buffer and was identical to the procedure outlined 
in section 2.4.2.  Note that 34.25µl of prewarmed elution buffer was always 
used for elution of DNA extracted from C. albicans cells. 
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2.5 Primers and probes 
 Fungal universal primers ITS3 and ITS4 (White et al., 1990) were 
obtained from Sigma.  The primers amplified a region between the 3’ end of 
the 5.8S rRNA gene and the 5’ end of the 28S rRNA gene, which 
encompassed the ITS2 region (see fig 2.1).  Sequences of species-specific 
probes for detection of five Candida species that targeted this region were 
obtained from Shin et al. (1999).   These species-specific sequences detected 
the following species (the name in parentheses was the name given the 
electrochemically labelled probe used in this work): C. albicans (CA PR), C. 
tropicalis (CT PR), C. parapsilosis species-complex (CP PR), C. glabrata (CG 
PR) and C. krusei (CK PR).  The sequences were used to synthesize 
oligonucleotides which were labeled at the 5’ terminal nucleotide with a 
proprietary ferrocene compound by ATDBio (Southampton).  Some of the 
original probes produced unsatisfactory results and a number of different 
probes were designed.  Furthermore, the ITS3 and ITS4 probes were not 
suitable for satisfactory amplification of low amounts of target DNA.  Several 
new forward and reverse primers were designed by eye using a matrix of 
fungal ITS2 sequences.  Following tests of all primer combinations 
experimentally the primer pair ITS3.3 and ITS4.2 was found to yield the best 
results and these primers were used for amplification of low amounts of fungal 
DNA. 
 
A pan-fungal probe (PanF PR) was designed manually by analyzing a matrix 
of fungal 18S ribosomal DNA sequences that had been obtained from 
GenBank and identifying an appropriate target site for a probe (see below).  
This probe was then BLASTed (Altschul et al., 1997) against a database 
containing human, trypanosome, plasmodium and fungal 18S ribosomal DNA 
sequences to ensure that it would hybridize to the fungal sequences but not to 
human or other organisms’ DNA.  The same matrix was then used to identify 
potential primers to amplify the area surrounding the PanF PR target site.  
Following PCR trials the forward primer Fungal18sF2 and the reverse primer 
Fungal18sR4 were chosen for use with the PanF PR probe.  All of the primer 
and probe sequences used are listed in table 2.2.  Primers were synthesized 
by either Sigma or IDT Technologies. 
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Figure 2.1.  Schematic representation of the 18S, 5.8S and 26S rRNA genes with the internal 
transcribed spacer (ITS) regions.  The target sites of the primers have also been indicated. 
 
2.6 Assessing cross-reactivity of probes using bioinformatics. 
 Fungal ITS2 sequences were obtained from Genbank and sequence 
alignments performed using the MEGA Version 4.0 software (Tamura et al., 
2007).   This alignment was used as a database for a BLAST search with 
each of the Candida species-specific probes.  Any non-target species that 
were found to have ≥ 60% identity to any of the species-specific probes were 
used in assays to test for cross-reactivity.  
  
A sequence alignment of 18s rRNA genes from fungi but which also included 
human, plasmodium and trypanosome sequences was constructed and used 
to identify primers and probes for universal detection of fungi.  Potential 
primers were screened experimentally to find the best combination, but to 
decide between potential probe target sites a BLAST search was performed 
using the 18s rRNA alignment as the database against which the potential 
probe sequences were screened.  In this case it was desirable that all of the 
fungi had a high percentage of matched bases while the non-fungal 
sequences were as low as possible. 
 
ITS3 
primer 
ITS4 
primer 
ITS2 
26S 5.8S 
ITS1 
18S 
18sF2 
primer 
18sR4 
primer 
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Table 2.2.  Primer and internal probe sequences used in the electrochemical detection assay.  All probes had a diferrocene label attached by a carbon linker molecule 
to the 5’ terminal nucleotide. 
Forward Primer 
Name 
Primer sequence (5′ - 3′) 
Reverse Primer 
Name 
Primer sequence (5′ - 3′) 
ITS3 GCA TCG ATG AAG AAC GCA GC ITS4 TCC TCC GCT TAT TGA TAT GC 
ITS3.1 GGA TCT CTT GGT TCT CGC AT ITS4.1 CCT ACC TGA TTT GAG GTC A 
ITS3.2 CAT CGA ATC TTT GAA CGC ACA ITS4.2 AGT CCT ACC TGA TTT GAG G 
ITS3.3 TGC CTG TTT GAG CGT CAT TTC ITS4.3 CCT ACC TGA TTT GAG GTC 
Fungal18sF2 GCC ATG CAT GTC TAA GTA TAA Fungal18sR4 CCT CGT TAA GGG ATT TAA ATT GT 
Probe Name Probe Sequence (5′ - 3′) Species detected 
CA PR ATT GCT TGC GGC GGT AAC GTC C 
CA PR2 TGC GGC GGT AAC GTC CAC CA 
CA PR3 ATC GCT TTG ACA ATG GCT TA 
C. albicans 
CT PR CAA AAC GCT TAT TTT GCT AGT GGC C C. tropicalis 
CP PR GGT ACA AAC TCC AAA ACT TCT TCC A C. parapsilosis 
CG PR TAG GTT TTA CCA ACT CGG TGT TGA T 
CG PR2 CCT CGT GTC CCA CAT ACT GA 
CG PR3 TCA GTA TGT GGG ACA CGA GCG CAA G 
C. glabrata 
CK PR AGT GGC CCG AGC GAA CTA GAC TTT T C. krusei 
PanF PR GGT GAT TCA TAA TAA CTT TTC G All fungi 
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2.7 PCR conditions 
2.7.1 PCR conditions for testing assay specificity 
 All PCR reactions were performed in Peltier PTC thermal cyclers (MJ 
Research).  Asymmetric PCR conditions using a 5:1 ratio of reverse:forward 
primers were used to generate an excess of single stranded target DNA for 
the assay.  PCR reactions to amplify target for use in electrochemical assays 
were set up in at least triplicate.  PCR reactions were carried out using GE 
Healthcare’s Illustra Taq DNA polymerase in a volume of 30µl containing the 
following reagents: PCR buffer (10mM Tris-HCl, pH 9.0, 50mM KCl, 1.5mM 
MgCl2) (GE Healthcare), 100nM forward primer, 500nM reverse primer, 
0.15mM each dNTP, 1U IllustraTaq DNA polymerase (GE Healthcare) and 2µl 
extracted DNA, corresponding to 10-100ng.  The remaining volume was made 
up to 30µl with molecular grade water (Sigma; 0.1µm filtered, DNase, RNase 
and protease free).  These conditions were satisfactory for the C. parapsilosis, 
C. glabrata, C. tropicalis and C. krusei specific probes but not the C. albicans 
specific probe.  Establishing an assay for detection of C. albicans DNA proved 
difficult and required alteration of some of the PCR components - an 
alternative, in-house buffer was used to amplify C. albicans DNA that 
contained 10mM Tris-HCl (pH 8.3), and 50mM KCl while MgCl2 was added 
separately at a concentration of 3mM.  For all of the probes the amplification 
conditions used for amplification of the ITS primer pairs were: 94oC for 1min; 
94ºC for 20s plus 55ºC for 20s plus 72ºC for 20s for 40 cycles; 72oC for 
3mins.  For PCR amplification using the 18s primers the above program was 
altered to have an extension step of 72ºC for 40s as the product was longer. 
 
2.7.2 PCR for DNA sequencing 
 PCR reactions to amplify target DNA for sequencing were carried out 
using the ‘standard’ PCR conditions described above but in a reaction volume 
of 50µl and symmetric PCR conditions were used.  Following PCR the 
products were cleaned using the Qiaquick PCR cleanup kit (Qiagen) following 
manufacturer’s instructions and DNA concentration was estimated using a low 
molecular weight mass ladder (Fermentas)  Sequencing reactions were 
carried out by MWG or Cogenics.  BLAST searches were performed against 
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the GenBank sequence database to confirm the identity of the sequenced 
fungal isolates. 
 
2.7.3 PCR conditions for testing assay sensitivity 
 The PCR conditions described above were inadequate for amplification 
of low amounts of target DNA and had to be changed.  Research into 
alternative Taq DNA polymerases and PCR buffers by researchers at Atlas 
Genetics had identified a better enzyme and improved buffer solution.  My 
conditions were therefore changed to use the the hotstart Taq polymerase 
Jumpstart (Sigma) and a 10X PCR buffer comprising 100mM Tris-HCl (pH 
8.3), and 500mM KCl which was made in the Atlas Genetics laboratory.  The 
PCR used a total volume of 50µl containing the following reagents: PCR 
buffer (see above), 100nM forward primer, 500nM reverse primer, 0.15mM 
each dNTP, 3mM MgCl2 and 2.5U Jumpstart Taq DNA polymerase (Sigma) 
made up to 50µl using molecular biology grade water (Sigma).  The cycling 
conditions used were: 95oC for 1min; 94ºC for 30s plus 58ºC for 30s plus 
72ºC for 1min for 40 cycles; 72oC for 3mins. 
 
2.7.4 Visualisation of PCR products 
 A 10µl aliquot of the PCR products was added to 2l of 6X loading dye 
and visualized on a 1% (w/v) agarose gel made up in Tris-Borate-EDTA (TBE) 
buffer (0.09M Tris base, 0.09M boric acid, 2mM EDTA pH 8.0) containing 
0.5µg ml-1 ethidium bromide to confirm the presence of amplified target DNA.  
Samples were run at 10V cm-1.  20µl of the remaining PCR product was used 
for the electrochemical assay. 
 
2.8 Measurement of Electrochemistry 
 A probe mix was prepared for each sample to be assayed containing 
the following reagents: 3µM of the relevant probe and 10U T7 exonuclease 
(New England Biolabs) made up to 5µl with molecular grade water (Sigma).  
This probe mix was added to 20µl of PCR product and incubated for 20mins 
at 37oC to allow hybridization of the probe to single stranded target DNA and 
subsequent digestion of the duplex by T7 exonuclease.  Once incubation was 
complete 20µl of the probe reaction mix was pipetted onto screen printed 
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carbon electrodes with a silver/silver-chloride reference electrode.  The 
electrodes used for specificity testing were manufactured by Gwent Electronic 
Materials Ltd. and those used for sensitivity testing were manufactured by G. 
M. Nameplate.  The observed current due to oxidation of the released 
ferrocene-labeled nucleotide following DPV was measured using a 
potentiostat (Autolab PGSTAT30, EcoChemie) and dedicated software (GPES 
version 4.9, EcoChemie). DPV measurements were made using the following 
settings: modulation time 0.04s; interval time 0.1s; initial procedure -0.1V; end 
potential 0.5V; step potential 0.003V; modulation amplitude 0.05V. 
 
2.8.1 Synthetic target assay 
 5µM of a 60-mer synthetic oligonucleotide molecule (Sigma) which 
matched 60bp of the ITS2 region of the target species, and contained the 
probe binding site, was added to 2µl of 10X Illustra Taq PCR buffer.  3µM of 
the appropriate probe and 10U of T7 exonuclease were added, followed by 
H2O to give a final volume of 20µl.   Reaction mixes were incubated at 37
oC 
for 20mins as above and the entire 20µl sample used to obtain 
electrochemistry readings as above. 
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Chapter 3 - Model of the Electrochemical Assay. 
3.1 Introduction. 
 The assay under development by Atlas Genetics is novel, but operates 
in a similar way to other well established molecular sensing techniques.  
Perhaps the most closely related method is the Taqman assay using a dual-
labelled oligonucleotide probe.  This procedure is a modification of 
conventional PCR which allows amplification to be monitored by the inclusion 
in the reaction of a third DNA oligonucleotide which is labelled at the 5′ end 
with a molecule capable of fluorescing when excited by U.V. light and at the 3′ 
end by a molecule which quenches the fluorescence of the first when they are 
in close proximity.  This dual-labelled oligonucleotide binds to a target site 
within the area being amplified by the primers during  the annealing step of 
PCR and is then digested by the 5′ - 3′ exonuclease activity of Taq 
polymerase.  The fluorescence-labelled mononucleotide is then able to diffuse 
away from the quencher-labelled mononucleotide and this produces a 
measurable increase in fluorescence when U.V. light of the appropriate 
wavelength is applied to the sample.  As amplification continues the amount 
of available target increases and so the amount of fluorescence increases.  
There is always a background fluorescence associated with these assays, 
caused by weak fluorescence of the quenched label on the 5′ end of the intact 
probe; it provides a base level of fluorescence which is essential for 
determining when DNA amplification reaches the exponential phase and is 
usually used quantitatively to determine the amount of template DNA present 
at the start of the reaction.   
 
The Atlas Genetics electrochemical assay also uses a third DNA 
oligonucleotide for detection of amplified products but this molecule is labelled 
at only its 5′ end with a proprietary ferrocene-based molecule which can be 
oxidised, producing a measurable electric current, when voltage of a particular 
value is applied.  This latter property can be exploited to allow multiplex 
detection of probes labelled with ferrocene molecules that oxidise at different 
voltages, in a similar way to Taqman assays that use different fluorescent 
probes that emit light at different wavelengths following excitation.  The assay 
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differs further from the Taqman method in that it is an end-point detection 
assay - amplification of target by PCR is first completed and then the probe is 
added to the reaction alongside a dsDNA-specific exonuclease.  The probe 
hybridises to amplified target and is digested to release mononucleotides.  
The ferrocene-labelled mononucleotide products of this digestion diffuse to 
the surface of an electrode where they are oxidised following application of 
voltage sweep and it is the current produced by the transfer of electrons 
during this event that is recorded (Fig 3.1).  A background signal is also 
associated with the electrochemical assay due to oxidation of low levels of 
undigested probe present at the electrode surface.  Reaction conditions can 
have an effect on the background current and can result in either an increase 
or a decrease in the signal. 
 
While a model of how the assay produces current has been suggested, 
exactly how the different factors involved in the assay affect current output 
has not yet been precisely established.  Some of these factors will now be 
introduced and data acquired during my research that sheds light on aspects 
of them will be discussed.  It is important to note that the results which follow 
were derived at different times during the project and some were performed 
under different conditions than others.  However, at each point that a change 
in procedure took place comparative experiments were performed to ensure 
that the new system gave similar, comparable results to the old system.  The 
most notable improvement was the eventual reduction of background current 
to zero which can be seen in some of the results.  The possible reasons for 
this are discussed in section 3.5 below. 
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Figure 3.1.  Example data showing current peaks produced following oxidation of ferrocene in the assay.  
A voltage sweep from -100mV to +500mV was used and peak oxidation occurred at ~180mV.  The 
probe used was CT PR. 
 
3.2 PCR amplification. 
3.2.1 Asymmetric PCR 
 The first part of the assay, PCR, is of critical importance as the current 
generated by the assay is proportional to the amount of target DNA present 
which is in turn dependent on PCR amplification; the procedure must be 
optimal to ensure the production of as much target as possible.  Asymmetric 
PCR conditions using a 5 to 1 ratio of target strand synthesising primer to 
complementary strand synthesising primer (in this assay a 5:1 ratio of 
ITS4:ITS3) for asymmetric PCR had previously been shown to yield optimal 
results for assays with bacterial target DNA (S. Boundy, pers comm) and it 
was decided to maintain these conditions for use in the fungal assay.  One 
drawback to asymmetric PCR compared with symmetric PCR is that the 
exponential phase of the reaction does not last as long, hence less product is 
formed in the final cycles of the reaction.  However, symmetric PCR produces 
a population of predominantly dsDNA molecules which would mean that the 
target DNA molecules would be duplexed with their complementary strands 
making it difficult for the probes to bind.  This would result in lower currents 
being produced compared to asymmetric PCR conditions which, while not   
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Figure 3.2.  Comparison of the effect of asymmetric and symmetric PCR conditions on the current ouput 
of the assay using target derived from C. tropicalis DNA and the probe CT PR.  Error bars represent SD 
(n=4). 
 
producing as much target DNA, produce more ssDNA.  Increased ssDNA 
target was hypothesised to yield a better signal compared to symmetric PCR 
conditions.  The two methods were directly compared using the same 
template and probe and the mean results are displayed in Fig. 3.2.   The mean 
current generated with amplicon derived from asymmetric conditions was 
significantly higher than the mean current generated by symmetric conditions: 
110.6 ± 7.9nA compared with 78.7 ± 13.9nA (P<0.01).  Despite the statistical 
significance, the difference between these mean values was only 31.9nA 
which was a relatively small difference and one that could occur between 
measurements of replicates with the same experimental conditions.   
 
The relatively high currents generated by the assay in the presence of dsDNA 
target suggested that some mechanism was allowing the probe to hybridise to 
the target and be digested by T7 exonuclease with reasonable success.  One 
possibility was that the probe molecule was able to displace the 
complementary strand from the target site and hybridise in a similar manner to 
single strand invasion events that occur during homologous recombination.  
Another possibility was that the ITS4 primer, which synthesised the probe’s 
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target strand, was a more efficient primer that ITS3 and so, even when the 
primers were present at equal concentrations, the products of the reaction still 
contained a proportion of ssDNA target which produced a signal when 
analysed electrochemically.  The design flaws associated with primer ITS3, 
which may have limited its efficiency, are discussed further in section 3.2.2.   
 
The exact reasons for production of a relatively high signal by symmetric PCR 
were not investigated further.  The key conclusion was that asymmetric PCR 
conditions gave better results in the electrochemical assay and were 
incorporated into the routine assay procedure. 
 
3.2.2 Primer Design 
 The efficiency of primers used for the PCR was also absolutely critical 
in obtaining a good signal output, especially when a low amount of template 
DNA was being used.  The initial primer pair that was used, ITS3 and ITS4, 
had produced good results when target fungal DNA was present in large 
amounts in PCR i.e. tens of nanograms.  However, when the amount of DNA 
present in the reaction was reduced to femtogram levels detection was no 
longer possible, either visually by running products on a gel, or 
electrochemically.  Upon examination of the primers it was discovered that 
two of the 3′ terminal nucleotides of each primer were complementary to both 
itself and its partner (Fig 3.3A and B) and it was thought that this potential 
self-dimerising behaviour might have affected the amplification of target DNA, 
particularly when low amounts of target were present because, when little 
template DNA is present, mispriming in the early stages of PCR has a much 
more pronounced effect; at best it may sequester primer molecules and 
prevent them from binding to the template genomic DNA, and at worst may 
actually produce a primer-dimer product which becomes the preferred 
template in the early stages of the reaction.  In either case, amplification of the 
desired target is reduced with the effect that the signal produced in the assay 
is also reduced.  New primer pairs were therefore redesigned to other 
conserved regions within the 5.8s and 28s rRNA. 
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Assays using these primers with low amounts of target DNA produced 
considerably higher values of current than those performed with the ITS3 and 
ITS4 primers; Figure 3.4 shows comparative results generated by each primer 
pair.  The old primer pair, ITS3 and ITS4, gave a mean current of 72.4 ± 
2.4nA compared with 165.3 ± 12.4nA and 83.8 ± 6.6nA for primer pairs for 
ITS3.1/ITS4.1 and ITS3.2/ITS4.2 respectively.  The considerably larger 
currents produced by assays utilising ITS3.1/ITS4.1 were a remarkable 
demonstration that differences in primer sequences, and therefore the 
efficiency of PCR, can produce large differences in current.  Additionally, the 
DNA-free samples produced very similar values of current between the primer 
pairs, ranging between 12.8 ± 4.4nA and 15.4 ± 1.3nA, indicating that the 
background current was independent of the PCR primers. 
 
ITS4: 5′-TCCTCCGCTTATTGATATGC-3′ 
       || 
ITS3:    3′-CGACGCAAGAAGTAGCTACG-5′  
Figure 3.3A.  Potential hetero-dimerisation between primers ITS3 and ITS4. 
 
Figure 3.3B.  Two potential self-dimerisation configurations with primer ITS3.  
Note that ITS4 is also capable of self-dimerisation between its 3′ termini. 
ITS3: 5′-GCATCGATGAAGAACGCAGC-3′ 
            || 
ITS3:    3′-CGACGCAAGAAGTAGCTACG-5′ 
 
ITS3: 5′-GCATCGATGAAGAACGCAGC-3′ 
    ||  || |    | ||  || 
ITS3: 3′-CGACGCAAGAAGTAGCTACG-5′ 
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Fig 3.4.  Mean currents produced in assays with the primer pair ITS3/ITS4 compared to the newly 
designed primer pairs ITS3.1/ITS4.1 and ITS3.2/ITS4.2.  Error bars represent SD (n=3). 
 
As mentioned previously, the primer pair ITS3/ITS4 was good enough to 
demonstrate the specificity of the species specific probes in assays that used 
large amounts of target DNA.  Primer redesign had to be carried out to 
develop more efficient primers for amplification and detection of low amounts 
of target DNA.  This is discussed further in section 5.2.2. 
 
3.2.3 Magnesium Chloride (MgCl2) Concentration. 
 The concentration of magnesium chloride (MgCl2) is an important 
component of the reaction, both for efficient amplification of DNA by PCR and 
digestion of the bound probe:target heteroduplex by T7 exonuclease (Kerr & 
Sadowski, 1972).  The initial experiment to determine the optimum 
concentration of MgCl2 to add to the PCR used concentrations of 1.5mM, 
2.0mM, 2.5mM and 3.0mM with DNA extracted from two strains of C. albicans 
and amplified by Illustra Taq polymerase (GE Healthcare).  The gel image of 
the products is presented in Fig 3.5 and showed that only a MgCl2 
concentration of 1.5mM gave a product.  As a result, the use of this 
concentration became incorporated into the assay procedure.   
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Figure 3.5.  Results from the experiment to obtain the optimum concentration of MgCl2 to add to the 
PCR.  Each set of three samples is comprised of two reactions with DNA from 2 strains of C. albicans 
and the third sample in each set is a DNA-free negative reaction. 
 
With hindsight, the above result was in all likelihood an anomaly, most likely 
due to use of poor quality extracted DNA; it was certainly odd that only one of 
the two C. albicans strains produced an amplicon at 1.5mM MgCl2.  When 
10µl the extracted DNA was loaded onto a gel there was insufficient DNA 
present to be visualised, indicating a problem with DNA extraction.  At the 
time, however, there were no other results from DNA extractions or from PCR 
amplifications available for comparison and so the assay procedure was set at 
a final concentration of 1.5mM MgCl2. 
 
The opportunity to review the concentration of MgCl2 used in the assay came 
when trying to improve the signal produced with the CA PR3 probe.  
Researchers at Atlas Genetics had optimised their assays and were regularly 
incorporating 3mM MgCl2 into their reaction mixes; they had also switched to 
a different Taq polymerase.  As these conditions were producing much better 
results with electrochemical assays it was decided to change to the new DNA 
polymerase and reconfigure the assay conditions for the fungal probe suite.  
 
The MgCl2 concentration was varied alone in the initial experiments (i.e. the 
Illustra Taq DNA polymerase was still used) and figure 3.6 shows the results 
of a MgCl2 titration experiment.  The results clearly showed that as the 
amount of MgCl2 was increased in the experiment so too did the current 
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Figure 3.6.  Mean currents from assays testing different concentrations of MgCl2 added to the PCR 
reactions using Illustra Taq DNA polymerase.  Error bars represent SD (n=3). 
      
produced when target DNA was present and the mean currents ranged 
between 62.1 ± 3.6nA at 1.5mM MgCl2 and 158.3 ± 2.6nA at 4mM MgCl2.  
The currents produced by the DNA-free samples did not behave in the same 
way, however.  There was an initial increase from 47.3 ± 4.7nA to 78.6 ± 
8.6nA when the MgCl2 concentration was increased from 1.5mM to 2mM and 
this ~30nA increase was similar to the increase observed in the corresponding 
target-containing samples.  However, when the MgCl2 concentration was 
increased from 2.0mM to 3.0mM the mean background current actually 
decreased to 47.9 ± 3.8nA while the target-containing sample increased by 
~46nA from 96.9 ± 6.3nA to 142.4 ± 3.4nA.  When the MgCl2 concentration 
was increased to 4.0mM the background signal was again increased by 
~30nA to 75.7 ± 13.4nA and the target-containing sample increased by only 
~16nA to 158.3 ± 2.6nA.  The reason for the variation observed in the DNA-
free samples was unclear and, in fact, only the result produced by the 
samples containing 3mM MgCl2 was anomalous, the others gradually 
increasing as MgCl2 concentration increased.  Such an increase might be 
explained by a combined effect of both increased activity of T7 exonuclease 
as the MgCl2 concentration was increased to the optimum concentration of 
5mM suggested by Kerr and Sadowski (1972), as well as the increased 
formation of weakly bound primer:probe heteroduplexes.  Fig 3.7 shows 
potential primer:probe interactions which, if formed during the assay, would be 
suitable targets for digestion and subsequent release of a ferrocene-labelled  
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Figure 3.7.  Possible primer:probe duplexes with probe CA PR3 and primers ITS3 and ITS4. 
  
mononucleotide by T7 exonuclease.  Such interactions would be more likely 
to occur in conditions of reduced stringency which would result from 
increasing the amount of MgCl2 in PCR. 
 
Ultimately, the reasons for the behaviour of the background current are 
unknown and were not investigated any further.  A concentration of 3mM 
MgCl2 was incorporated into the remaining assays to be carried out with 
Illustra Taq DNA polymerase and CA PR3 as this gave the best 
signal:background ratio and meant that the fungal assay conditions were 
more similar to the conditions used routinely by researchers at Atlas Genetics. 
 
The assay also had to be optimised for use with the Jumpstart Taq DNA 
polymerase and another MgCl2 titration experiment was performed to find the 
optimum concentration to work alongside this enzyme.  A range of MgCl2 
concentrations of 1.5mM, 2mM, 3mM and 4mM were used in PCR with 
Jumpstart Taq polymerase and target DNA detected with CA PR3.  The mean 
currents obtained are shown in fig 6.8 and were 19.7 ± 2.5nA, 57.5 ± 4.1nA, 
119.7 ± 13.6nA and 145.3 ± 12.9nA for 1.5mM, 2mM, 3mM and 4mM 
respectively.  This again demonstrated the general trend that increasing 
MgCl2 led to an increase in current.   
 
Since MgCl2 is important for the T7 exonuclease stage of the assay as well as 
PCR, and the optimal MgCl2 concentration for this enzyme has been reported 
to be 5mM (Kerr & Sadowski, 1972), the possibility that simply adding 
additional MgCl2 to assay samples post-PCR to increase the MgCl2  
ITS3:  3′ CGACGCAAGAAGTAGCTACG 5′ 
       |||| | 
CA PR3:             5′ ATCGCTTTGACAATGGCTTA 3′ 
ITS4:         3′ CGTATAGTTATTCGCCTCCT 5′ 
                     |||  |  |   | | 
CA PR3:       5′ ATCGCTTTGACAATGGCTTA 3′ 
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Figure 3.8. Mean currents produced by assays using Jumpstart Taq and different concentrations of 
MgCl2 present in the PCR mix.  The concentrations in parentheses indicate the final concentration of 
MgCl2 in the assay following addition of 5µl probe-T7 mix to 20µl PCR product.  The error bars represent 
standard deviation from the mean (n=3). 
 
concentration to the optimum amount for T7 activity was investigated.  Since 
the assay conditions when using Jumpstart DNA polymerase required a 50µl 
reaction it was possible to carry out a direct comparison using the remaining 
PCR products from the titration experiment described above and supplement 
them with additional MgCl2 and perform a direct comparison of mean current 
generated by the assays to test this theory.  The mean currents generated by 
the samples supplemented with additional MgCl2 (Fig 3.9) showed an 
increase in signal up until the point where 3.2mM MgCl2 (2.4mM + 0.8mM 
supplemented) was present in the reaction with mean currents of 17.5 ±2.2nA, 
50.3 ± 5.2nA and 82.2 ± 10.4nA being produced.  The signal then decreased 
to 64.9 ± 4.1nA when 4.0mM MgCl2 was present in the reaction (3.2mM ± 
0.8mM MgCl2 added post-PCR).  The mean currents produced by samples 
which were supplemented with MgCl2 produced similar levels of current at 
1.2mM and 1.6mM MgCl2: 17.5 ± 2.2nA and 50.3 ± 5.2nA respectively 
compared with currents of 19.7 ± 2.5nA and 57.5 ± 4.1nA produced by the 
equivalent, unsupplemented samples.  However, when the samples 
containing 2.4mM and 3.2mM MgCl2 in the PCR reaction were supplemented 
with MgCl2 they produced currents of 82.2 ± 10.4nA and 64.9 ± 4.1nA 
respectively, compared with currents of 119.7 ± 13.6nA and 145.3 ± 12.9nA 
produced by the equivalent, unsupplemented samples.  This result clearly  
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Figure 3.9.  Mean currents produced by samples with additional MgCl2 added post-PCR compared to 
samples with no additional MgCl2.  The MgCl2 concentration has been calculated following dilution of 
20µl PCR product with 5µl probe-T7 exonuclease.  The DNA-free samples all produced zero current and 
are not shown.  Error bars represent SD (n=3). 
 
indicated that addition of MgCl2 post-PCR in fact had a detrimental effect on 
the level of current produced.  This was an unexpected result and one that 
could not be readily explained.  Further investigation into these phenomena 
was not carried out due to time constraints. 
 
The general trend was that increasing MgCl2 concentration increased the 
current produced in the assay.  It was unclear whether this effect was due to 
improved amplification in the PCR or improved digestion of bound probe – or 
a combination of these processes.  Addition of MgCl2 after PCR was complete 
actually produced lower currents compared to untreated samples with the 
same initial amount of MgCl2.  This happened in spite of the fact that the total 
MgCl2 concentration had not exceeded the optimum amount for T7 activity 
and was in fact closer to this level than the untreated samples.  It is likely that 
further investigation would cast light on which process is the more reliant on 
MgCl2 and establish a way to optimise the amount of Mg
2+ ions available to 
each stage of the reactions.  For the purposes of developing and testing the 
probes a concentration of 3mM MgCl2 added to PCR was used. 
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3.3 Ferrocene-labelled probes 
3.3.1  Probe Optimisation. 
 In the assay, the ferrocene labelled probe is added to the PCR 
products alongside T7 exonuclease and the hybridisation reaction and the 
digestion of dsDNA occur simultaneously at 37°C which is the optimum 
temperature for T7 exonuclease activity.  The signal generated by the assay 
is dependent on a number of factors, the most important of which is probe 
concentration - if too little probe was added this would limit the amount of 
ferrocene liberated by exonuclease digestion and lead to generation of a 
suboptimal signal, if too much was added then the background signal 
produced by oxidation of undigested probe would mask the signal produced 
by samples with target DNA.  Performing experiments to optimise probe 
concentration for the fungal probe assay provided an opportunity to study how 
probe concentration affected the current produced by the assay.  
 
Initial experiments at Atlas had been carried out using 3µM of probe.  In order 
to find the optimum probe concentration for the fungal detection assay a 
titration experiment was set up using a range of probe concentrations from 
500nM to 5µM.  The mean currents produced are shown in figure 3.10.  As 
expected there was an increase in current as the probe concentration 
increased and a plateau in current was observed at probe concentrations of 
3.5µM and above.  This was also true for the DNA-free samples which 
measured the background current produced due to oxidation of undigested 
probe molecules in the reaction.  Although their distribution was a little more 
variable the signal reached a plateau at probe concentrations of 3.5µM and 
above.  At all concentrations tested the samples with target present produced 
higher levels of current than the same amount of undigested probe with the 
ratio of signal to background varying between 2.4 to 4.4; the probe 
concentration that gave the highest ratio was 2.5µM and this concentration 
was incorporated into the initial assay conditions. 
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Figure 3.10.  Mean currents produced in the probe titration assay using probe CA PR.  Error bars 
represent SD (n=4). 
 
3.3.2  Assay signal vs. background signal 
 The results in fig 3.10 raised an interesting question – why is the value 
of current less when an undigested probe is present in the reaction compared 
to the same amount of digested probe?  In other words, what is the 
mechanism by which the assay distinguishes between samples with no target 
DNA present and assays with target?  The working model of the assay 
assumes that there are two species of molecule capable of producing current.  
The first are the undigested ferrocene-oligonucleotide molecules and the 
second are the ferrocene-mononucleotide molecules produced following 
digestion of bound probe molecules by T7 exonuclease.  The model predicts 
that there are a number of potential reasons which could account for the 
observed difference in current.  The first is that oxidation of ferrocene is 
dependent on the surrounding atoms and the ferrocene label at the end of an 
oligonucleotide would exhibit less efficient transfer of electrons due to 
interference from the molecules of DNA.  Unfortunately such considerations 
are the remit of electrochemists to study and experimental investigation of this 
possibility was considered beyond the scope of this work. 
 
The second theory relies on the importance of diffusion of electro-active 
molecules to the electrode surface in the production of current.  It postulates 
that the smaller ferrocene-mononucleotides can diffuse more efficiently 
through the reaction medium than the bulkier, intact ferrocene-
oligonucleotides.  Since the current produced is dependent on the number of 
ferrocene molecules present at the electrode surface and there will be more of  
  - 44 - 
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
20 mins in
tube, no
diffusion
20 mins on
electrode
diffusion
30 mins in
tube, no
diffusion
30mins on
electrode
diffusion
20mins in
tube, no
diffusion
20 mins on
electrode
diffusion
Background Initial
Measurement
Background + 10mins C. tropicalis 4pg DNA
C
u
rr
e
n
t 
(n
A
)
 
Figure 3.11.  Mean currents produced by assays testing the effect of on-electrode incubation with probe 
CT PR.  The error bars represent SD (n=3). 
 
the fast diffusing ferrocene-mononucleotide molecules present compared to 
undigested probe molecules over the same time period, the samples with 
digested products produce a higher signal.  If diffusion is indeed a key factor 
for current production then allowing the undigested probe extra time to diffuse 
to the electrode surface should result in an increase in current compared to 
time zero.  An assay was set up in which the probe hybridisation and T7 
digestion of some of the PCR products was carried out directly on the  
electrode for 20mins before measurements were taken and some products 
were incubated at room temperature (which allowed extra time for diffusion to 
occur) for a further 10mins before currents were measured.  The currents 
produced by these samples were compared to samples which had the 
hybridisation-digestion reaction occur in a test tube and the products applied 
to an electrode and measured immediately.  The results are shown in fig 3.11 
and showed that there was a connection between increased incubation on the 
electrode and increased current.  Target-free background samples that were 
incubated in tubes and electrochemically analysed as soon as they were 
pipetted onto the electrode produced a mean current of 8.7 ± 2.2nA compared 
a value of 82.2 ± 4.7nA for samples that had been incubated onto an 
electrode for 20mins.  The mean currents obtained following incubation of 
samples for a further 10mins at room temperature showed a significant 
increase in mean current for the samples incubated on electrodes with a 
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mean current of 180.3 ± 33.9nA being produced (P<0.05).  The samples 
incubated in tubes produced a mean of 8.0 ± 1.1nA.  When samples 
containing target DNA were incubated in tubes they produced a mean current 
of 76.9 ± 8.2nA compared to 328.0 ± 15.6nA for samples incubated for 
20mins on the electrode (P<10-5). 
 
The results demonstrated that incubation of samples on the electrode had a 
highly significant effect on the value of current produced.  This effect was 
likely to be due to increased diffusion of ferrocene-labelled molecules to the 
electrode surface.  The times allowed for the products of the reaction to 
diffuse to the electrode surface were still not enough to allow diffusion of all of 
the undigested ferrocene-labelled oligonucleotides and there was still a 
difference between the background signal and the signal produced when 
target DNA was present.  Fig 3.11 shows that it took 20mins of on electrode 
incubation (i.e. 20mins of diffusion) with undigested probe to produce the 
same level of current as digested products applied to the electrode and 
measured immediately.   
 
If the difference in current between the intact probe vs. digested probe was 
entirely due to diffusion then it follows that, given enough time for undigested 
products to diffuse to the electrode surface, the background current would be 
equal to the current generated by digested products.  This experiment was not 
attempted but would confirm the extent to which diffusion plays a role in 
generation of signal in the assay.  
 
3.4 T7 exonuclease digestion 
 T7 exonuclease is a double stranded DNA-specific exonuclease which 
digests dsDNA in a 5′ → 3′ direction to produce mononucleotides. Prior 
experimentation by Atlas Genetics researchers had led to the standard 
practice of using 10U of T7 exonuclease in the hybridisation/digestion stage of 
the assay.  While the exonuclease activity was reported as being specific only 
to dsDNA it was prudent to confirm this experimentally as any ssDNA activity 
could be responsible for digestion of unbound probe and the production of 
background signal in target-free reactions and such a finding would be of  
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Figure 3.12.  Mean currents produced in assays testing the ability of T7 exonuclease to digest unbound 
probe in the Illustra Taq PCR buffer.  Error bars represent SD (n=4). 
 
consequence to the assay.  Assays were set up with 3µM CA PR added to the 
1X IllustraTaq PCR buffer solution and different amounts of T7 exonuclease 
added to the reactions.  The background signal was provided by assays with 
no added T7 exonuclease and was measured to be 112.9 ± 3.6nA (fig 3.12).  
Assays which had 2U, 10U and 30U of T7 exonuclease added gave mean 
currents of 116.2 ± 24.9nA, 120.0 ± 7.6nA and 93.9 ± 0.7nA respectively.  
There was no significant difference between the mean currents produced 
when no T7, 2U of T7 and 10U of T7 were present in the assay.  When 30U of 
T7 was present the mean current was significantly lower than the background 
value (P<0.001).  One possible reason for this was that a change in the 
reaction constituents caused by the glycerol and other compounds present in 
the T7 exonuclease storage buffer were present in sufficient quantities to  
inhibit the diffusion of the electroactive molecules.  This possibility is 
discussed in more deteail in section 6.X.  Regardless, the results 
demonstrated that there was no ssDNA activity associated with T7 
exonuclease and it was not involved in production of background current. 
 
3.5 Reduced background due to alternative reaction conditions 
 Researchers at Atlas Genetics had optimized a new set of PCR 
conditions for the assay that minimized the background signal reducing it to 
zero.  The new conditions involved using a PCR buffer made in-house (see 
chapter 2 for details) and a different Taq DNA polymerase (Jumpstart, Sigma).  
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Figure 3.13 shows example currents of assays using the old PCR conditions 
vs. the new conditions to demonstrate the zero background current. 
 
The reasons for the reduction of the background signal are not known.  It was 
noted that the Jumpstart enzyme storage buffer contained a number of 
surfactants which may have affected the reaction matrix, inhibiting the 
diffusion of the undigested probe to the electrode, although the value of 
current obtained with target-containing samples was not diminished, as would 
be expected if this was the sole reason for the removal of the background 
signal.  The effect of surfactants was briefly explored and the findings are 
presented in section 7.2 though the surfactants used were not of the same 
type or at the same concentration as would have been in the Jumpstart 
reaction conditions so the results are not comparable.  Although it would have 
been of interest to thoroughly investigate this issue, understanding every 
aspect of the assay was not absolutely necessary (nor could enough 
resources be channelled into a proper investigation) and the fact remained 
that the output had been vastly improved by this modification.   
 
 
 
 
 
 
 
 
A B 
Figure 3.13.  Voltammograms comparing the background signal produced by (A) the old PCR 
conditions (using Illustra Taq DNA polymerase) vs. (B) the new PCR conditions (using Jumpstart 
DNA polymerase). 
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3.6 Bioinformatics analyses. 
3.6.1 Phylogenetic analysis 
 It was considered advantageous to the project if a rapid means of 
assessing ITS2 regions of non-target species for potential cross-reactivity with 
the species-specific probes could be developed.  Constructing phylogenies 
based on ITS2 sequence data was a potential means to do this but was far 
from a foolproof solution.  The problem was that phylogenies makes use of 
the sequence data as a whole and the inferred relationships may not reflect 
the presence of localized sequences of high similarity that may represent a 
potential ‘false’ probe binding site.  Figure 3.14 shows one such phylogeny 
based on ITS2 data from 36 species which places C. glabrata relatively 
distantly from C. famata and C. guilliermondii – the two cross-reacting 
species.  If potential targets for cross-reactivity with the CG PR probe were to 
be chosen based on the data in figure 3.12 then the species C. bracarensis, 
C. kefyr and Saccharomyces cerevisiae would be the most likely suspects.  
While C. bracarensis and S. cerevisiae had not yet been tested, it had been 
shown that C. kefyr did not cross react with CG PR.  A more specific method 
was therefore required to reliably identify localized areas of sequence in non-
target species which had high similarity to probe binding sites and might 
cause a false positive result to be obtained. 
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Figure 3.14.  Maximum parsimony phylogeny based on a matrix of 47 fungal ITS2 sequences from 36 
species.  The consensus tree is shown. 
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3.6.2  Use of the BLAST algorithm. 
 A more effective method was to use the BLAST algorithm to query a 
database of all of the fungal ITS2 sequences from the matrix used to 
construct fig 3.14 with another database made of all of the probe sequences.  
The output from the BLAST search indicated all of the species which 
possessed localized regions of sequence with high similarity to the probe 
sequences for all of the species.  The results (table 3.1) were much easier to 
interpret than a phylogeny and could be used to identify the potential cross-
reacting binding site and check it against the entirety of the probe sequence to 
ascertain the likelihood of cross-reactivity occurring.   The results identified a 
number of species were that could potentially cross-react with CG PR: C. 
guilliermondii, C. famata, S. cerevisiae, C. pelliculosa, C. bracarensis and C. 
zeylanoides.  C. guilliermondii and C. famata had already been found to cross 
 
Table 3.1.  Part of the BLAST output of the CG PR probe when queried against the database of fungal 
ITS2 sequences.   
Probe Query Species Total  matches E-value Bit Score 
CG_PR Cglabrata_RA39_1mis_1indel 25 1.90E-10 50.05 
CG_PR Cglabrata_CBS138 25 1.90E-10 50.05 
CG_PR Scerevisiae 15 1.80E-04 30.23 
CG_PR Cbracarensis_AY589573.2 15 1.80E-04 30.23 
CG_PR Czeylanoides_HPA1 17 0.674 18.33 
CG_PR Cpelliculosa_HPA1 17 0.674 18.33 
CG_PR Cfamata_UBCC4223_1_mis 17 0.674 18.33 
CG_PR Cfamata_CBS767 17 0.674 18.33 
CG_PR Cguilliermondii_CBS566 17 0.674 18.33 
CG_PR F.oxysporum_1106 8 2.7 16.35 
CG_PR F.oxysporum_1106 7 10.5 14.37 
CG_PR Cr.albidus_voucher_MCCC2E00 8 2.7 16.35 
CG_PR Rhizomucor_pusillus_CBS354.68 8 2.7 16.35 
CG_PR Absi.corymbifera_FSU787 8 2.7 16.35 
CG_PR Ctropicalis_RA122_2indels 8 2.7 16.35 
CG_PR Ctropicalis_RA122_2indels 7 10.5 14.37 
CG_PR Ctropicalis_RA122_2indels 7 10.5 14.37 
CG_PR Ctropicalis_RA1484_1indel 8 2.7 16.35 
CG_PR Ctropicalis_RA1484_1indel 7 10.5 14.37 
CG_PR Ctropicalis_RA1484_1indel 7 10.5 14.37 
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react with the CG PR probe (see section 4.3.3 below) but the other species 
had not been examined. 
 
The e-value and bit score placed S. cerevisiae and C. bracarensis above the 
other species even though the actual number of matched base pairs was 
lower in the former species.  This raised the question of which statistic was 
the most useful for predicting cross-reactivity and to answer this, assays with 
the CG PR probe were performed using PCR products amplified using DNA 
from S. cerevisiae, C. pelliculosa and C. zeylanoides (DNA from C. 
bracarensis was not available for the experiment).   
 
The mean currents are shown in figure 3.15 and indicate that cross reactivity 
was observed between the species tested and CG PR.  The background 
current was measured at 25.3 ± 7.2nA while the mean currents for the non-
target species were 52.3 ± 2.3nA (C. zeylanoides), 67.0 ± 7.8nA (C. 
pelliculosa) and 49.2 ± 3.2nA (S. cerevisiae) and these compared to a signal 
of 82.9 ± 6.7nA obtained by the assays with C. glabrata.  These results were 
confirmation that a BLAST query could identify species likely to cross-react 
with a probe.  Table 3.1 showed that the potential probe binding site in S. 
cerevisiae had the lowest e-value out of all of the species tested, while the 
data for the binding sites present in C. pelliculosa and C. zeylanoides were 
the same.  However, C. pelliculosa produced the highest mean signal out of 
the three species while the values obtained by C. zeylanoides and S. 
cerevisiae were very similar.  It was possible that differences in the production 
of amplicon in the PCR stage was a factor in the production of different levels 
of current In assays with amplicon from these species, particularly as the 
amount of template DNA added to each reaction was not standardized.    
Hence no solid conclusions can be made as to the predictive power of the 
BLAST search results in respect of the level of signal in the assay, only that it 
can indicate potential cross-reactivity which is still of immense use in itself. 
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Figure 3.15.  Mean currents produced by assays using the CG PR probe to detect DNA from potentially 
contaminating species.  Error bars represent SD (n=4). 
 
Of the other probes that were used to query the ITS2 matrix CA PR3 and CK 
PR generated results that suggested potential for cross-reactivity with non-
target species; a region within the C. dubliniensis ITS2 sequence was 
identified which shared 14bp (70% similarity) with the CA PR3 probe and 
regions within the C. inconspicua and P. fermentans ITS2 sequences were 
identified which shared 10bp (40% similarity) and 12bp (48% similarity) with 
the CK PR probe.  Section 4.3.2 shows the results obtained when the CA PR3 
probe was tested with a number of Candida species including C. dubliniensis 
and demonstrates that no cross-reactivity was observed.  Further assays were 
performed with the CK PR probe and the potentially cross-reacting species; 
as well as the usual DNA-free negative and target-containing PCR positive, a 
non-target negative sample was included in the form of assays performed on 
products amplified from C. tropicalis DNA.  The results produced were much 
lower than expected for all species tested (fig 3.16) with the mean current 
produced by the target-containing samples reaching only 10.1 ± 0.8nA.  The 
background signal produced by the DNA-free sample was measured at 5.1 ± 
1.0nA while the non-target negative produced a signal of 3.8 ± 1.2nA.  The 
potentially cross-reacting species, P. fermentans and C. inconspicua 
produced mean currents of 4.6 ± 0.6nA and 6.0 ± 2.6nA respectively.  These 
values were not significantly different to the background, suggesting that 
cross-reactivity with these species was not likely to be a problem.  The results 
should be treated with caution, however, due to the anomalous values of  
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Figure 3.16.  Mean currents produced by assays with probe CK PR and a number of non-target species.  
Note the anomalously low values of current produced by all samples in the assays.  Error bars represent 
SD (n=4). 
 
current that were obtained.  Replication and possible further experimentation 
were not able to be performed due to time constraints. 
 
The results of the BLAST query performed using the other probes (including 
the redesigned C. glabrata specific probe, CG PR3) indicated that cross-
reactivity was unlikely to occur with any of the species represented in the ITS2 
sequence matrix (data not shown). 
 
3.6.3 Use of BLAST query output to inform probe design. 
 The experiments described above for the probe CG PR provide some 
support for the notion that cross-reactivity is a potential problem only when the 
percentage of matching bases is above a certain percentage, but that is not 
the whole story.  As stated above, the BLAST query identified that the CA 
PR3 probe had a 70% similarity to part of the C. dubliniensis ITS2 region, 
which was more than the similarity of CG PR to C. guilliermondii or C. famata, 
but the CA PR3 probe did not cross-react.  This showed that it was not just 
the number of bases that was important, but the position of matching bases 
played a major role in cross-reactivity.  For example, in the C. dubliniensis 
ITS2 there is a region in which 14 out of 20 bases match the CA PR3 probe 
binding site but, crucially, the first three bases at the 5′ end were mismatched.  
It was thought likely that this is what prevented the CA PR3 probe giving a 
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positive signal with C. dubliniensis.  Conversely, in the cross-reacting species 
C. guilliermondii and C. famata there are 17 and 18 matched bases to the CG 
PR probe binding site and the first seven of the 5′ bases are an exact match 
to the sequence of CG PR and these non-target species produce a relatively 
high current when assayed with this probe (see chapter 4).  Figure 3.17 
shows the potential binding site in the ITS2 regions of C. pelliculosa and C. 
zeylanoides where it can again be seen that the first six or seven of the 5′ 
bases respectively are an exact match to the probe sequence. 
 
The observations made above suggest that it is the identity of the initial bases 
at the 5′ end of the probe sequence that determine whether cross-reactivity is 
likely to occur or not.  The ‘total matches’ statistic from the BLAST output is 
probably the most useful statistic to use to decide if a probe may cross-react 
with a non-target species, since a greater number of matching nucleotides 
increases the probability that there will be matches at the 5′ end of the probe 
and non-target binding site.  Although the conclusion is by no means cast-iron 
there is compelling evidence in support of it and, if it can be more strongly 
supported, it would allow greater freedom in designing probes for new target 
species as only the first few bases need be mismatched to non-target species 
in order to ensure specificity of the probe in the assay. 
 
The use of the BLAST algorithm to query the fungal ITS2 sequence matrix 
with the probe sequences was an extremely useful method to establish non-
target species that could potentially give false positive results with a given 
probe and the sequence data could then be examined further to examine the 
exact nature of the similarities. 
 
C. pelliculosa  5′ TAGGTTCTTCCAACTCGTTATATCA 3′ 
                      |||||| | |||||||| | |   
CG PR         5′ TAGGTTTTACCAACTCGGTGTTGAT 3′ 
 
C. zeylanoides  5′ TAGGTTTATCCAACTCGTTGACCAG 3′ 
       |||||||  |||||||| ||   | 
CG PR    5′ TAGGTTTTACCAACTCGGTGTTGAT 3′ 
 
Figure 3.17.  Potential probe binding sites of C. pelliculosa and C. zeylanoides to the C. glabrata-
specific probe CG PR. 
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3.7 Design of the panfungal probe, PanF PR using bioinformatics. 
 As well as screening species specific probes to detect potential cross-
reactivity, the BLAST strategy could be used to rapidly screen probes 
designed to detect multiple species.  When attempting to design a probe 
capable of detecting DNA from any fungal species this approach was used to 
confirm the ability of potential panfungal probe sequences, which had been 
designed by eye, to include all of the pathogenic fungal species for which 
sequence data had been acquired and at the same time confirm that it should 
exclude non-target species i.e. human.   
 
The probe, designated PanF PR, was designed to the 18s rRNA gene and 
was initially designed by eye using a matrix of sequences from mainly 
pathogenic yeasts but that also included sequences from pathogenic 
Aspergillus species and the human 18s rRNA sequence.  It was not easy to 
locate a suitable conserved sequence in the rRNA genes and the probe 
sequence was not a perfect match to any of the sequences, but was designed 
with as few mismatches as possible.  In order to confirm its similarity to a 
wider range of fungi more 18s sequences from pathogenic fungi were 
incorporated into the sequence matrix as well as sequences from eukaryotic 
pathogens of humans that may be found in blood: Plasmodium vivax, 
Trypanosoma brucei gambiense and T. brucei rhodesiense and this expanded 
sequence database (26 fungal + 4 non-fungal sequences) was queried using 
the potential PanF PR sequence.  Part of the BLAST output is shown in table 
3.2, showing all 26 fungal sequences giving matches  which ranged from 22 
matching bases (100% similarity) to 17 matches (77% similarity).  The only 
non-target species that was included in the output was for Plasmodium vivax 
which produced a weak hit of 11bp on the opposite strand (data not shown).  
The probe binding sites for the species included in the query matrix are shown 
in fig 3.18.  One of the most common mismatches was at the second position 
which was a guanine residue in the probe sequence but was an adenine 
residue in 14 out of the 26 fungal species.  Since this polymorphism was 
present at the critical 5′ end of the target site there was a chance that the 
probe wouldn’t bind efficiently.  However, as mentioned previously, the CK PR 
probe had a greater number of mismatches at its 5′ end but was still capable  
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Table 3.2. Output from the BLAST search performed using the PanF PR probe as a query sequence, 
sorted by decreasing number of base pair matches.   
Species 
Total 
matches 
% total 
matches Species 
Total 
matches 
% total 
matches 
Lomentospora prolificans 22 100 Candida_zeylanoides 21 95 
Candida_inconspicua 21 95 Cryptococcus_curvatus 21 95 
Candida_pelliculosa 21 95 Ajellomyces_capsulatum 21 95 
Candida_glabrata 21 95 Penicillium sp 20 91 
Candida_parapsilosis 21 95 Scopulariopsis brevicaulis 20 91 
Candida_tropicalis 21 95 Candida_lusitaniae 20 91 
Candida_albicans 21 95 Yarrowia_lipolytica 20 91 
Kluyveromyces_marxianus 21 95 Cryptococcus_neoformans 20 91 
Pichia_guilliermondii 21 95 Aspergillus_terreus 19 86 
Candida_dubliniensis 21 95 Aspergillus_fumigatus 19 86 
Debaryomyces_hansenii 21 95 Fusarium_solani 19 86 
Issatchenkia_orientalis 21 95 Saksenaea_vasiformis 17 77 
Saccharomyces_cerevisiae 21 95 Rhizopus oryzae 17 77 
 
 
of differentiation between target and non-target containing samples.  Given 
the difficulty of finding conserved panfungal sequences it was decided to 
obtain the probe and test it experimentally.  In addition to the probe sequence, 
fungal specific primers had to also be designed to amplify the target site.  
Again, there was difficulty in designing these to be panfungal but appropriate 
sequences were found which differed sufficiently at their 3′ ends to exclude 
the non-target species from being amplified while including all fungi for which 
sequence data had been acquired.  A number of primers were able to be 
designed by eye and after pair-wise primer trials the pair 18sF2 and 18sR4 
(table 2.2) were determined to be the most successful and were used in 
assays with the PanF PR probe. 
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PanF_PR                         GGTGATTCAT AATAACTT-- ---TTCG 
C. albicans     .A........ ........-- ---.... 
C. glabrata     .A........ ........-- ---.... 
C. parapsilosis     .A........ ........-- ---.... 
C. tropicalis           .A........ ........-- ---.... 
C. krusei     .A........ ........-- ---.... 
C. dubliniensis    .A........ ........-- ---.... 
C. lusitaniae    .A........ ........-- ---G... 
C. famata     .A........ ........-- ---.... 
C. kefyr     .A........ ........-- ---.... 
C. guilliermondii    .A........ ........-- ---.... 
P. anomala     .A........ ........-- ---.... 
C. zeylanoides    .A........ ........-- ---.... 
C. lipolytica             .......... ....T...-- ---G... 
C. inconspicua            .A........ ........-- ---.... 
Saccharomyces cerevisiae  .A........ ........-- ---.... 
Aspergillus fumigatus   .....A.... ........-- ---AA.. 
A. terreus     ......C... ........-- ---AA.. 
Cryptococcus neoformans   .....A.... ........-- ---C... 
Cr. curvatus        .......... ........-- ---C... 
Fusarium solani    .......... G......C-- ---C... 
Saksenaea vasiformis           .....C.... .....T..-- ---AG.T 
Rhizopus oryzae    .....A.... .....T.A-- ---AG.. 
Penicillium sp.     .......... ........-- ---CA.. 
Ajellomyces capsulatum   .......... ........-- ---G... 
Scopulariosis brevicaulis  .......... .......G-- ---G... 
Lomentospora prolificans  .......... ........-- ---.... 
Human      .....C..TA G.....C.CG ---GG.C 
Plasmodium vivax    A.G..A.T.. ..C..AGAAG TGACA.. 
Trypanosoma brucei rhodesiense .T...C...A TTC.TTCCG- ---.G.. 
Trypanosoma brucei gambiense  .T...C...A TTC.TTCCG- ---.G.. 
 
Figure 3.18.  Probe binding sites in the 18s rRNA gene of 26 fungal species + 4 non-fungal species. 
  
3.8 Conclusions. 
 The basic model of the assay was introduced and experimental results 
presented which validated this model, at least partially.  The importance of the 
PCR amplification step or, more specifically, the PCR primers, for reliable and 
satisfactory production of signal in the assay was demonstrated and this was 
of major importance for the work into assay sensitivity (chapter 5).  A likely 
mechanism for the differentiation between signal and background was also 
presented which accounts for the results produced by the assay, though it is 
not likely to be only mechanism which exercises an effect on the assay signal 
as there are a number of factors at work which may affect the assay.  
Nonetheless, the assay has been shown to work in principle and the reaction 
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conditions were able to be optimised to yield currents with a relatively good 
signal:noise ratio.   
 
The occurrence of false positive results with the probes was also introduced.  
Thorough initial screening of probes is a necessity to avoid the possibility of 
cross-reactivity leading to false positives in later experimentation.  
Phylogenetic reconstructions can indicate sister species based on DNA 
sequence information but this does not necessarily correlate to likelihood of 
cross-reactivity.  A more robust bioinformatic approach to probe design was 
therefore developed that could be employed to rapidly screen probes to 
ensure specificity.  Furthermore, it was shown that this method could also 
inform novel probe design by ensuring that target species could be detected.  
A panfungal probe was able to be designed using this method.  Having 
established the model and experimental conditions for the assay the next 
stage in the development was to test the species-specific probes and the 
newly-designed panfungal probe experimentally to ensure their specificity and 
sensitivity.   
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Chapter 4 - Specificity of the probes. 
4.1  Introduction. 
 For a diagnostic test it is essential that probes be specific to their target 
– detection by a probe of non-target species is unacceptable as it represents 
a failure of the probe to detect a single target species and, particularly in the 
case of diagnosis of invasive Candida infections, could lead to inappropriate 
antifungal therapy being administered with possibly life-threatening 
consequences.  For an end-point PCR hybridization assay such as the Atlas 
electrochemical assay the specificity lies in the choice of DNA target and can 
be built into either or both the primers used in PCR amplification and the 
probe molecule.   
 
The remit of the species-specific part of the detection assay was to be able to 
detect DNA from the five most clinically relevant species of Candida.  There 
are many potential DNA regions that could be targeted for species-specific 
probes but it was decided that the ITS2 region of the rDNA genes, with its 
repeated nature and high degree of interspecies variability, would provide the 
necessary specificity for the assay.  Probe sequences specific for C. albicans, 
C. parapsilosis, C. glabrata, C. tropicalis and C. krusei (CA PR, CP PR, CG 
PR, CT PR and CK PR respectively) that targeted this region were acquired 
from Shin et al. (1999).  PCR primers designed to the conserved rRNA genes 
have been used for phylogenetic studies by other researchers (e.g. White et 
al., 1990) and the fungal universal primers ITS3 and ITS4, which amplify the 
ITS2 region (fig 4.1), were used to amplify target DNA for detection with the 
assay.  Species-specific primers could potentially have been designed and 
would have added another layer of specificity to the assay, but would have 
made it more difficult to multiplex the assay.  The use of generic primers 
would also allow additional probes for additional target species to be easily 
incorporated into the existing assay without having to optimize PCR 
conditions for each primer-probe combination. 
 
The first challenge to the assay, therefore, was to test the universal nature of 
the primers alongside the specificity of the probes.  It was of paramount 
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C._albicans_GQ280318.1     CGCATCGATG AAGAACGCAG CGAAATGCGA TACGTAATAT GAATTGCAGA TATTCGTGAA TCATCGAATC TTTGAACGCA 
C._parapsilosis_EU871507.1 .......... .......... .......... ..A....... .......... .......... .......... .......... 
C._glabrata_AB305094.1     .......... .......... .......... ........G. .......... AT.C...... .......... .......... 
C._tropicalis_GQ376071.1   .......... .......... .......... .......... .......... .......... .......... .......... 
C._krusei_L47113.1         .......... .......... .......... ...C..G.G. .........C C..-...... .......G.T C......... 
 
C._albicans_GQ280318.1     CATTGCGCCC TCTGGTATTC CGGAGGGCAT GCCTGTTTGA GCGTCGTTTC TCCCTCAAAC -CGCTG--GG TTTGGTGTTG 
C._parapsilosis_EU871507.1 .......... .T........ .AA....... .......... .....A.... .......... -.TTC.--.. .......... 
C._glabrata_AB305094.1     .......... .......... ...G...... .......... .....A.... CTT....... A..T..--T. ......AG.. 
C._tropicalis_GQ376071.1   .......... .T........ .AA....... .......... .....A.... .......... -.C.C.--.. .......... 
C._krusei_L47113.1         .......... CTC..C.... ...G...... .......... .......... CAT..TGCG. -GTGC.CA.A G....G.--. 
 
C._albicans_GQ280318.1     AGCAATACGA CTTGGGTTT- ------GCTT GAAA-----G ACGGTAGTGG --TA------ --AGGCGGGA TCGC-TTTGA 
C._parapsilosis_EU871507.1 ...G.....- -C.......- ------.... ....-----. .----.---- ---------- --......AG -TA--.AAAC 
C._glabrata_AB305094.1     ..TG....T- -C.C.T...T GAGTTAA... ....TTGTA. G.CA..TCA. TA.GTGGGAC ACGA...CA. G.TTC.C.AT 
C._tropicalis_GQ376071.1   .........- -C.A.....- ------.T.. ....-----. .----.T.-- --..------ --.C.T..A. A.T--.A.TT 
C._krusei_L47113.1         ...GGAG..G ACGAC..G.A AAG--A..G. CGG.-----. CT.CG.C.C. CC.G------ --.AAG..AG CGAAGC.G.C 
 
C._albicans_GQ280318.1     CAATG----- ---------- ---------- GC-TTAGG-- TCTAAC---C AAAAACA-TT GCTTGCGG-- --------CG 
C._parapsilosis_EU871507.1 T....----- ---------- ---------- .A--....-- .T.-TT---T TTTTC..-C. CA..------ ---------. 
C._glabrata_AB305094.1     T...CTGCTG CTCGTTTGCG CGAGCGGCGG .GG...ATAC .G..TTAGGT TTT.C..AC. CGG..TT.AT CTAGGGAGG. 
C._tropicalis_GQ376071.1   T..GC----- ---------- ---------- .AC.....-- .T..T.---. ......G-C. TA..TT---- ---------. 
C._krusei_L47113.1         .G.GC----- ---------- ---------- .AAC...ACT .T.TTT---. .GGG..G-C. TGGC.GC--- --------.. 
 
C._albicans_GQ280318.1     GTA-ACGTCT AC-------- -------CAC GTATATCTTC A-AACTTTGA CCTCAAATCA GGTAGGACTA CCCGCTGAAC 
C._parapsilosis_EU871507.1 ...--.AAAC T.-------- -------..A AC..TCT.C. --..A..C.. .......... .......... .......... 
C._glabrata_AB305094.1     A..AGT.AG. GTTTTGTGCG TGCTGGG..G AC.G.CG.CT TT..G..... .......... ......GT.. .......... 
C._tropicalis_GQ376071.1   C..-GT.G.C ..-------- -------... AAT.TAT... .T........ .......... .......... .......... 
C._krusei_L47113.1         AG.-G..AG. GT-------- -------TG. .-.G.CAACA .A..GC.C.. .......... .......A.. .......... 
 
C._albicans_GQ280318.1     TTAAGCATAT CAATAAGCGG AGGAA 
C._parapsilosis_EU871507.1 .......... .......... ..... 
C._glabrata_AB305094.1     .......... .......... ..... 
C._tropicalis_GQ376071.1   .......... .......... ..... 
C._krusei_L47113.1         .......... .......... ..... 
 
Figure 4.1.  Sequence alignment of the 3′ end of the 5.8s rRNA gene, the ITS2 region and the 5′ end of the 26s rRNA gene of the five Candida target species. 
The binding positions of the ITS3 and ITS4 primers have been underlined. 
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Figure 4.2.  Ethidium bromide gel picture showing PCR amplicons from 10 Candida species using the 
primers ITS3 and ITS4.  DNA from each species was amplified in quadruplicate.  Top row lane 1: 100bp 
ladder; lanes 2-5 No-DNA; lanes 6-9 C. krusei (~350bp); lanes 10-13 C. glabrata (~420bp); lanes 14-16 
C. albicans (~340bp).  Middle row lane 1: 100bp ladder; lane 2 C. albicans (~340bp); lanes 3-6 C. 
parapsilosis (~310bp); lanes 7-10 C. tropicalis (~325bp); lanes 11-14 C. lusitaniae (~255bp); lanes 15-
16 C. famata (~380bp).  Bottom row lane 1: 100bp ladder; lanes 2-3 C. famata  (~380bp); lanes 4-7 C. 
kefyr (~430bp); lanes 8-11 C. dubliniensis (~343bp); lanes 12-15 C. guilliermondii (~380bp). 
 
importance that the probes not cross react with non-target species as they 
were the only component of the assay that provided specificity.  As the 
precision, accuracy and reproducibility of the results produced by the assay 
had not yet been properly validated, there were no discrete criteria by which 
the success or failure of a probe was judged.  Therefore a retrospective 
criterion was established whereby if a positive sample produced a mean 
current that was at least three-fold higher than the highest background it was 
considered to have successfully detected the target species and 
demonstrated specificity. 
 
4.2 Testing the ITS3 and ITS4 primers in PCR. 
 The initial PCR reactions to test the ITS3 and ITS4 primers were set up 
using 1.5mM MgCl2 and the Illustra Taq polymerase and buffer (materials and 
methods section).  These conditions allowed successful amplification of the 
ITS2 region in 10 Candida species tested and an amplicon was produced 
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when both symmetric and asymmetric conditions were used; the size of each 
amplicon corresponded to the expected size based on sequence information 
(fig. 4.2).  The high intensity of the amplicons from all 10 species visualized on 
the agarose gel indicated that the PCR conditions were capable of efficient 
amplification of the ITS2 region from fungal DNA. 
 
4.3 Testing specificity of probes with DNA from type Candida strains. 
 The results from assays with the five species specific probes are 
described in the following sections. The probes performed with varying 
degrees of success and these experiments highlighted different problems with 
probe design.  Of the initial probes that were trialled three produced 
unsatisfactory results for different reasons and the problems which were 
encountered are discussed in the following sections.  Those that gave 
satisfactory results and provided reliable detection of only their target species 
are presented first, followed by the probes that were problematic and required 
further design and/or optimization. 
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Figure 4.3.  Bar graph showing the mean currents produced in assays conducted with CP PR vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=4). 
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Figure 4.4.  Bar graph showing the mean currents produced in assays conducted with CT PR vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=8). 
 
4.3.1 Specificity of probes CP PR and CT PR. 
To test the specificity of the species-specific probes experimentally the assay 
was performed with each of the probes using DNA extracted from 10 type 
strains of Candida species (Table 2.1) as well as a DNA-free negative sample 
which would provide a measure of the background current.  Figure 4.3 shows 
the mean currents obtained with the CP PR probe using the IllustraTaq assay 
conditions.  The mean current produced with the target C. parapsilosis DNA 
was 120.0 ± 33.5nA compared with a background current of 19.0 ± 5.6nA and 
non-target currents of between 13.3 ± 2.7nA and 23.5 ± 7.3nA.  This satisfied 
the criterion of the target mean current being two to three-fold higher than the 
background and indicated that there was no problem as regards cross-
reactivity with non-target species. 
  
The mean results obtained with the C. tropicalis specific probe CT PR against 
the test panel of Candida species were similarly successful (fig 4.4).  The 
mean current produced with target DNA was 156.5 ± 26.7nA which compared 
to a background current of 21.5 ± 5.1nA and non-target currents of between 
24.2 ± 8.4nA and 31.1 ± 8.7nA.  This allowed excellent discrimination between 
the background and non-target signals and the signal produced due to the 
presence of target DNA. 
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The two probes tested above worked well without further optimization and 
were shown to give an excellent current in the electrochemical assay with 
target species with no evidence of cross reactivity with non-target species 
from the Candida test panel. 
 
4.3.2  Testing problematic probes: CA PR.  
 The results of the assay with the C. albicans specific probe, CA PR, 
are shown in figure 4.5.  The mean current produced by the target, C. 
albicans DNA-containing sample was 58.6 ± 2.71nA and this compared with 
values of between 27.5 ± 6.3nA (C. krusei) and 40.5 ± 14.3nA (C. famata).  
The background signal in the assay was 27.47 ± 4.2nA.  The values obtained 
with this probe did not allow significant discrimination between target and non-
target containing samples the problem being that the positive signal was lower 
than observed with the other probes that were considered to be successful.  
The reason for this was unclear as the same ferrocene label had been used in 
the synthesis of this probe as for the others.  However, the CA PR probe did 
differ from the others in that it had been synthesized at a different time.  It was 
decided to have a new batch of the CA PR probe synthesized to see if there 
was a difference between two probes with the same DNA sequence 
synthesized at different times.   
 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
DN
A-
fre
e
C.
al
bi
ca
ns
C.
du
bl
in
ie
ns
is
C.
gl
ab
ra
ta
C.
pa
ra
ps
ilo
sis
C.
tro
pi
ca
lis
C.
kr
us
ei
C.
lu
si
ta
ni
ae
C.
gu
ilie
rm
on
di
i
C.
fa
m
at
a
C.
ke
fy
r
C
u
rr
e
n
t 
(n
A
)
 
Figure 4.5.  Bar graph showing the results of the electrochemical assay with the C. albicans specific 
probe, CA PR, nine other Candida species and DNA-free reactions.  The error bars represent SD (n=4). 
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The newly synthesised probe (which will be referred to as CA PR NEW) was 
used in an assay alongside the old CA PR probe (CA PR OLD) with C. 
albicans DNA to check its performance (figure 4.6).  CA PR OLD produced a 
mean background current of 35.5 ± 7.5nA and a positive signal of 66.9 ± 
0.9nA compared with a background of 61.7 ± 13.1nA and a positive signal of 
73.0 ± 8.0nA with CA PR NEW.  The newly synthesized probe produced a 
slightly higher positive signal but at the cost of producing a background signal 
that was 1.7 times that of the new probe.  Since both probes shared the same 
target site this anomaly was probably associated with the electrochemical 
label, though in what capacity is unknown.  If it is assumed that all of the 
probe binds target DNA and is digested by T7 exonuclease in the assay, the 
results suggested that the label had not been coupled properly to the probe: 
when target DNA is present the probes are completely digested such that all 
of the label becomes free and so similar currents would be produced in the 
assays with target DNA, which was the case.  However, when no target DNA 
is present, the potentially less strongly coupled label on the CA PR NEW 
probe may decouple from the probe and diffuse to the electrode surface, thus 
producing an increased background current compared with the CA PR OLD 
probe. 
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Figure 4.6.  Mean results of the assay comparing the performance of CA PR OLD and CA PR NEW.  
Error bars represent SD (n=4). 
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The anomaly was investigated further using a synthetic target assay, the 
results of which are shown in figure 4.7.  This assay did not support the 
hypothesis of a weakly coupled label on the CA PR NEW probe.  There was a 
significant difference (P<0.01) between the mean current of 511.3 ± 29.3nA 
produced by CA PR OLD and the mean current of 377.9 ± 10.8nA produced 
by CA PR NEW.  The difference between the DNA-free negative currents was 
also significant (P<0.01) but the values only differed by ~23nA: 105.3 ± 4.4nA 
for CA PR OLD vs. 128.0 ± 7.4nA for CA PR NEW.  The relatively similar 
currents produced by the no-DNA negatives combined with the significantly 
lower signal produced by the CA PR NEW probe in an assay with synthetic 
target DNA did not point to the conclusion that unstable label was the cause 
of the strange results obtained with this probe. 
   
The reduced signal produced by the CA PR NEW probe was unexpected and 
upon further investigation it was discovered that the ferrocene label used for 
the synthesis of CA PR NEW was not the same as the label used when CA 
PR OLD was synthesized.  Data obtained by other researchers at Atlas 
Genetics suggested that the label may perform less well than the original label 
used to synthesise CA PR OLD and so the anomalies reported above may 
have been due to batch differences.  
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Figure 4.7. Mean currents from a synthetic target assay comparing CA PR OLD vs. CA PR NEW.  Error 
bars represent SD (n=4). 
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C.albicans_CBS562      TCATCGAATC TTTGAACGCA CATTGCGCCC TCTGGTATTC CGGAGGGCAT GCCTGTTTGA GCGTCGTTTC TCCCTCAAAC 
C.dubliniensis_CBS7987 .......... .......... .......... .......... .......... .......... .......... .......... 
 
C.albicans_CBS562      CGCT-GGGTT TGGTGTTGAG CAATACGACT TGGGTTTGCT TGAAAGACGG TAGTGGT--A AGGCGGGATC GCTTTGACAA 
C.dubliniensis_CBS7987 .C..A..... .......... .......... .......... .......T.A .......AT. ......AGAT ....-..... 
 
C.albicans_CBS562      TGGCTTAGGT CTAACCAAAA ACATTGCTT- -GCGG-CGGT AACGTCCACC ACGTATATCT TCAAACTTTG ACCTCAAATC 
C.dubliniensis_CBS7987 .......... G......... ........AA G....T.TC. GG....GC.. .TT.TAT... .......... .......... 
 
C.albicans_CBS562      AGGTAGGACT ACCCGCTGAA CTTAAGCATA T 
C.dubliniensis_CBS7987 .......... .......... .......... . 
 
Figure 4.8.  Sequence alignment showing the highly similar ITS2 sequences of C. albicans and C. dubliniensis.  The position of the newly designed CA PR2 probe is 
shown by this style of underlining; the newly designed CA PR3 probe binding site is indicated by this style of underlining.
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A further possibility was that the CA PR probe sequence itself could be the 
reason for the low current produced in the assay.  The art of probe design for 
the electrochemical assay has not yet been completely perfected and it was 
not known exactly which features make a good probe for the system.  It was 
decided to design a new C. albicans specific probe, CA PR2, synthesise it 
with a reliable label and test it against the original CA PR OLD probe.  The 
design of new C. albicans specific probes was limited to a very small region 
due to a high degree of similarity of the ITS2 between C. albicans and C. 
dubliniensis (fig 4.8).  However, enough differences were available for the 
design of the probe CA PR2.  Figure 4.9 shows the mean currents generated 
in assays using synthetic target DNA between CA PR OLD and CA PR2.  
 
The mean current produced by CA PR OLD was 613.2 ± 51.5nA compared 
with 213.5 ± 14.2nA produced by CA PR2; the older probe produced an 
almost three-fold higher signal, indicating that the probe redesign had failed to 
yield an improved product.  The CA PR2 probe had been designed to the area 
6bp downstream of the start site of the CA PR OLD binding site and extended 
4bp beyond it.  So the reason for the poor signal produced by CA PR2 
compared with CA PR OLD could not be blamed on the choice of target 
region but must instead be connected with the DNA sequence of the target or 
the ferrocene label itself.  This was not investigated further. 
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Figure 4.9.  Mean currents produced in synthetic assays with CA PR OLD vs. CA PR2.  Error bars 
represent SD (n=3). 
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Since the previous C. albicans specific probes had been designed to a small 
area of the ITS2 region it was decided to design a new probe, CA PR3, to an 
entirely different region of the C. albicans ITS2 region in an effort to obtain a 
probe capable generating satisfactory results (figure 4.8).  Figure 4.10 shows 
the results of an assay with target generated from PCR comparing the CA 
PR3 probe with the CA PR OLD probe.  The CA PR3 probe produced mean 
currents of 76.2 ± 7.1nA and 80.0 ± 20.9nA when target DNA was present 
compared to currents of 46.5 ± 5.4nA and 41.0 ± 3.0nA obtained with CA PR.  
A similar disparity of results was also observed between the currents 
produced with the DNA-free negative samples: 46.4 ± 1.5nA and 23.6 ± 
13.9nA for CA PR3 and CA PR OLD respectively.  The CA PR3 probe gave a 
more satisfactory positive signal than CA PR OLD and it was decided to 
continue with this probe and try and optimize the assay to increase the current 
produced when target DNA was present.  
  
To achieve this it was decided to readdress the issue of MgCl2 concentration 
in the assay.  A 1972 paper by Kerr & Sadowski suggested that the optimum 
conditions for T7 exonuclease activity required a higher concentration than 
the 1.5mM MgCl2 that was used in the assay. 
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Fig 4.10.  Mean currents obtained in electrochemical assays using target obtained by PCR comparing 
the currents generated by CA PR OLD and the newly designed CA PR3.  The error bars represent SD 
(n=3). 
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Figure 4.11.  Mean currents obtained in experiments testing different amounts of MgCl2 in the assay with 
CA PR3.  Error bars represent SD (n=3). 
  
previously.  Figure 4.11 shows the results from an experiment to test the 
effect of different MgCl2 concentrations on the amount of current produced.  
The results were discussed in more detail in Chapter 3 and so will not be 
further explored here.  According to the above results a MgCl2 concentration 
of 3mM gave the best discrimination between background current and the 
current produced by target-containing sample – 47.9 ± 3.8nA vs. 142.4 ± 
3.4nA.  This concentration of MgCl2 was incorporated into future assays with 
the CA PR3 probe and these conditions were used to generate the results of 
the specificity test against nine non-target Candida species which can be 
seen in figure 4.12.  The mean current produced when target DNA was 
present was 162.9 ± 19.6nA compared with a background current of 50.7 ± 
4.2nA and non-target currents of between 45.1 ± 1.5nA and 53.8 ± 6.0nA.  
The differentiation between the signal obtained with target and non-target 
samples was now sufficient and cross-reactivity was not a problem with any of 
the species tested.  The CA PR3 probe was therefore considered to be 
satisfactory. 
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Figure 4.12.  Bar graph showing the mean currents produced in assays performed with CA PR3 vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=3). 
 
4.3.3  Testing problematic probes: CG PR. 
 The C. glabrata specific probe CG PR was tested for specificity 
against the panel of 10 Candida species and the results are shown in figure 
4.13. The mean current produced when C. glabrata DNA was present was 
120.6 ± 21.6nA while the mean background current when no-DNA was 
present was 26.3 ± 7.3nA.  The mean currents produced by non-target 
species ranged between 21.7 ± 5.0nA and 98.9 ± 21.3nA.  The results 
demonstrated that the CG PR probe was cross-reacting with two non-target 
species, C. famata and C. guilliermondii which gave mean currents of 94.6 ± 
14.4nA and 98.9 ± 21.3nA respectively.  Analysis of the ITS2 region of these 
species identified a region of high similarity with the CG PR target site (fig 
4.14) which was most likely the reason for the cross-reactivity.  The C. famata 
target site had 18 matching bases while the C. guilliermondii target site had 
17 matches.  This discovery underlined the importance of extensive 
investigation when determining the specificity of molecular assays.  Shin et al. 
(1999) performed specificity tests with their species-specific probes using only 
the other four clinically relevant Candida species and so did not screen either 
C. famata or C. guilliermondii for cross-reactivity with the C. glabrata-specific 
probe.  This was despite the fact that C. guilliermondii DNA was available and  
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Figure 4.13.  Bar graph showing the mean currents produced in assays performed with CG PR vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=8). 
 
was used to test the efficiency of their Candida genus-specific probe.  The 
result above suggested that Shin’s C. glabrata-specific probe may not have 
been specific.  However, this was not certain as the procedure used in that 
method was fundamentally different and used higher probe annealing 
temperatures which may have preserved the specificity of the probe.  
Fortunately there were other regions available for probe design in the C. 
glabrata ITS2 region that were sufficiently dissimilar to the other species.  
 
The probe CG PR2 was designed to a different region of the C. glabrata ITS2 
which was different between the three species.  Fig 4.15 shows the mean 
currents obtained with this probe in a specificity test against the 10 Candida 
species.  The mean current produced by CG PR2 with target DNA was 77.0 ± 
11.4nA compared with a mean background current of 26.2 ± 6.7nA and non-
target mean currents of between 26.4 ± 2.5nA and 44.8 ± 14.6nA.  These 
results were reasonably good but the signal obtained with target DNA was still 
quite low compared with the signals obtained with the CT PR and CP PR 
probes.  A possible reason for this emerged when it was discovered that the 
CG PR2 probe was not an exact match to the C. glabrata target site.  An error 
made when transcribing the target sequence from MEGA went unchecked 
and meant that cytosine was included as the 5′ terminal nucleotide when it 
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should have been guanine.  As the 5′ nucleotide carries the ferrocene label it 
was conceivable that a mismatch here would have a substantial negative 
effect on the signal generated in the assay.  As a result it was decided to 
design another C. glabrata specific probe to the same target site as CG PR2 
but to extend the probe length by 5bp to make it a similar length to CT PR and 
CP PR.  This probe, CG PR3, was designed in the forward orientation to keep 
the assay straightforward in terms of primer concentrations in asymmetric 
PCR.  Figure 4.16 shows the results from assays with CG PR3 and the test 
panel of 10 Candida species. 
  
The mean current produced by the probe when C. glabrata DNA was present 
was 116.0 ± 47.7nA compared to a mean current of 23.7 ± 4.8nA when no 
DNA was present and mean currents of between 12.1 ± 4.4nA and 28.4 ± 
10.1nA when non-target DNA was present.  These results were excellent and 
demonstrated that there was good discrimination between positive and 
negative samples with no evidence of cross reactivity with any species tested. 
 
4.3.4 Testing problematic probes: CK PR. 
 The CK PR probe initially gave promising results when first tested 
(figure 4.17) where it produced a mean current of 127.0 ± 25.5nA in assays 
with C. krusei DNA compared with a background mean current of 14.9 ± 
5.6nA and mean currents of between 12.6 ± 5.7nA and 24.0 ± 3.8nA in 
assays with non-target Candida species.  However, as time passed and 
further work was conducted on the probe it became apparent that the mean 
current produced by the probe was decreasing.  Figure 4.18 shows the mean 
currents produced by assays with CK PR and C. krusei DNA over time and 
shows a decrease in signal over time with the mean current dropping from 
127.0 ± 25.5nA, when the probe was first assayed, to a low of 10.1 ± 0.8nA 
after 10 months.  The background signal also displayed a decreased signal 
over this time from 14.9 ± 5.6nA to 5.1 ± 1.0nA. 
  - 74 - 
 
 
C.glabrata       GCATCGATGA AGAACGCAGC GAAATGCGAT ACGTAATGTG AATTGCAGAA TTCCGTGAAT CATCGAATCT TTGAACGCAC 
C.guilliermondii .......... .......... .......... .A.....A.. .........T ..T....... .......... .......... 
C.famata         .......... .......... .......... .A.....A.. .........T ..T....... .......... .......... 
 
C.glabrata       ATTGCGCCCT CTGGTATTCC GGGGGGCATG CCTGTTTGAG CGTCATTTCC TTCTCAAACA CATTGTGTTT GGTAGTGAGT 
C.guilliermondii .......... .......... A.A....... .......... .........T C........- .CCC.G.... ....T..... 
C.famata         .......... .......... A.A....... .......... .........T C........- .T.C.G.... ....T..... 
 
C.glabrata       GATACTCTCG TTTTTGAGTT AACTTGAAAT TGTAGGCCAT ATCAGTATGT GGGACACGAG CGCAAGCTTC TCTATTAATC 
C.guilliermondii ........T- ------...C GGAC.----- ---....--- G.TT.CT..A AAAGT.TTG. .ATGG.---- ---------- 
C.famata         ........T- ------...C G.AC.----- ---....--- G.TT.CT..A AATGT.TTG. .ATG..---- ---------- 
 
C.glabrata       TGCTGCTCGT TTGCGCGAGC GGCGGGGGTT AATACTGTAT TAGGTTTTAC CAACTCGGTG T-TGATCTAG GGAGGGATAA 
C.guilliermondii .AG.A..A.A .A.T..TGT. .A.-----C. CTC.A..... .......AT. .......T.. AA..G.G.G. C.G.AT..TT 
C.famata         ..G.A..G.A .A.T..T.TA T.A-----C. TTC.A..... .......AT. .......T.. AA.AG.T..A T.GTAT..TT 
 
C.glabrata       GTGAGTGTTC TGTGCGTGCT GGGCAGACAG ACGTCTTTAA GTTTGACCTC AAATCAGGTA GGGTTACCCG CTGAACTTAA 
C.guilliermondii C.-G..A..G .TG..CC.GC CTTACA...- ..-CAAAC.. .......... .......... ..AA...... .......... 
C.famata         C.CG..A... .AG..TC.GC CTTACA.T.T .A-CAAAC.. .......... .......... ..A....... .......... 
 
Fig 4.14.  Sequence alignment of the ITS2 region of C. glabrata, C. famata and C.guilliermondii.  The target sites of the C. glabrata specific probes are underlined: CG 
PR; CG PR2; and CG PR3.  NB. CG PR2 was designed to target the reverse DNA strand while CG PR3 used the same target sequence as CG PR2, extended by 
5bp at the 3′ end, but was designed to bind to the forward strand. 
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Figure 4.15. Bar graph showing the mean currents produced in assays performed with CG PR2 vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=4). 
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Figure 4.16.  Bar graph showing the mean currents produced in assays performed with CG PR3 vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=3). 
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Figure 4.17.  Bar graph showing the mean currents produced in assays performed with CK PR vs. the 
test panel of 10 Candida species.  Error bars represent SD (n=8). 
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Figure 4.18.  Bar graph showing the mean currents produced in assays performed with CK PR using 
target DNA over a period of 11 months.  Error bars represent SD (n=3 for assay at 2 months, 4 for 
assays at 3, 10 and 11 months, and 8 for assay at 0 months). 
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The trend was not observed with any of the other probes and was unique to 
CK PR.  Since both the background and positive signals were affected the 
problem was likely to be related to the probe and/or the label.  Upon analysis 
of the label using the OligoAnalyser program from Integrated DNA 
Technologies 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx) the 
probe was discovered to possess a degree of self-complementarity and may 
have formed hairpin structures which could have interfered with probe:target 
binding at lower temperatures (fig 4.19). 
 
If formation of this secondary structure was responsible for the decrease in 
signal then it may have been possible to restore the signal by denaturing the 
probe prior to addition to target DNA.  Fig 4.20 shows the currents produced 
in assays using probe that had been denatured for 10s in the presence of 
target DNA amplified using the Jumpstart PCR conditions. 
 
Figure 4.19.  Potential hairpin structure of probe CK PR.  Fc represents the ferrocene label attached at 
the 5′ end of the oligonucleotide.  
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Figure 4.20.  Mean currents produced in assays using heat-denatured probe CK PR compared with 
assays using undenatured CK PR.  Error bars represent SD (n=3). 
 
Denaturation did not have a significant effect on the signal produced by the 
target-containing samples.  It did, however, result in an increase in 
background signal which was probably due to the instability of the ferrocene-
oligonucleotide binding at high temperatures as discussed in chapter 7.  The 
decreased signal was not likely to be due to degradation of the ferrocene label 
as the other probes had been kept under the same conditions as CK PR and 
had not displayed any loss of signal.  Furthermore this decline in signal could 
not be explained by degradation of the probe oligonucleotide as this would 
have resulted in an increase in the background signal as shorter ferrocene-
labelled nucleotde fragments would be present in assays and yield higher 
currents. 
 
Another potentially problematic issue with CK PR was the presence of two 
‘indel’ events in the probe relative to the target sequence.  Fig 4.21 shows the 
alignment of CK PR to its target site where it can be seen that there is a 
missing cytosine at position 3 which causes the sequence to misalign for 4bp 
before inclusion of an extra cytosine at position 6 which brings the remainder 
of the sequence back into alignment.  Had the probes been designed de novo 
this error would not have occurred but the probe sequences were taken  
  - 79 - 
 
 
CK PR:   5′ agtggcccgagcgaactagactttt 3′ 
            ||  | ||||||||||||||||||| 
Target:  5′ agctggccgagcgaactagactttt 3′ 
 
Figure 4.21.  Alignment between probe CK PR and its target site in C. krusei ITS2 region. 
 
directly from the paper by Shin et al. and were assumed to be flawless.  While 
it is a distinct possibility that this pattern of mismatches so close to the crucial 
ferrocene-labelled 5′ end of the probe would have a detrimental effect on 
binding and therefore exonuclease digestion and current production, it doesn’t 
explain why the initial results with CK PR produced satisfactory currents which 
then decreased over a period of months to levels which were approximately a 
tenth of the original values. 
 
The exact cause of the decreasing current levels produced by CK PR was 
never discovered but there were obvious problems with its design that would 
be expected to be detrimental to its performance.  While a new probe could 
have been designed with relatively little difficulty in the ITS2 region, the 
expense of probe synthesis and ferrocene coupling combined with the risk 
that a new probe may not have been satisfactory meant that this was never 
attempted.  The currents with CK PR, while much lower than the other probes, 
were still able to discriminate between background current and current from a 
target-containing sample and were deemed adequate for continued 
investigation. 
 
4.3.5 Testing probes using DNA from clinical Candida isolates 
 All of the above work used the type strain of each Candida species but 
to ensure that the probes could detect wild isolates it was necessary to test 
the assay using DNA from clinical strains of Candida species.  Assays were 
performed using DNA from four wild isolates of the relevant species as well as 
from the type strain and DNA-free samples were also included to produce 
background values for each probe.   
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All species-specific probes were able to detect DNA from wild isolates (Fig. 
4.22).  The currents obtained with the wild isolates were of similar values to 
the currents generated by the type strain of each species, despite the wide 
range of geographical and/or environmental origin of the wild isolates, 
indicating that there were no stain-related differences within these species 
and the probes were able to reliably detect them, although the number of 
isolates tested was relatively small due to the limited availability of strains.  
There was some variation between the signals obtained by different probes 
with CK PR giving the lowest signals (as would be expected) of around 40nA 
and CA PR3 and CP PR giving the highest of around 140nA.   
 
These results demonstrated the ability of the probes to reliably detect strains 
that were not just wild isolates but had been isolated from patients with 
candidaemia. 
 
4.4  Testing PanF PR probe against fungal isolates 
 The results of testing detection using extracted DNA from 15 fungal 
species are shown in figure 4.23.  The mean currents obtained varied 
relatively widely from 118.2 ± 15.4nA (Cr. victoriae) to 385.4 ± 35.5nA (Cr. 
gattii) compared to the background signal of 29.4 ± 4.4nA.  This demonstrated 
that DNA from a wide variety of fungi could be successfully amplified and 
detected using the PanF PR probe and associated primers, and was 
confirmation of the utility of the developed bioinformatic approach of probe 
design.  The assay was a success and the currents produced were generally 
higher than seen before.  The currents produced ranged widely between 
species but the exact reason for this was not known.  One possible reason 
was that differences in the amount of template DNA added to the PCR caused 
a wide variation in the signal produced, as the amount used was never 
standardized.  Out of the 15 species tested, 14 are associated with human 
disease; Cr. victoriae is a known plant pathogen but no cases of its causing 
human disease have been reported.   
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Fig. 4.23.  Mean currents produced by assays using a pan-fungal probe to detect DNA from 15 fungal 
species.  Error bars represent standard deviation (n=3). These results show presence of fungal DNA in 
a sample. 
 
4.5.  Testing the probes against human DNA 
 Each of the probes was tested against fungal target DNA in the 
presence of sufficient human DNA to provide approximately the same number 
of rDNA copies as the fungal target.   The mean currents produced by PanF 
PR and CK PR, which were the best and worst performing probes 
respectively, are shown in Fig. 4.24  Successful discrimination was achieved 
with all probes and the presence of human DNA alone did not increase the 
signal above the background, indicating that cross-reactivity was not an issue.  
The currents produced by the mixed fungal+human DNA samples also 
indicated that sequestration of primers by human DNA was also not an issue 
when this amount of DNA was used.  
 
While equal numbers of human rRNA and fungal rRNA targets would not arise 
in a clinical sample in which the ratio of human cells to fungal cells is 
extremely high, of the order of 109:1 it was not possible to test such a 
condition with the assay in its current form.  This more clinically realistic 
situation was tested in chapter 6 where attempts were made to detect fungal 
DNA in spiked blood samples. 
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Figure 4.24.  Mean currents produced in assays with probes CK PR and PanF PR to test the effect of 
human DNA on the assay.  Error bars represent SD (n=3). 
 
4.6 Conclusions. 
 The results showed that the Candida species-specific probe suite 
consisting of CA PR3, CP PR, CG PR3, CT PR and CK PR are specific to 
their target species and are capable of detecting DNA from clinical isolates as 
well as the type strain.  There were some difficulties encountered with the 
design of probes – from problems with their specificity (CG PR) to an 
inexplicable degradation of signal over time (CK PR).  The former problem 
was able to be overcome by probe redesign but the latter problem was not 
immediately apparent and as a result was not formally investigated due to 
time and cost constraints. 
 
  In the process of redesigning the probes a useful method was 
developed using bioinformatics analyses which could predict cross reactivity 
between probes and non-target species and could be used to screen potential 
probe sequences, greatly speeding up the process of probe design and 
optimization.  This method led to the design of the successful panfungal PanF 
PR probe which gave relatively high signals with 15 fungal species tested. 
 
 The probe suite was now decided upon and the specificity of the 
probes confirmed.  In order to be useful the probes had to be shown to be 
able to detect DNA from very low amounts of Candida DNA.  The next step 
was to optimize the assay to enable detection of a single genome of fungal 
DNA in an assay with all of the probes. 
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Chapter 5 - Limit of Detection 
5.1 Introduction 
 Invasive fungal infections (IFI) can be diagnosed definitively upon 
isolation and identification of fungi from blood but diagnosis is often made 
based on suspicion if fungi are recovered from other normally sterile sites, 
such as CSF, and if the patient exhibits numerous risk factors that predispose 
towards IFI.  These include a weakened immune system, recent surgery to 
the gastro-intestinal tract and failure to respond to antibiotics.  The diagnosis 
of IFI on clinical suspicion is of particular importance as conventional 
diagnosis relies on culture of fungi from a clinical sample and this takes days 
to achieve; furthermore the sensitivity of culture has been questioned and a 
fungus may not be recovered at all.  With this in mind, diagnosis on clinical 
suspicion alone allows antifungal treatment to be administered immediately 
and increases the likelihood of patient recovery.  There are still problems 
inherent in this approach, however, and the main issue is that of antifungal 
drug resistance.  There are numerous antifungal agents that may be 
administered to treat IFIs but not all of them are effective against all species of 
fungi and their use must be directed both by the cost of treatment and the 
production of possible side-effects in the patient.  Since clinical suspicion 
alone cannot reliably identify the species of fungi which is causing an IFI a 
clinician must await the results of further tests to ascertain the identity of the 
offending organism.  Molecular methods based on PCR offer rapid 
identification of fungi in clinical samples to species level by using unique 
stretches of the genetic code to allow detection and identification of fungi.  
These tests are much more rapid than culture and have the potential to 
greatly increase the accuracy of diagnosis of IFIs, provided they are capable 
of detection of clinically relevant amounts of fungal cells in clinical samples.  
 
Of the different types of clinical sample that can be tested to try and detect 
fungal DNA blood is the most likely sample type to use in the case of a 
disseminated fungal infection leading to IFI.  It is a potentially difficult sample 
type to deal with as there is a very large background of human cells present 
as well as a large number of macromolecules which would interfere with 
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molecular processes such as PCR and detection by fluorescence methods.  
Any method involving amplification of fungal DNA in blood would require pre-
treatment to remove this material prior to nucleic acid amplification.  This 
could be achieved by capturing and separating out the fungal cells from blood 
and using them directly in a PCR reaction, with without first extracting total 
DNA.  The other option is to simply extract total DNA from the blood sample 
so that the mix of extracted fungal and human DNA is used in the downstream 
PCR reaction.  The latter method is considerably easier to achieve but relies 
on specificity of the primers and probes for target fungal DNA, otherwise there 
is the possibility of false positives and false negatives being produced, 
particularly given the very small amounts of fungal DNA present in the 
samples compared with human DNA.  With this in mind it is easy to see why it 
is of paramount importance that the PCR conditions are optimised for 
amplification of very low amounts of target DNA.  Key factors to achieve this 
are use of a hotstart Taq DNA polymerase to prevent amplification of 
undesired products in the initial stages of PCR, as well as primers which have 
been designed to minimise interactions at their 3′ termini. 
 
The symptoms of fungaemia may present with a fungal load as low as 5-10 
c.f.u. ml-1 of blood and may be over 100 c.f.u ml-1 (Loeffler et al., 2000) so it is 
essential that the fungal detection assay be capable of detecting fungi in this 
range.  Following the successful test of the specificity of the Candida species-
specific probes the next step was to test the sensitivity of the assay and, if 
necessary, optimise the procedure to allow detection of a single cell of 
Candida yeast in a 1ml blood sample.  Before attempting to detect cells in a 
blood sample it had first to be confirmed that the assay was capable of 
detecting extracted DNA equivalent to a low number of fungal genomes.   
 
Genome size data from the online fungal C-values database (Kullman et al., 
2005) was used to determine the mass of a single genome of each of the 
Candida species in order to prepare appropriate dilutions of extracted 
genomic DNA.  The only estimates available for a diploid genome were for C. 
albicans which reportedly had a 37fg diploid genome and it was decided to 
use this value for all of the diploid Candida species (C. albicans, C. 
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parapsilosis, C. tropicalis and C. krusei); the estimate used for the genome 
size of the haploid C. glabrata was 13fg.  Appropriate dilutions of extracted 
DNA were made based on these estimates. 
 
5.2 Initial attempt at detection of low amounts of extracted DNA 
 The first experiments into assay sensitivity used the improved PCR 
conditions that were outlined in section 2.7.3 with the exception that the 
original primers ITS3 and ITS4 were used.  DNA dilutions corresponding to 
the diploid C-value were not made in the early stages of experimentation, 
hence the amounts of DNA used do not correspond to 1, 10, 100 etc. 
genomes. 
 
Figure 5.1 shows sample results from assays attempting to detect between 
50pg and 15fg of DNA (equivalent to ~1300 genomes and ~0.41 genomes) 
with probes CT PR and CP PR.  The assay with CT PR was only able to 
detect down to 500fg of C. tropicalis extracted DNA while the assay with CP 
PR could detect reliably down to 500fg DNA but produced inconsistent 
detection at 50fg and 15fg with only one assay out of three producing a signal; 
the DNA-free sample also produced a very low signal in one out of the three 
replicates.  The results demonstrated that the new conditions of increased 
MgCl2 concentration and use of a hotstart Taq polymerase were not sufficient 
to allow detection of the smallest amounts of Candida DNA.   
 
The PCR reaction is the limiting step of the assay because if insufficient target 
amplicon is produced it leads to little or no current being generated in the 
following probe hybridisation-digestion reaction.  Therefore optimisation of the 
PCR was deemed to be the most important step to permit detection of 1 
genome of Candida DNA. 
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Figure 5.1.  Mean currents obtained with low amounts of (A) C. parapsilosis and (B) C. 
tropicalis genomic DNA.  Error bars represent SD (n=3). 
  
 
5.2.1 Further optimisation of PCR conditions for detection of low 
amounts of Candida DNA – cycling conditions. 
 There were several aspects of PCR that had by now been optimised to 
achieve low levels of detection: MgCl2 concentration, Taq polymerase 
concentration and Taq polymerase properties (i.e. hotstart DNA polymerase).    
The cycling time had never been examined before and it was reasonable to 
hypothesise that the straightforward step of increasing the number of cycles 
could increased amplification of target DNA.  An assay was carried out using 
C. tropicalis DNA to compare the signal obtained when PCR was carried out 
at 50 cycles, compared with the signal produced following a 40 cycle PCR (fig 
5.2).   
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Figure 5.2.  Mean currents produced in an assay using C. tropicalis DNA amplified by 40 cycle PCR 
compared with 50 cycle PCR.  Error bars represent SD (n=3). 
 
The mean current produced with 5pg DNA at 50 cycles was significantly 
higher than the signal produced at 40 cycles, 98.8 ± 3.2nA vs. 76.6 ± 6.1nA 
respectively (P<0.005; t-test, n=3).  However, while the ~20nA difference in 
signal was statistically significant, it was not a very large difference in actual 
terms and similar fluctuations in mean current had been observed in results 
from assays carried out using identical conditions at different times.  
Furthermore, the mean current obtained using 500fg of DNA at 40 cycles was 
actually slightly higher than it was at 50 cycles, 19.0 ± 3.0nA compared to 
18.5 ± 7.4nA.  These results demonstrated that simply increasing the number 
of cycles of the PCR was not sufficient to increase the current produced by 
the assay and therefore allow reliable detection of low amounts of fungal 
DNA. 
 
5.2.2 Further optimisation of PCR conditions for detection of low 
amounts of Candida DNA – primers. 
 Primer sequence and concentration can affect the degree of 
amplification of target DNA in PCR.  Ultimately, the amount of target that can 
be amplified is related to the amount of primer molecules available to the 
reaction.  However, the relationship between amount of primer and amount of 
product is unlikely to remain linear; Li et al. (1990) suggested that primer-
dimerisation and mis-priming occur when PCR is carried out for >35 cycles 
 89 
and the presence of larger amounts of primer would increase the probability of 
these events occurring.  This would produce alternative targets for primer 
annealing and so decrease the availability of primers in the reaction and 
decrease the yield of the target amplicon, particularly when a low amount of 
starting template is present. 
 
A reasonable assumption to make was that an optimal, increased 
concentration of ITS3/ITS4 primers existed which would allow a greater 
amount of target DNA to be amplified during PCR which would result in a 
higher signal being produced following probe hybridisation-digestion.  Since 
the PCR conditions are designed for asymmetric amplification of DNA it was 
feasible that increasing the amount of the primer which amplified the target 
strand would result in increased ssDNA target and therefore a higher current 
produced by the assay.  To test this hypothesis ratios of 10:1 and 20:1 of 
target-producing primer:non-target producing primer (ITS4:ITS3) were used in 
assays with C. tropicalis DNA to compare the signals obtained with the 
standard 5:1 primer ratio.  The results (shown in fig 5.3) demonstrated that 
there was no significant difference between the signals produced when the 
amount of ITS4 used in the reaction was varied, indicating that the 5:1 ratio of 
IS4:ITS3 was not limiting the signal produced by the assay and therefore was 
not limiting the amount of product amplified by PCR. 
 
It was still possible that changing the primer concentrations could yield more 
target.  Whilst it was the excess ITS4 in the PCR which produced the ssDNA 
target for the probes, a suitable concentration of ITS3 was crucial in the early, 
exponential cycles of the PCR in order to produce enough template for the 
later, linear cycles of PCR which would yield ssDNA target.  By proportionally 
increasing the amount of each primer in the reaction it was possible that an 
increase in the amount of target would be achieved and therefore an 
increased production of current.  Fig 5.4 shows the mean currents produced 
in assays using five-fold higher concentrations of the ITS3 and ITS4 primers, 
500nM and 2.5µM respectively compared with the usual 
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Figure 5.3. Mean currents produced by assays with target DNA amplified by different ratios of ITS4:ITS3 
primers using C. tropicalis DNA.  The error bars represent SD (n=3). 
 
conditions of 100nM ITS3 and 500nM ITS4.  These results showed a highly 
significant decrease in signal when the primer concentrations were increased 
– the mean current decreased from 59.9 ± 5.6nA to 11.3 ± 2.1nA when five-
fold greater concentrations of the primers were used (P<0.0001). 
 
 This decrease in signal was very likely due to the primer interactions 
mentioned by Li et al. occurring at an early stage of the PCR due to the large 
excess of primer molecules present in the reaction.  Such interactions and 
consequent formation of primer-dimers would also have occurred in reactions 
in which the primers were present at their ‘standard’ concentrations.  
However, at these lower concentrations they would not have become such a 
dominant species of amplified material in the early stages of the PCR reaction 
and the genomic DNA target would have provided adequate template to 
produce the desired target DNA.   
 
To demonstrate that this was likely to be the case, some degree of interaction 
would have to be identified in the primers. The Oligoanalyser program 
provided by Integrated DNA Technologies was used to analyse the primers 
for possible interactions leading to primer artefacts.  It was discovered that the 
primers had complementary 3′ ends consisting of two G-C bonds (fig 5.5) and 
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Figure 5.4.  Mean currents produced in assays with C. tropicalis DNA amplified with two different 
concentrations of the primers.  Error bars represent SD (n=3). 
 
this was thought to have contributed to the decreased signal observed when 
the concentration of the primers was increased.  Due to this potential defect it 
was decided to design new primers for amplification of the ITS2 region in 
fungi that were free from such 3′ interactions that could limit amplification of 
target DNA. 
 
Following the design and testing in pair-wise combinations of three new 
forward and three new reverse primers designed to the 3′ end of the 5.8S 
rRNA gene and 5′ end of the 26S rRNA gene respectively, the primer pair 
ITS3.3 and ITS4.2 was selected as the most efficient primer pair since they 
could amplify DNA equivalent to ~1.08 genomes of C. tropicalis to levels that 
were visible on an agarose gel (fig 5.6).  There was evidence of contamination 
in the samples amplified using ITS3.1/ITS4.2 and ITS3.3/ITS4.2, suggesting 
that the ITS2 primer was contaminating.   
 
 5′ GCA TCG ATG AAG AAC GCA GC 3′  
        || 
     3′ CG TAT AGT TAT TCG CCT CCT 5′ 
 
Figure 5.5.  Alignment showing the complementary 3′ ends of primers ITS3 (top) and ITS4 (bottom). 
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Unfortunately this was not realised at the time – the contamination observed 
was assumed to have occurred by chance in this experiment and the 
possibility of contamination of the stock ITS4.2 primer was not considered.  
This possibility may have led to the difficulties experienced later on when 
detection of low amounts of DNA was attempted (see below and chapter 6).  
Nevertheless, the primers were then tested in electrochemical assays to 
detect 4pg and 40fg of DNA extracted from C. parapsilosis (equivalent to 
~108 and ~1.08 genomes).  The mean currents that were produced are 
presented in figure 5.7 and were much higher than seen before: when 4pg 
DNA was used as target the mean current produced was 330.0 ± 30.4nA and 
when 40fg DNA was amplified by ITS3.3/4.2 the mean current was 118.8 ± 
49.2nA.  This result demonstrated a great improvement in production of 
electrochemical signal with the assay and showed just how important the PCR 
step was for the production of current and, in particular, how important it was 
to have efficient primers for amplification of small amounts of starting template 
DNA.   
 
The successful detection of 40fg of C. parapsilosis extracted DNA (equivalent 
to ~1.08 genomes) was a great leap forwards towards reliable detection of a 
single genome of DNA in a reaction which was essential to detection of a 
single genome in a 1ml sample. However, this result also demonstrated that 
PCR amplification of 40fg of target DNA was not completely reliable as only 
two out of three replicates gave a PCR product and concurrent signal and the 
currents produced were quite different, 153.6nA and 84.0nA.   
 
 
 1       2       3      4       5     6       7        M       8      9     10     11     12     13     14          15    16     17     18      M     19     20     21  
Figure 5.6.  Gel image showing PCR products obtained in reactions with three improved primer pairs 
using low amounts of C. tropicalis genomic DNA as template: M – 100bp ladder, 1-2, 8-9 & 15-16 - 
~100 genomes C. tropicalis DNA, 3-4, 10-11 & 17-18 - ~10 genomes C. tropicalis DNA, 5-6, 12-13 & 
19-20 - ~1 genome C. tropicalis DNA, 7, 14 & 21 – DNA-free negative control. 
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Figure 5.7.  Mean currents produced in assays with C. parapsilosis DNA amplified by ITS3/ITS4 primers 
compared with ITS3.3/ITS4.2 primers.  Error bars represent SD (n=3 for 4pg DNA and DNA-free results 
and n=2 for 40fg result as one replicate failed to give PCR product). 
  
This result led to the routine set up of 6 replicates of PCR amplifications with 
~1 genome equivalent of DNA added to try and obtain at least 3 data points 
with which to calculate a mean and standard deviation.  This would not 
validate the assay in terms of reliability of detection of 1 genome of DNA in a 
reaction but would simply allow the determination of the levels of signal 
obtained by each probe to show that detection was possible.  The question of 
reliability of the assay could then be addressed once detection of a single 
genome could be shown to be obtainable by all of the probes.  
 
5.3 Contamination. 
 The generic nature of the primers used to amplify the ITS2 region and 
18s rRNA region was advantageous as it greatly simplified the setup of the 
PCR reaction to generate target DNA for the assay and would allow for the 
addition of new probes for the detection of other fungal species to the assay 
with minimal optimisation but it was not without potential problems.  An 
obvious issue is the situation where DNA from one or more other fungal 
species was present alongside DNA from the target species.  These species 
would then be in competition for PCR reagents which would likely cause a 
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reduction in the amount of target DNA, leading to lower currents and an 
increased risk of a false negative being reported. 
 
Another possible problem was the production of false positives due to 
contamination by target fungal nucleic acid present in the environment.  One 
possible source of this was in the form of fungal cells present in the 
environment.  The use of gloves when preparing reagent mixes etc. would be 
enough to prevent commensal species such as C. parapsilosis and C. 
albicans from contaminating PCR mixes, but the presence of airborne cells 
delivered by the air conditioning apparatus could not be ruled out.  This was a 
particular issue due to the location of the lab - beside a wooded area with a 
stagnant body of water and a deal of decomposing vegetation which would 
provide an excellent habitat for many species of fungi including Candida.  A 
more troublesome source of contaminating DNA was cell-free target DNA 
amplicon which may have been released following handling of PCR products 
e.g. when loading agarose gels for analysis.  This source of contamination 
would only become evident over time as levels of amplicon built up over 
successive rounds of post-PCR sample handling. 
False positive and false negative results caused by contamination had not 
been observed when testing the probes for specificity.  There were a number 
of reasons why this was the case.  Firstly, the use of large amounts of target 
DNA (10 – 100ng) in the PCR reactions meant that there would have been 
little competition for PCR reagents and so false negative results would not 
have been observed.  Secondly, as discussed above, the ITS3/ITS4 primers 
used in these test were not sensitive enough to detect small amounts of target 
DNA hence a small amount of contaminating material would have gone 
unnoticed.  Thirdly, fewer PCR amplifications had been carried out and so 
there was less contaminating amplicon present in the atmosphere.  After 
performing PCR amplifications for some time the products began to exhibit 
contamination,  so to address this PCR reagents were stored and PCR master 
mixes were prepared in a ‘DNA free’ room where amplified DNA was never 
admitted.  However, even under these conditions extensive contamination 
was observed in the PCR products – a comparison between reactions set up 
in the ‘DNA free’ room and in a class 2 biological safety cabinet (BSC)  
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Figure 5.8.  DNA-free PCR products set up in (A) ‘DNA-free’ room and (B) class 2 BSC. 
 
demonstrated that the ‘DNA free’ room was quite heavily contaminated by 
fungal nucleic acid (fig 5.8) which was likely to have been delivered by the air 
conditioning unit installed in the room.  The uniform size of the amplicon also 
suggested a single source of contaminant nucleic acid.  As a result of this 
test, set up of PCR mixes was moved to the class 2 BSC.  With the additional 
provision of an UV source and use of a pre-prepared dNTP mix (Promega) 
contamination was limited, although it was never eliminated altogether - fig 
5.8 shows examples of PCR products obtained in different assays, following 
the move to the safety cabinet, which show very different instances of 
contamination. 
 
The varying amplicon size of contaminating material in the reactions with 37fg 
of C. parapsilosis DNA suggested that the contaminating material had come 
from several different sources.  This suggested that it was unlikley that one or 
more of the PCR reagents had been contaminated, as contaminating 
amplicons would then be uniform in DNA-free samples, and the use of the 
class 2 BSC meant that environmental sources of contaminating DNA could 
be ruled out.  As a result, it was thought that the contaminating material in this 
case originated from amplified DNA present in the atmosphere.  As shown in 
figure 5.9 the contamination of samples was sporadic and so, in order to 
achieve sensible results demonstrating limit of detection of 1 genome of DNA 
in vitro, it had to be shown that an electrochemically analysed PCR sample  
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Figure 5.9.  PCR products obtained with ITS3.3/ITS4.2 primers when attempting to amplify a range of 
(A) C. albicans DNA and (B) C. parapsilosis DNA.  Note the range of sizes of contaminating bands in 
image (B). 
 
which produced no current either contained no DNA or contained non-target 
DNA, either of which could be regarded as a negative sample for the 
purposes of the assay. 
 
5.4 Demonstration that no signal indicates no target. 
 Since the problem of contamination could not be completely overcome 
it was essential to show that a result with zero current corresponded either to 
a PCR product with no amplicon or to a non-target contaminating amplicon.  
An opportunity to demonstrate the latter point arose when performing an 
assay with the CG PR3 probe.  The DNA-free negative samples all showed 
signs of contamination with bands of several different sizes present.  
However, the region of C. glabrata amplified by primers ITS3.3/ITS4.2 is 
easily distinguishable from the other Candida species due to its size of 274bp.  
Fig 5.10 shows the products from the PCR amplification with DNA-free 
samples in this experiment.  The samples in lane 2 and lane 6 appear to be 
the correct size to be product from C. glabrata DNA and they were also the 
only DNA-free negative samples to produce a current when analysed 
electrochemically with probe CG PR3 (table 5.1).   
 
This result demonstrated the continued specificity of the probes in assays 
following PCR amplification with the primer pair ITS3.3/ITS4.2, which had  
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Figure 5.10. DNA-free samples amplified with primers ITS3.3/ITS4.2 exhibiting contamination from 
different species.  The samples were analysed electrochemically with probe CG PR3 and gave the 
following signals (1) 0.0nA, (2) 11.1nA, (3) 0.0nA, (4) 0.0nA, (5) 0.0nA and (6) 14.2nA.  Lanes 2 and 6 
contained amplicon of a size which corresponded to the expected size of the C. glabrata product. 
 
never been explicitly tested, and was compelling evidence that a signal would 
only be produced in the presence of target DNA.  This meant that, in assays 
with any of the probes, DNA-free negative samples which showed 
contamination could be a posteriori regarded as containing DNA from the 
target species if a positive signal was produced in the electrochemical 
analysis, thereby rendering the sample a ‘target-containing sample with an 
indeterminate amount of target DNA’ and such samples could be ignored 
when assessing the background level of current generated by genuine DNA-
free or non-target DNA negative samples.  In a similar way, contaminated 
samples which produce no current can a posteriori be considered non-target 
 
Table 5.1.  Currents produced by all of the samples used in the assay with CG PR3 which exhibited 
extensive contamination in the DNA-free samples 
Amount of C. 
glabrata DNA 
Sample 1 
(nA) 
Sample 2 
(nA) 
Sample 
3 (nA) 
Sample 4 
(nA) 
Sample 
5 (nA) 
Sample 6 
(nA) 
1.05pg 137.00 124.00 131.00 N/A N/A N/A 
105fg 111.00 81.90 85.60 N/A N/A N/A 
10.5fg 64.20 46.70 33.60 10.20 54.80 35.10 
DNA-free negative 0.0 11.10 0.0 0.0 0.0 14.20 
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DNA negative samples if zero current was produced by them in the 
electrochemical assay.  It should be noted that agarose gel analysis of PCR 
products is not a feature of the assay, but only a checking step for 
experimental purposes.  It does, however, allow deductions such as this to be 
made.  The eventual assay procedure would rely solely on the current 
production to determine the presence or absence of target DNA and so it was 
important to establish reliably that any positive signal indicated only the target 
DNA. 
 
Contamination of samples was a problem in this work for several reasons.  As 
discussed above, continual amplification of Candida DNA in the laboratory is 
likely to have generated much airborne nucleic acid which can easily 
contaminate PCR samples.  The use of generic primers, capable of efficient 
amplification of target from small DNA amounts, will then amplify even the 
smallest amounts of contaminating fungal DNA when it is present.  However, 
the above results demonstrate that the specificity of the probes is maintained 
when target DNA is present in extremely small amounts and the signal 
produced by the assay is a reliable indicator of the presence or absence of 
target DNA.  It can therefore be reasoned that ‘if there is signal then there is 
target’.   
 
It was considered likely that contamination would continue to materialise 
during experiments and so assays were altered in light of this to include six 
replicates of DNA-free samples so that enough non-target or no-amplicon 
negatives would be produced to give a measure of any background signal 
 
5.5  Detection of template DNA equivalent to one genome.  
 With the design of more efficient primers, the limitation of 
contamination and faith in the specificity of the probes, work could now begin 
in earnest on demonstrating a limit of detection of 1 genome per reaction for 
each of the target species with the relevant probe. 
 
A 10-fold dilution series of genomic DNA from the four diploid target species 
(C. albicans, C. parapsilosis, C. tropicalis and C. krusei) was prepared with 
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concentrations ranging from 3.7pg µl-1 – 37fg µl-1 (equivalent to ~100 
genomes µl-1 to ~1 genome µl-1).  Another 10-fold dilution series of genomic 
DNA with concentration ranging between 1.05pg µl-1 and 10.5pg µl-1 
(equivalent to ~80 genomes µl-1 to ~0.8 genomes µl-1) was prepared for the 
haploid species C. glabrata.  The intention was originally to make a C. 
glabrata DNA dilution series from 1.5pg µl-1 to 15fg µl-1 but a miscalculation 
was made when diluting the stock solution of DNA which led to the 
preparation of the above dilutions.  PCR reactions were prepared and 1µl of 
the template DNA solutions were used to amplify target DNA for 
electrochemical analysis with the relevant species’ probe. 
 
 
5.5.1 Detection of C. albicans DNA. 
 Fig 5.11 shows the mean currents produced by the assay with the C. 
albicans DNA dilutions series and probe CA PR3.  The mean current ranged 
from 233.7 ± 6.0nA with 3.7pg of DNA to 80.5 ± 8.7nA with 37fg of DNA and 
all six DNA-free samples gave zero currents.  This was an excellent result and 
demonstrated that detection of DNA equivalent to a single genome of C. 
albicans present in a 50µl reaction could be successfully detected. 
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Figure 5.11.   Mean currents obtained in assays with CA PR3 and target DNA derived from low amounts 
of genomic DNA.  The error bars represent SD (n=3 for assays using 3.7pg and 370fg DNA and n=6 for 
assays with 37fg DNA and DNA-free samples). 
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5.5.2 Detection of C. parapsilosis DNA. 
 Figure 5.12 shows the mean currents produced by assays with C. 
parapsilosis DNA dilutions and the probe CP PR.  Mean currents ranged from 
261.0 ± 64.5nA for assays using 3.7pg DNA to 54.6 ± 27.1nA for assays using 
37fg DNA.  The relatively large value obtained for the standard deviation of 
the currents obtained at 37fg was as a result of two high outlying currents of 
65.0nA and 87.3nA.  This high variation was probably due to the PCR 
amplification step being unable to generate reproducible amounts of target 
DNA when low amounts of genomic DNA were used as target for the reaction.  
Nonetheless, the results demonstrated that DNA equivalent to a single 
genome of C. parapsilosis could be detected in a 50µl reaction. 
 
5.5.3 Detection of C. glabrata DNA. 
 Figure 5.13 shows the mean currents obtained in the assays with low 
amounts of C. glabrata genomic DNA.  The mean currents ranged between 
130.7 ± 6.5nA at 1.05pg DNA to 40.8 ± 19.0nA at 10.5fg DNA.  There was 
again a relatively high standard deviation observed when a very low amount 
of DNA (10.5fg) was used as template for the reaction.  This was due to a low 
current of 10.2nA which corresponded to a very weak PCR product and two 
other relatively low currents of 33.6nA and 35.1nA which corresponded to 
PCR products which contained a contaminant amplicon; the low signals may 
have been due to a lower amount of target being produced because of 
competition for PCR reagents by two different sources of DNA.  The results 
did however demonstrate that the assay could detect C. glabrata DNA down 
to 10.5fg (~0.8 genomes) in a 50µl reaction. 
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Figure 5.12.  Mean currents obtained in assays with CP PR and target DNA derived from low amounts 
of genomic DNA.  The error bars represent SD (n=3 for assays using 3.7pg and 370fg DNA, n=4 for 
assays with 37fg DNA and n=5 for assays with the DNA-free samples). 
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Figure 5.13.  Mean currents obtained in assays with CG PR3 and target DNA derived from low amounts 
of genomic DNA.  The error bars represent SD (n=3 for assays using 1.05pg and 105fg DNA, n=6 for 
assays with 10.5fg DNA and n=4 for assays with the DNA-free samples). 
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Figure 5.14. Mean currents obtained in assays with CT PR and target DNA derived from low amounts of 
genomic DNA.  The error bars represent SD (n=3 for assays using 3.7pg and 370fg DNA, n=6 for 
assays with 37fg DNA and with the DNA-free samples). 
 
 
 
5.5.4 Detection of C. tropicalis DNA. 
 Figure 5.14 shows the results of assays with low amounts of C. 
tropicalis DNA.  The mean currents obtained ranged between 86.3 ± 11.1nA 
at 3.7pg DNA and 12.2 ± 7.3nA at 37fg DNA.  Again, the standard deviation 
obtained at the lowest DNA amount was relatively large and there was 
nothing anomalous about the PCR products.  This was further evidence that 
the PCR amplification was much less reproducible when extremely small 
amounts of DNA were added to the reaction.  It had also been found that CT 
PR can potentially form an extensive hairpin structure involving its 5′ terminus 
(fig 5.15) which may have proved detrimental to the current produced by the 
assay.  Despite this, the detection of low amounts of C. tropicalis DNA was 
shown to be achieved by the probe CT PR. 
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Figure 5.15.  Potential hairpin structure of probe CT PR.  Fc represents the ferrocene label 
attached at the 5′ end of the oligonucleotide. 
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Figure 5.16. Mean currents obtained in assays with CK PR and target DNA derived from low amounts of 
genomic DNA.  The error bars represent SD (n=3 for assays using 3.7pg and 370fg DNA, n=5 for 
assays with 37fg DNA and n=6 for assays with the DNA-free samples). 
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5.5.5 Detetction of C. krusei DNA. 
 Figure 5.16 shows the results of assays using the dilution series of C. 
krusei DNA.  The mean currents obtained were very low compared with the 
signals of the other probes, ranging between 35.4 ± 0.7nA obtained with 3.7pg 
DNA to 5.3 ± 1.1nA obtained with 37fg DNA.  The standard deviations were 
also considerably smaller with these results and it was not clear why.  
Nonetheless, despite the very small currents generated with 37fg DNA the 
fact that the DNA-free background was zero meant that it could be regarded 
as positive detection of C. krusei DNA down to a single genome equivalent in 
a 50µl reaction. 
 
5.5.6.  Limit of detetction of PanF PR probe with C. albicans DNA. 
 The PanF PR probe was tested using a C. albicans DNA dilution.  The 
mean currents produced (fig 5.17) were 188.7 ± 58.0nA with 3.7pg DNA, 
121.7 ± 11.1nA with 370fg DNA and 40.4 ± 12.8nA with 37fg DNA; the 
background current was 0nA.  This was another excellent result with 
comparatively high mean currents generated at all DNA amounts tested.  As 
only C. albicans DNA was tested, the result could not however be assumed to 
hold for all other fungal species as there may be specific differences that 
would result in a lower signal being produced and this would have to be tested  
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Figure 5.17.   Mean currents produced with probe PanF PR in assays with C. albicans DNA.  Error bars 
represent SD (n=3 for 3.7pg and 370fg samples and n=6 for 37fg and DNA-free samples). 
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experimentally.  Given the high mean currents produced by PanF PR in 
assays with 15 fungal species (section 4.4) it was likely that the probe would 
be able to detect low amounts DNA from most fungal species. 
 
5.6.  Conclusions. 
 Detection of DNA equivalent to one genome in a 50µl reaction was 
shown to be possible for all of the probes.  Establishing the limit of detection 
was made difficult by inefficient primers and the presence of contaminating 
DNA. However, following the redesign of primers and the preparation of 
reagents in a cleaner environment, the assay was shown to be robust enough 
to detect target DNA when it was present in the reaction at low amounts. 
 
The signals generated by each probe varied and the probes CA PR3, CP PR 
and CG PR3 gave the highest mean currents with a single genome of 80.5 ± 
8.7nA, 54.6 ± 17.1nA and 40.8 ± 19.0nA respectively.  The C. krusei specific 
probe CK PR gave the poorest results with 1 genome giving a mean current 
of only 5.3 ± 1.1nA.  This was a particularly weak signal and was only 
considered successful detection by virtue of the zero background level 
produced by the new PCR conditions.  This further highlighted the need for 
redesign of the C. krusei probe sequence.  It was also noted that the CT PR 
probe gave a relatively low signal of only 12.2 ± 7.3nA.  As noted above, the 
probe is potentially capable of forming secondary structures structure 
involving its 5′ end which may have affected its digestion and decreased the 
current produced.  It was likely that this probe could also be redesigned in an 
effort to obtain improved results more in line with the other probes. 
 
The results would have been improved by replication with a greater number of 
samples to further validate the assay’s ability to detect small amounts of target 
DNA.  This was not attempted here as all that was required was a 
demonstration of the assay’s ability to detect a single genome in a reaction to 
allow the project to progress to detection of a low amount of DNA from a 
spiked 1ml blood sample.  
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Chapter 6 - Detection of fungal DNA from blood. 
6.1 Introduction 
 The previous chapters have described the optimisation of the fungal 
probe detection suite using extracted DNA added directly to the PCR reaction.  
In order to validate the assay further, detection of fungal DNA must be 
achieved from blood samples. 
 
Blood is a difficult medium to work with as it contains a variety of components 
– erythroctes, leukocytes, platelets and a host of salts, sugars, proteins and 
other macromolecules.  Some of these compounds affect PCR by inhibiting 
Taq DNA polymerase while the leukocyte population of cells represents a 
large source of human DNA which may inhibit PCR by competing non-
specifically for primers.  Because the fungal load of a candidaemic individual 
can be as low as 5 c.f.u ml-1, detection of fungal DNA in blood is difficult 
(Loeffler et al., 2000). 
 
For successful amplification of DNA from blood an effective extraction protocol 
is necessary whereby the human cells are lysed and all of the potentially 
inhibitory macromolecules present in the blood lysate are removed from the 
sample.  Additionally, the fungal cells must themselves be lysed to release 
their genomic DNA.  These tasks require two separate treatments, further 
complicating the business of DNA extraction for detection of fungi.  
Furthermore, the procedure must be capable of recovering minute amounts of 
fungal DNA in a background of proportionally vast amounts of human DNA. 
 
Blood can be processed into three different fractions: whole blood is the 
‘crude’ sample which contains all of the cellular and macromolecular 
constituents and is the ‘dirtiest’ sample.  Plasma is the supernatant obtained 
following centrifugation of an uncoagulated whole blood sample to pellet the 
cells – it retains the dissolved salts, macromolecules and clotting factors.  
Serum is similar to plasma but lacks the clotting factors as it is prepared by 
allowing the blood to coagulate before centrifugation.  The clot is then pelleted 
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and the serum supernatant can be extracted.  For this reason serum is the 
‘cleanest’ sample but is still rich in proteins, salts and sugars. 
 
The choice of which fraction to use for a DNA based diagnostic assay is 
influenced by the balance of recovery of nucleic acid vs. contamination by 
molecules inhibitory to PCR amplification of target DNA (note that DNA from 
leukocytes could be included in this category).  Fungal cells will obviously be 
found in the cell fraction of a blood sample and so use of plasma and serum 
fractions for detection of DNA risks eliminating a primary source of fungal 
DNA from a sample.  Exogenous DNA from damaged fungal cells may be 
present in plasma and serum samples, but the lifespan of such DNA 
molecules is uncertain since DNase activity has been reported in both serum 
and plasma fractions of human blood samples (Cherepanova et al., 2007).  
Molecular assays have been shown to successfully detect fungal DNA from 
clinical samples of blood serum (McMullan et al., 2008) and studies 
comparing the detection of fungal DNA in whole blood, plasma and serum 
have shown that detection may in fact be more reliable when plasma or serum 
samples are used (Bougnoux et al., 1999; Metwally et al., 2008; Lau et al., 
2009) although the number of samples tested was relatively small.   
 
The researchers at Atlas Genetics developed a prototype DNA extraction 
protocol for use on bacterial pathogens present in clinical samples based on 
the Sigma Genelute column extraction kit.  This was a relatively rapid and low-
tech method for extraction of nucleic acid from samples and it was decided to 
try and adapt this method for extraction of fungal DNA from spiked blood 
samples.  
 
6.2 Extraction of nucleic acid from fungal DNA-spiked whole blood and 
plasma samples  
 Blood was acquired from a healthy volunteer and deposited into 
vacutainers and processed to yield plasma, serum and whole blood fractions 
as described in Chapter 2.  For the initial experiment to test the extraction 
procedure three 1ml samples of whole blood and plasma were used.  The 
reason for excluding serum samples from this first test was solely due to the 
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difficulty of processing large numbers of samples due to the multiple 
centrifugation steps and handling of a biohazardous material. 
 
The 1ml samples were prepared in different ways in order to test different 
factors of the extraction procedure.  Samples of whole blood and plasma were 
kept free of C. albicans DNA, another sample of each had 37pg of C. albicans 
DNA (~1000 genomes) added before the extraction procedure, and the third 
aliquot of each sample was kept free of C. albicans DNA until after the 
extraction procedure when 37pg of C. albicans DNA was added to the eluted 
material.  These conditions would allow the effect of the background human 
DNA to be measured in isolation and would also show if there was any 
difference between fungal DNA recovered from a blood sample compared 
with the same amount added to the eluate from an unspiked blood sample. 
  
Once the extractions were complete three 30µl aliquots of each of the 100µl 
eluates was added to 20µl of a PCR mix to give three replicates for each set 
of DNA extraction conditions.  Positive control samples with 37pg of extracted 
C. albicans DNA added to the PCR were set up to allow comparison of the 
PCR products generated from DNA extracted from blood.   
 
 
Figure 6.1.  PCR products from amplifications with extracted products from spiked and unspiked whole 
blood and plasma samples. 
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The DNA was amplified and the products were run on an agarose gel to 
check the products (fig 6.1).   
 
All of the samples that were spiked with C. albicans DNA produced amplicon 
of similar intensity to the PCR positive control, indicating that the extraction 
method was efficient at recovering a large amount of C. albicans DNA from 
blood.  The unspiked whole blood samples all had evidence of non-fungal 
PCR products of ~600bp and ~1000bp which were likely to have originated 
from the human DNA fraction while one sample contained a third amplicon 
which was very likely to be fungal in origin indicating that contamination may 
have occurred.  The spiked whole blood samples contained single amplicons 
corresponding to the expected size of the C. albicans product, suggesting that 
the C. albicans DNA had out-competed the human genomic DNA for the 
ITS3.3/ITS4.2 primers.  There were signs of fungal contamination in all of the 
reactions that were set up using material that had been extracted from the 
unspiked plasma samples, as well as in two of the DNA-free negative 
samples.  Given the relative difficulty involved in carrying out the DNA 
extractions from blood, rather than repeat the extraction 
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Figure 6.2.  Mean currents produced in assays using DNA extracted from spiked and unspiked whole 
blood and plasma samples.  Error bars represent SD (n=3 for all results except for the PCR negative 
control, where n=6).  
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to obtain contamination-free results the PCR products were analysed 
electrochemically using probe CA PR3 in spite of the evident contamination.  
The results are shown in fig 6.2.  The mean current produced by the positive 
control samples was 189.9 ± 20.7nA.  Two of the negative control samples 
produced positive signals while the other four gave zero currents, yielding a 
mean of 7.0 ± 11.2nA.  All of the unspiked plasma samples produced current 
which resulted in a mean of 21.1 ± 13.8nA indictaing that the samples had 
been contaminated by a small amount of C. albicans DNA.   The whole blood 
and plasma samples which had been spiked prior to DNA extraction gave 
good levels of signal, 153.4 ± 6.6nA and 141.4 ± 6.6nA respectively, indicating 
positive detection of C. albicans DNA in these samples.  The blood and 
plasma samples which had C. albicans DNA added to the extraction eluate 
produced slightly higher mean currents compared to the pre-extraction spiked 
products: 168.9 ± 17.1nA for whole blood and 187.5 ± 10.3nA for plasma.  
The difference was very small, however, and was probably due to the loss of 
fungal DNA due to the inefficient nature of the column-based DNA extraction 
method used.  There was certainly no evidence of inhibitory substances being 
copurified with the DNA in either the whole blood or plasma samples. 
 
These results indicated that there was little difference between mean currents 
produced by whole blood or plasma that had been spiked with C. albicans 
DNA.  The experiment was not repeated with serum samples as it was 
thought unlikely that the removal of clotting factors from a plasma sample 
would have much effect on the current produced by the assay.  It was also 
decided that, given the ease of preparation of whole blood samples, all further 
work to detect low amounts of C. albicans DNA in blood would use whole 
blood samples. 
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6.3. Optimisation of assay conditions for detection of ~1 genome C. 
albicans DNA in 1ml blood samples. 
 
6.3.1 Establishing limit of detection of C. albicans extracted DNA in 
blood. 
 Following the success of detecting a relatively large amount of C. 
albicans DNA spiked into 1ml blood samples the next step was to determine 
the limit of detection of DNA extracted from blood and, if possible, optimise 
the extraction procedure to achieve a limit of detection of 1 genome ml-1 of 
blood.  The first attempt used 1ml blood samples spiked with 3.7pg C. 
albicans DNA (~100 genomes), 370fg C. albicans DNA (~10 genomes) and 
37fg C. albicans DNA (~1 genome).  The samples were eluted in 100µl buffer 
as before and 30µl of each eluate was used as template in PCR 
amplifications.  The products obtained can be seen in figure 6.3 and show the 
presence of additional bands in samples using DNA extracted from blood.  
The bands are similar to those observed in the unspiked whole blood samples 
in figure 6.1 and are almost certainly linked to the presence of extracted 
human DNA in these samples.  One possible explanation is that they are 
amplicons produced by priming of human DNA by the ITS3.3/4.2 primer pair.  
It can be inferred that the primer binding sites have only partial similarity as 
the bands are relatively weak and are only observed when competition for the 
primers by C. albicans DNA is low i.e. when the amount of C. albicans DNA 
present in the reaction is less than or equal to 3.7pg.  The positive control and 
the samples containing ~100 and ~10 genomes produced an amplicon that 
corresponded to the expected size of C. albicans but the samples containing 
~1 genome showed the presence of only the human-related amplicon.  It was 
possible that sub-visual amplicons were present in these samples and would 
be detected when the samples were analysed electrochemically.  Of the six 
DNA-free negative controls one showed a contaminant amplicon which was 
slightly larger than the expected size of C. albicans and so, as a non-target 
amplicon, was likely to produce a zero current in the assay.    
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Figure 6.3.  PCR products obtained with C. albicans DNA extracted from 1ml blood samples. 
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Figure 6.4.  Mean currents obtained with low amounts of C. albicans extracted DNA spiked into 1ml 
blood samples.  Error bars represent SD (n=6 for DNA-free samples and n=3 for all other samples). 
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The PCR products were analysed electrochemically using CA PR3 and the 
mean currents are shown in fig 6.4.  The positive control of ~100 genomes of 
extracted DNA in the PCR reaction gave a mean current of 152.0 ± 14.8nA 
compared to means of 75.6 ± 8.9nA, 35.6 ± 6.4nA and 4.4 ± 7.6nA for ~100,  
~10 and ~1 genomes spiked into whole blood respectively.  All six of the DNA 
free samples gave zero current. 
 
The reason for the difference in signal between the positive control sample 
containing ~100 genomes and the sample containing extracted material from 
a blood sample spiked with ~100 genomes is likely to be due to several 
factors.  Firstly, no extraction process is 100% efficient and this would result in 
a loss of DNA; secondly, of the 100µl of eluted DNA only 30µl is used as 
template in each PCR replicate so it is likely that only ~300fg is present in 
each reaction; and finally, there is a large amount of human DNA that co-
elutes with the C. albicans DNA and, as discussed above, this would appear 
to compete for PCR reagents.  According to this reasoning, these factors 
would reduce the amount of target DNA produced by PCR and hence reduce 
the current produced in the assay.  
 
 Nonetheless, all of the samples containing template extracted from spiked 
blood samples containing ~100 and ~10 genomes gave consistent currents in 
the assay.  The assays which used template from blood spiked with ~1 
genome produced current in only one out of the three replicates, indicating 
that the method was not capable of reliable detection of this level of fungal 
DNA.  When the amount of fungal DNA in a 1ml blood sample is as low as ~1 
genome the effects described above would have a much greater effect on the 
amount of DNA available for PCR.  The practice of eluting DNA in 100µl and 
then splitting this into three fractions to use as template for PCR was 
particularly unsatisfactory in this respect.   
 
6.3.2 Adapting extraction protocol to improve detection of ~1 genome. 
 The most obvious stage in the extraction procedure at which a large 
amount of DNA was lost was when the 100µl eluate was split into three 
fractions to produce triplicate samples of template for PCR.  An obvious way 
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to improve the extraction procedure was therefore to use a smaller volume for 
elution of DNA and use all of this extracted material as template for PCR.  
This solution was not without potential problems, however, as decreasing the 
volume of eluent is known to result in a reduced yield of DNA.  Nevertheless, 
this adaptation to the extraction procedure was attempted and DNA from 
three separate 1ml blood samples spiked with ~1 genome of C. albicans DNA 
was eluted in 30µl buffer to provide material for three replicate assays.   
Figure 6.5(A) shows the PCR products where it can be seen that only one of 
the reactions using DNA extracted from the spiked blood samples gave a 
visible PCR product.  This sample contained two products one of which was of 
the expected size for C. albicans (~200bp) while the other was likely to be a 
fungal contaminant (~320bp).  The samples were analysed electrochemically 
and the mean currents can be seen in fig 6.5(B).  The PCR positive containing 
~1 genome added directly to the PCR reaction gave a mean signal of 85.3 ± 
13.6nA compared to a mean of 15.0 ± 17.2nA produced by the samples 
extracted from blood.  The large standard deviation was caused by the widely 
varying production of current in the three samples: 0nA, 33.8nA and 11.1nA.  
The adapted extraction protocol had apparently improved detection since 2 
out of 3 samples gave a signal compared with 1 out of 3 using the original 
protocol, but it was evidently still not capable of yielding sufficient target 
material to allow reliable detection of ~1 C. albicans genome in 1ml blood and 
further optimisation was required. 
 
 
 
Figure 6.5.  (A) PCR products obtained using 30µl of eluted DNA from blood samples spiked with ~1 
genome C. albicans DNA. (B) Mean currents obtained in assays using the PCR products.  Error bars 
represent SD (n=3). 
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Upon consulting with Sigma-Aldrich about the GenElute kit it was suggested 
that heating the elution buffer to 60°C before applying it to the extraction 
column and applying the eluate to the spin column a second time may 
increase the yield of DNA.  The amount of elution buffer used was also 
increased to 34.25µl which was the maximum amount that could be added to 
the PCR mix.  Total DNA was extracted from 1ml blood samples spiked with 
~1 genome of C. albicans DNA by a protocol incorporating the above changes 
and was used as template in PCR. 
 
The PCR products were considerably better using this extracted material as 
template.  Figure 6.6 demonstrates that all of the samples containing material 
extracted from spiked blood samples gave a visible amplicon of the expected 
size for C. albicans.  Furthermore there was a clearly visible smear of high 
molecular weight DNA, likely to be total genomic DNA; such a smear had also 
been observed in figure 6.3 but was much weaker.  This was further evidence 
that the DNA extraction technique had been much improved by the changes 
to DNA elution.    There was evidence for a second, smaller amplicon in the 
second and third samples, as well as the second PCR positive sample 
suggesting that these samples may have been contaminated.  The DNA-free 
samples were all clear, however, indicating that contamination was not a 
systemic problem in the experiment. 
 
 The samples were analysed electrochemically and the mean currents 
obtained are displayed in figure 6.7.  The PCR positive gave a mean current 
of 58.0 ± 18.2nA compared to 26.3 ± 14.3nA obtained with DNA extracted 
from spiked blood samples.  It was worth noting that the lowest signal 
produced was 13.6nA and this was obtained with the extracted sample that 
contained the strongest contaminant amplicon.  It was possible that 
competition for PCR components had led to a reduction in the signal.  
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Figure 6.6.  PCR products obtained using 34.25µl of eluted total DNA from blood samples spiked with 
~1 genome C. albicans DNA.  Eluate was passed through the column twice to enhance yield. 
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Figure 6.7.  Mean currents obtained in assays using the PCR products generated by the enhanced 
extraction procedure.  Error bars represent SD (n=3). 
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 Nonetheless, the difference observed between the means of the PCR 
positive and the extracted samples demonstrated that the improved DNA 
extraction procedure was still far from perfect.  On the other hand, the 
procedure had resulted in all three extracted samples producing a current, 
indicating that the improved procedure had considerably increased the 
reliability of detection of ~1 genome of C. albicans DNA in 1ml of blood. 
 
6.4.  Limit of detection of whole cells of C. albicans in blood. 
 Following the optimisation of DNA extraction for detection of a single 
genome of C. albicans DNA spiked into 1ml blood samples the next obstacle 
was to try and extract and detect DNA from a single C. albicans cell in 1ml 
blood samples.  Extracting DNA from intact cells requires further treatment of 
samples as the yeast cells need to be lysed to release DNA.  The existing 
extraction protocol includes a chemical lysis step using detergent and 
guanidine thiocyanate to disrupt lipids and membrane proteins of human cells 
but it was not known if this would be sufficient to lyse the complex cell walls of 
yeast.  Options for lysis of yeast cells include physical, chemical and 
enzymatic methods.  A chemical lysis using NaOH was initially attempted but 
was unsuitable as it caused coagulation of blood and loss of total DNA (data 
not shown).  Of the remaining options the enzymatic approach was favoured. 
 
6.4.1.  Enzymatic lysis of funal cells prior to extraction 
 An enzymatic lysis step using 5U of lyticase was incorporated into the 
DNA extraction procedure.  DNA was extracted from 1ml blood samples 
spiked with either 10 C. albicans cells (n=1) or 1 C. albicans cell (n=3).  The 
10-cell sample was eluted in 105µl elution buffer which was split into three 
fractions of 34.25µl to be used as template for PCR while all three of the 
single cell samples were eluted into 34.25µl and used as template for PCR.  
The amplification of the extracted products was not successful (fig 6.8) with 
only one amplicon of the appropriate size being produced by the samples  
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Figure 6.8.  PCR products obtained using material extracted from 10 cell and 1 cell-spiked blood 
samples. 
 
containing template from the 1 cell-spiked samples and none at all from the  
10 cell extracts.  The latter samples also showed contamination by an ~280bp 
amplicon which was evidently present in the initial eluate and, following 
splitting of the 105µl eluate into three fractions, it was present in all three PCR 
amplifications.  A similar sized contaminant was also observed in one of the 
samples amplified from DNA extracted from a 1 cell-spiked sample which 
showed that the contaminant, while not systemic, was occurring with relatively 
high frequency.   
 
The contaminant product was sequenced to establish its identity and, 
although the electropherogram was messy, the sequence had a high similarity 
to Saccharomyces cerevisiae.  The presence of DNA from this yeast in the 
PCR amplifications was difficult to account for as it was not routinely used in 
the Atlas Genetics lab where the DNA extraction and PCR was performed.  
The most likely source of contamination was from the laboratory at the 
University of Bath where the stock primer solutions and the initial preparation 
of yeast cell suspensions was made, although an environmental source at the 
Atlas Genetics laboratory could not be ruled out. 
 
The only C. albicans-sized amplicon produced by template from the 1 cell-
spiked material appeared to be stronger than expected - it was of a greater 
intensity than amplicons produced by conventionally extracted DNA 
equivalent to 1 genome.  A weakly amplified C. albicans-sized product was 
also observed in one of the DNA-free samples.   
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Upon electrochemical analysis of the products, currents were produced by all 
samples with a C. albicans-sized product: 18.9nA for the contaminated DNA-
free sample, 52.5nA for the 1 cell-spiked sample and values of 66.1nA, 
39.0nA and 55.3nA for the PCR positive samples.  The similarity of the value 
produced by the 1 cell-spiked sample to the control samples was further 
indication that it was likely to be an anomalous result as all previous work with 
DNA extracted from 1 genome-spiked samples had resulted in signals lower 
than the PCR positive control. 
 
The initial attempt to extract DNA from small numbers of yeast cells spiked in 
blood had not been successful.  It seemed logical, following the failure of the 
above experiment, to focus on achieving lysis of 10 C. albicans cells initially, 
before trying to lyse and extract DNA from single cells spiked into blood.  
Furthermore, it was apparent that improved results could be obtained by 
altering the extraction procedure so that elution of DNA in a preheated volume 
of 34.25µl elution buffer was performed as standard, regardless of how much 
C. albicans DNA had been spiked into the sample.   
  
6.4.2  Detecting DNA extracted from a suspension of 10 C. albicans cells 
 Following from these proposed improvements, a repeat of the above 
yeast-cell lysis and DNA extraction procedure was attempted in the absence 
of blood using a 10µl suspension of 10 C. albicans cells only.  Three separate 
extractions were performed and DNA eluted in the smaller volume 
recommended above to obtain template DNA for three PCR amplifications. 
 
 
Figure 6.9.  PCR products obtained using extracted DNA from three separate 10 cell-spiked blood 
samples.  Note the very weak amplicon present in the first of the DNA-free samples. 
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The extracted samples gave improved PCR products (fig 6.9), with two out of 
three samples using DNA extracted from 10 cells producing amplicon.  
Unfortunately these products also contained contaminant amplicons of 
~280bp similar to those observed before.  It was noteworthy that the 
contaminant should only appear in the samples which also produced target 
amplicon as it suggested that total DNA may have been somehow lost from 
the first extracted sample.   
 
The products were analysed electrochemically and showed that the first DNA-
free sample had been contaminated by DNA from C. albicans (21.9nA signal) 
and that the two extracted samples that had produced amplicon did indeed 
contain C. albicans DNA, giving signals of 17.8nA and 21.8nA.  These results 
compared with a mean current produced by the PCR positive control of 50.7 ± 
11.4nA, obtained using 1 genome as template indicating that a relatively large 
loss of signal may have been occurring in the extraction procedure of 10 cell-
spiked samples.  The presence of contaminant DNA may also have been a 
factor, however, as this would have competed for PCR reagents and inhibited 
amplification of the target DNA.  However the results did demonstrate that 
detection was possible, if not reliable. 
 
An important point to note is that the electrochemical signal produced by PCR 
products from extracted genomic DNA are not directly comparable to signals 
produced by DNA extracted from cells.  A better control would have been 10 
C. albicans cells added directly to the PCR.  Numerous attempts were made 
to amplify DNA from 10 cells added directly to the PCR but no amplification 
was ever observed (data not shown).  An alternative control would have been 
DNA that had been extracted from a suspension 10 C. albicans cells in the 
absence of blood but this was not considered until after the experiments. 
 
The above procedure was applied to spiked blood samples to ascertain its 
reliability.  Six 1ml blood samples were spiked with a 10 cell C. albicans 
suspension and cells were lysed and DNA extracted as above and used as 
template for PCR.  Fig 6.10 shows the PCR products obtained with the 
extracted DNA where it can be seen that two out of the six samples produced 
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a faint amplicon corresponding to the size of the C. albicans product while the 
larger contaminant amplicon observed before was present in five out of six 
samples.  Nonetheless the products were analysed electrochemically and five 
out of six PCR products gave signals which ranged from 3.2nA to 30.3nA (the 
sample without any product gave a zero current).  These values were again 
considerably lower than the signals produced by the PCR control (mean of 
62.4 ± 7.2nA). 
 
The continued presence of the contaminant in the samples extracted from 
blood was a confounding factor in the results obtained with whole cell 
extraction products.  It was noted that the contaminant only arose after the 
inclusion of the lysis step using lyticase buffer.  The buffer had been prepared 
long before the sensitivity work was attempted and had been prepared in non-
aseptic conditions for use in DNA extractions from large amounts of yeast and 
it was possible that the contaminant had entered the lysis buffer when it was 
first prepared but was never observed in PCR products with extracted DNA 
due to competition from the very large amounts of target yeast DNA that 
would have been present.  A new batch of lyticase was used to make a fresh 
lysis buffer in aseptic conditions for the next attempt at extraction from 10 cell-
spiked blood samples. 
 
 
Fig 6.10.  PCR products obtained using extracted DNA from 10 cell-spiked 1ml blood samples eluted in 
a smaller elution volume. 
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6.4.3 Using improved lyticase step for extraction from 10 C. albicans 
cells    
 Previously the use of 5U of lyticase in the lysis/extraction procedure 
was problematic due to the relatively large volume of lysis buffer used.  This 
increased the total volume of lysate and therefore more centrifugation steps 
were required during the procedure.  By using a new lyticase buffer it allowed 
for the preparation of a more concentrated lyticase buffer which would reduce 
the volume required and so reduce the amount of sample handling steps.  Six 
1ml blood samples were spiked with 10 C. albicans cells and, using this new 
lysis buffer which contained 50U lyticase, DNA was extracted and used as 
template for PCR. 
 
 Figure 6.11 shows the PCR products and it can be seen that, while the 
contamination appeared to be less severe, it had not been removed entirely 
by the change of lyticase buffer (N.B. The first three PCR samples containing 
extracted material were erroneously set up with 34µl of extra H2O but this 
didn’t appear to affect the reaction greatly).  On the other hand, there 
appeared to be a larger amount of product corresponding to the expected size 
of C. albicans in the reactions amplified from spiked blood samples compared 
to the previous attempts.  The samples were analysed electrochemically and 
the mean currents can be seen in figure 6.12.  The mean current obtained 
with the products amplified from DNA extracted from spiked blood was 16.3 ± 
12.6nA and the individual currents produced ranged from 2.48nA (no visible 
PCR product on gel) to 36.7nA (strongest PCR product).  Again, these values 
were still considerably smaller than the 1 genome-containing PCR positive 
(68.5 ± 3.6nA).  However, all six replicates had produced a signal indicating 
reliable detection of 10 cells in a 1ml spiked blood sample. 
 
 
Figure 6.11.  PCR products obtained using extracted DNA from 10 cell-spiked 1ml blood samples 
extracted using a fresh and more concentrated lyticase lysis buffer. 
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Figure 6.12.  Mean currents obtained in assays using the PCR products shown if fig 5.11.  Error bars 
represent SD (n=6 for DNA-free and spiked-whole blood samples, n=3 for PCR positive). 
 
6.4.4. Detection of single C. albicans cells spiked into 1ml blood 
samples. 
 Reliable detection of 10 cells spiked into a 1ml blood sample was 
achieved previously and the conditions used to obtain that result were used to 
extract DNA from 1ml blood samples spiked with a C. albicans cell 
suspension containing 1 cell.  In reality the blood was spiked with 10µl of a 
cell suspension that had been diluted to a concentration of 0.1 cells µl-1 and 
the actual number of cells added to the sample was liable to vary according to 
the Poisson distribution.  Accordingly twelve 1ml blood samples were spiked 
with the cell suspension in order to ensure that a reasonable number of 
samples would actually receive one or more cells.  DNA was extracted from 
blood and was used in PCR amplifications (fig 6.13). 
 
 Contamination of the DNA-free samples by two different targets was 
observed, including one that corresponded to the expected size of the C. 
albicans product.  The amplicons produced by the extracted DNA showed 
contamination from several sources and only three out of the twelve reactions 
were contamination-free while only a single sample produced an amplicon of 
the expected size for C. albicans. 
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 The samples were analysed electrochemically in spite of the 
contamination.  None of the products from extracted DNA gave a signal 
indicating that the extraction procedure was not sensitive enough to achieve 
detection of 1 cell ml-1 blood.  The absence of cells in the blood samples was 
unlikely to be the cause for the lack of PCR product and consequent lack of 
current since the cell density of the suspensions was confirmed by plate 
counts which suggested that at least one sample would contain fungal cells.  
Other possible explanations include the loss of DNA during the extraction 
procedure due to its inefficient nature and the relatively large sample volume 
that must be handled – the columns are designed for centrifugation of only 
700µl liquid at a time and a total of 2.25ml of sample had to be processed.  
Contamination was also still an important issue with the extraction procedure 
and persisted in spite of changes to some of the reagents but there was no 
way of knowing the source of the contaminants for sure, or the extent of their 
effect on the assay.  Unfortunately, further experiments to extract and amplify 
DNA from 1 C. albicans cell were not able to be performed due to time 
constraints.   
 
 
  
Figure 6.13.  PCR products obtained using extracted DNA from 12x 1 cell-spiked 1ml blood samples. 
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6.5  Discussion and Conclusions 
 There was a difference in the values of current obtained when 
extracted C. albicans genomic DNA was spiked into blood, extracted and 
used as template compared to the currents produced by assays using 
equivalent amounts of C. albicans cells spiked into blood with the samples 
amplified from genomic DNA giving higher signals; most strikingly in the case 
of detecting 1 genome of extracted DNA in blood compared to detecting DNA 
from 1 cell in blood where the latter failed to give any signal whatsoever.  
There are a number of possible reasons as to why this would be the case.  
The most basic explanation might be that the concentration of genomic C. 
albicans DNA was underestimated leading to a larger amount of template 
being present in the reactions than thought.  This could have happened when 
the initial concentration was measured by spectrometry or may have occurred 
due to user error when calculating and performing DNA dilutions to obtain a 
concentration of 37fg ul-1.  If time had allowed, replicated experiments with 
newly made DNA samples, or DNA samples from other Candida species, may 
have been able to lend support to this theory.   
 
It was also observed that the currents produced by assays using product 
amplified from 1 genome of DNA spiked into blood gave lower signals than 1 
genome added directly to a PCR reaction.  This could have been due to DNA 
loss occurring during the extraction procedure, since such methods are never 
100% efficient at recovering nucleic acid, or by the potential for PCR primers 
to be sequestered due to interactions with non-target DNA which would have 
been provided by the vast excess of human genomic DNA that would have 
been present in the extracted DNA sample.   
 
The prototype nature of the extraction procedure was far from ideal, with 
many centrifugation steps being required to process each sample which may 
have been detrimental to the procedure due to increased risk of contamination 
and loss of nucleic acid, further reducing the efficiency of this column-based 
extraction method.  This latter point was of particular importance when 
attempting to detect DNA from a single C. albicans cell in a 1ml blood sample.   
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It was possible that the extraction procedure could have been further 
optimised for recovery of small amounts of fungal DNA.  However, any 
modifications to the protocol would have to be technically simple to maintain 
the ease of use of the system.  An obvious potential modification to the 
procedure to allow detection of a single cell would have been to centrifuge the 
whole blood to pellet the cell fraction; the plasma could then be removed and 
the procedure carried out as normal resulting in smaller volumes being 
handled and fewer centrifugation steps, so reducing the potential for DNA 
loss.  This change combined with the use of smaller volumes of lysis buffer 
may have allowed the procedure to operate with only a single centrifugation 
step, enabling detection of a single C. albicans cell and improved detection of 
larger numbers of cells, as well as vastly increasing the turnaround time of 
experiments. 
 
Although discussion of how the final assay might work based on Atlas 
Genetics’ portable Velox system is ultimately beyond the scope of this work, it 
is pertinent to note that minimal sample handling is required prior to testing, 
and use of a relatively small sample size is a prerequisite for the system.  
Quite how the detection of, for example, 25 cells in a 5ml blood sample would 
be achieved using a 200µl fraction for analysis with little or no sample 
preparation is hard to imagine.  
 
While spiked blood samples from a healthy patient are useful for preliminary 
testing of a detection assay’s capability the use of clinical samples would 
provide much more definitive results.  Samples taken from patients with an 
episode of candidemic infection may differ from healthy blood samples, 
particularly in terms of the leucocyte cell population and can also provide a 
better measure of the sensitivity of an assay – indicating the likelihood of 
detection of fungal DNA from a sample taken under clinical conditions.  
Unfortunately the acquisition of such samples is no easy task and usually 
requires a prospective request for appropriate samples to be taken from 
candidaemic patients and this was not possible due to time constraints. 
 
 127 
Nonetheless, the assay was shown to be sensitive enough to detect 1 
genome of extracted C. albicans DNA per millilitre of blood but was less 
sensitive when intact cells were used, achieving a limit of detection of only 10 
cells per millilitre of blood.  This detection limit is within the clinical range for 
candidaemia of 5 to ≥100 c.f.u ml-1 (Loeffler et al., 2000) but a lower limit 
outside of the range would be preferable to avoid the possibility of false 
negative results.  It was also found that the type of blood sample made little 
difference to the results - there was no significant difference between the 
currents obtained when spiked whole blood samples were assayed compared 
to spiked plasma samples when relatively large amounts of C. albicans 
genomic DNA were used.   
 
Unfortunately time did not permit the testing of the limit of detection of the 
assay with the other Candida species and their probes.  Given the previous 
work performed on the probe suite it can be tentatively assumed that a similar 
limit of detection of 10 cells per ml of blood would be achievable by all of the 
other probes given minor optimisation, with the possible exception of the C. 
krusei specific probe CK PR, but experimental confirmation of this is, of 
course, an absolute necessity. 
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Chapter 7.  Further Observations on the Assay Model 
7.1 Introduction 
The general model of the assay was outlined in chapter 3 but the full workings 
have not been established.  While developing the fungal probe suite the 
opportunity occasionally arose to study different aspects of how the 
electrochemical assay produced signals in the presence of target DNA.  Some 
of this work was presented in chapter 3 by way of an introduction to the assay 
and to furnish the reader with the necessary background information to 
understand it and the results that it produced. 
 
This chapter presents further observations that were made concerning the 
assay which increase the understanding of the assay mechanisms and which 
may be of potential importance should additional optimisation be required to 
improve the results generated.   
 
7.2.  Effect of the reaction medium on assay signal. 
It had previously been established that diffusion was an important factor in 
production of the assay signal.  Therefore factors which affect diffusion should 
also have an effect on the current produced by the assay.  One factor which 
was examined was the composition of the reaction medium through which an 
electroactive molecule must move.  In the assay this medium is the post-PCR 
reaction mix, composed of various buffer components, salts, nucleotides, 
primer-dimer oligonucleotides and left-over Taq DNA polymerase 
supplemented by T7-exonuclease and its storage buffer components.  
According to the diffusion theory model, a more dilute reaction medium would 
allow larger molecules to move more rapidly through it.  This would result in 
the background current increasing to the same level as that produced by 
target containing samples and this could be tested with the assay.   
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Figure 7.1.  Mean currents obtained in assays with CT PR using PCR products diluted with H2O.  Error 
bars represent SD (n=4). 
 
PCR products were diluted 2, 5 and 10-fold with H2O before incubation with 
probe and T7 exonuclease.  The undiluted samples produced results as 
expected (fig 7.1) with a mean background current of 37.4 ± 8.2nA compared 
to a positive signal 96.8 ± 11.9nA.  When the PCR products were diluted 2-
fold the signal obtained with the positive sample decreased slightly to 81.8 ± 
11.9nA while the background signal increased by almost double to a value of 
71.3 ± 12.9nA.  At a five-fold dilution the positive signal and background signal 
were of a similar level with mean currents of 72.9 ± 4.5nA and 76.9 ± 19.0nA 
respectively and at a 10-fold dilution both samples exhibited a decrease in 
current which was less marked in the background sample which gave a signal 
of 53.0 ± 5.7nA compared to a positive signal of 39.9 ± 9.2nA. 
 
The results demonstrated that diluting the reaction medium with H2O had two 
noticeable effects on current production.  Firstly, there was an approximately 
linear decrease in the signal produced by the target-containing positive 
samples which fell from 96.8 ± 11.9nA to 39.9 ± 9.2nA; secondly, the 
background current exhibited an increase to similar levels as the positive 
samples at each dilution with the background current rising from its initial level 
at two- and five-fold dilutions before decreasing in a similar way to the positive 
sample current at 10-fold dilution.   
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These results provided some support for the theory that dilution of the 
reaction matrix allows increased diffusion of larger molecules to the electrode 
but also indicated that dilution was causing an overall decrease in signal at 
higher dilutions.  This was possibly due to the dilution of ionic species in the 
reaction mix which are involved in transfer of electrons and this would have 
inhibited electron transfer at the electrode leading to smaller currents.  In 
order to try and negate this effect another dilution experiment was set up with 
dilution of PCR product carried out using 1X PCR buffer in order to maintain 
the concentration of ions in the reaction medium.  The dilutions were also 
made over a larger range, from a 10-fold dilution to a 104 dilution. 
 
The results (fig 7.2) showed the predicted increase of the background signal 
when the samples were diluted but did not exhibit the decrease in positive and 
background currents that had been observed at higher dilutions when H2O 
was used as the diluent.  The mean current produced by target samples 
remained significantly higher than the background up to a 100-fold dilution.  At 
1000-fold and 10000-fold dilutions the mean currents produced by the 
background and positive samples differed by only 2 - 4nA. 
 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
180.0
B
a
c
k
g
ro
u
n
d
C
. 
tr
o
p
ic
a
lis
B
a
c
k
g
ro
u
n
d
C
. 
tr
o
p
ic
a
lis
B
a
c
k
g
ro
u
n
d
C
. 
tr
o
p
ic
a
lis
B
a
c
k
g
ro
u
n
d
C
. 
tr
o
p
ic
a
lis
B
a
c
k
g
ro
u
n
d
C
. 
tr
o
p
ic
a
lis
Undiluted 10-fold diluted 100-fold diluted 1000-fold diluted 10000-fold diluted
C
u
rr
e
n
t 
(n
A
)
Fig 7.2.  Mean currents produced by assays using PCR product diluted with 1X PCR buffer.  Error bars 
represent SD (n=4). 
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The effect of adding different amounts of Tween 20 to the reaction mix was 
tested to see if the reverse effect to that described above could be observed, 
whereby increasing the complexity of the reaction matrix could lead to a 
decrease in signal by reducing the ability of molecules to diffuse through it.  
The experiment was conducted using the now redundant CL PR probe which 
was designed to detect DNA from C. lusitaniae and the results are shown in 
figure 7.3 where it can be seen that there was a general decreasing trend of 
the mean current of both signal and background as the amount of Tween 20 
present in the reaction increased.  The target-containing samples produced a 
mean current of 60.0 ± 8.4nA in the presence of 0.01% Tween which 
decreased almost twofold to a value of 32.1 ± 2.6nA when the concentration 
of Tween was 0.5%.  The background signal decreased almost ten-fold, from 
a value of 11.6 ± 2.9nA at 0.01% Tween to 1.8 ± 0.2nA at 0.5% Tween, 
demonstrating that Tween was having an inhibitory effect on the production of 
signal in the assay.  Despite the reduction in assay signal attributable to the 
presence of Tween there was evidence that use of such a surfactant could be 
used to improve the signal:background ratio. 
 
 
 
 
Figure 7.3.  Mean currents produced in assays with probe CL PR in the presence of increasing amounts 
of Tween 20.  Ratios of signal:background are also shown.  Error bars represent SD (n=4).  
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While the results by no means conclusively proved that diffusion was the key 
assay process being affected, they did provide strong support for the theory 
that diffusion of electro-active molecules to the electrode surface was a major 
factor in production of current in the assay and allowed differentiation between 
the background signal produced by undigested probe and the positive signal 
produced by probe digested in the presence of target DNA and T7 
exonuclease.  They provided a degree of support for the hypothesis that the 
zero-background results obtained when using the Jumpstart Taq were due to 
the presence of surfactants in the enzyme storage buffer.  The results of the 
dilution experiments demonstrated that diluting out of ionic species with H2O 
can lead to a loss of current which, while not necessarily an important result in 
itself, does highlight the fact that there are numerous complex processes 
occurring in the reaction which interplay together to produce the assay signal 
and trying to investigate a single one in isolation is not always easy. 
 
7.3 Probe stability 
 The probes were all stored at -20°C and used frequently, some for over 
2 years, and only the CK PR probe displayed a considerable reduction in the 
value of current that it produced.  It was not possible to draw direct 
comparisons between the results obtained in the initial stages of the project 
and the final stages as the assay had changed in between, but figure 7.4 
demonstrates that the oldest probes were still capable of providing a 
satisfactory signal (which was actually much improved in some cases, thanks 
to an improved method and better designed primers) over 2 years after they 
were first acquired.  The results are not directly comparable as they were 
performed on PCR products using different amounts of DNA – nanogram vs. 
picogram amounts – and different PCR conditions.  Despite an approximately 
1000-fold reduction in the amount of template the observed decrease in signal 
between nanogram amounts of C. tropicalis DNA amplified using Illustrataq 
polymerase with ITS3/ITS4 conditions compared to picogram amounts of DNA 
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Figure 7.4.  Mean currents produced by assays using CT PR and CG PR probes on different dates to 
demonstrate the effect of long-term storage on probe stability.  Error bars represent SD (n=4 for the 
earlier assays and n=3 for the later assays). 
 
amplified using Jumpstart polymerase and ITS3.3/ITS4.2 was only 50%, from 
172.3 ± 6.2nA to 86.3 ± 11.1nA.  The signal obtained with picogram amounts 
of C. glabrata DNA amplified using Jumpstart polymerase and ITS3.3/ITS4.2 
actually showed an increased signal compared with the signal obtained using 
nanogram amounts of C. glabrata DNA amplified using Illustrataq and 
ITS3/ITS4 – from 96.1 ± 14.1nA to 130.7 ± 6.5nA. 
 
It was difficult to explain why the signal obtained with the CT PR probe should 
decrease across the two assays while the signal obtained with the CG PR3 
probe actually increased.  Part of the problem was that the properties of 
probes seemed to depend on a number of factors which meant that each 
probe had its own unique characteristics in terms of the signal produced with 
different reagents and DNA amounts.  This may have been for a range of 
reasons including batch differences when the ferrocene label was attached by 
ATDBio and differences in the probe sequence which may have affected the 
assay.  The latter point, in my opinion, is a very important issue as 
phenomena such as secondary structure formation or the stoichiometry of 
different combinations of base pairs may affect the production of signal and  
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Figure 7.5.  Mean currents produced in assays using probe added directly to PCR and digested using 
Taq polymerase vs. assays using products amplified in the same way but digested post PCR. 
 
therefore further inform design of reliable probes.  While these theories were 
testable, due to the high cost of reagents the required experiments could not 
be performed in the course of this work. 
 
The heat stability of the probe was also the subject of experimentation.  An 
obvious question was the possibility of performing the probe binding and 
digestion steps within the PCR reaction in exactly the same way as a Taqman 
assay.  Figure 7.5 shows the currents that were generated from an assay in 
which the probe CG PR was added to the PCR mix and samples amplified in 
a Roche lightcycler using cycling parameters developed for Taqman assays.  
A control consisting of the same PCR mix without probe CG PR was used to 
amplify samples simultaneously, and the probe and T7 exonuclease were 
added post-PCR to produce electroactive products for analysis.  The 
background current produced by samples containing probe that had been 
exposed to PCR conditions gave an unusually high signal of 62.6 ± 2.9nA 
compared to a background signal of 19.5 ± 6.1nA produced by the control 
samples (P<10-5).  It was also highly significantly greater than the 41.9 ± 
7.0nA signal produced by the target-containing control sample (P<0.005).  
The mean current produced by the target-containing 
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probe added to the PCR reaction was also relatively high at 65.1 ± 3.7nA and 
was significantly higher than the signal produced by the target-containing 
control (P<0.005) but was not significantly different to the background signal 
produced when probe was present in the PCR.   
The similarly high values of current produced by both the target and non-
target samples with CG PR added to the PCR suggested that a similar 
amount of oxidation was occurring in these samples and it was greater than 
when the probe was digested post-PCR by T7 exonuclease at 37°C.  A 
possible explanation for this was that the bond between the ferrocene label 
and the probe was not heat stable and the high temperatures experienced 
during PCR cycling were allowing release of the label from all of the probe 
molecules regardless of the presence of target DNA. 
 
This theory was tested by adding probe CG PR to 1X PCR buffer and 
subjecting the samples to the PCR conditions used above while other 
samples were kept at room temperature for the duration of the program.  
Electrochemistry readings were then taken from each sample type and the 
mean currents are shown in figure 7.6.  The samples incubated using the 
PCR parameters gave a signal of 171.2 ± 12.0nA which was very highly 
significantly greater than the signal obtained with the probe incubated at room 
temperature: 128.8 ± 8.0nA (P<0.001).  This demonstrated that simply heating 
the probe led to an increase in current meaning the assay could never be 
adapted to be used in the same way as Taqman or other related assays.  It 
would have been interesting to perform the experiment again, but with the 
caveat of preparing two sets of PCR mixes, one with and one without probe.  
Both sets would then be heated using the assay’s PCR parameters and probe 
added to the probe-less mix afterwards and electrochemical measurements 
taken.  Such an experiment would have given results that were more likely to 
reflect other factors present in the assay such as the reaction matrix and 
presence of other oligonucleotide molecules. 
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Figure 7.6.  Mean currents produced by PCR-cycled probe vs. probe incubated at room temperature. 
  
 
7.4 Using whole yeast cells as template for the assay 
 Experiments into the effects of having lysed yeast cell debris present in 
the assay were performed alongside comparative experiments using 
quantified numbers of whole cells added directly to PCR and extracted DNA 
from the same numbers of yeast cells as template.  Figure 7.7 shows the 
mean currents produced in assays using PCR products which were amplified 
from the following sources: excess extracted C. krusei DNA which was then 
spiked with cell lysate following PCR, known numbers of whole C. krusei cells 
or DNA extracted from known numbers of C. krusei cells.  The presence of 
cell lysate from 500 cells did not have a statistically significant effect on the 
mean current produced in the assay compared with the mean current 
produced by the samples with C. krusei DNA alone but this was very likely 
due to an outlying result produced by the latter samples which resulted in a 
relatively high standard deviation.  The mean current produced by DNA + 500 
cells lysate was significantly lower than the mean current produced by DNA + 
100 cells lysate (P<0.05) and DNA + 50 cells lysate (P<0.01).  There was no  
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Figure 7.7.  Mean currents produced in assays testing the effect of yeast cell lysate on current 
production using the probe CK PR.  Error bars represent SD (n=3). 
 
significant difference between the mean currents produced when lysate from 
100 or 50 cells was present in assays with excess DNA.  These results 
suggested that the presence of large amounts of lysate (≥500 cells) was 
having a detrimental effect on the current production in the assay. 
 
When whole cells were used in the assay compared to DNA extracted from 
the same number of cells there was a very highly significant difference 
between the mean currents produced by 500 cells vs. 500 genomes 
(P<0.0005) and 50 cells vs. 50 genomes (P<0.001) however there was no 
significant difference between the signals produced by 100 cells vs. 100 
genomes and this was again probably due to the presence of an outlying 
current which produced a relatively high standard deviation for the samples 
with 100 cells.   
 
These data indicate that, generally speaking, whole cells produce lower 
signals in the assay compared to a comparable amount of extracted DNA.  
There are a number of possible reasons why this would be the case such as 
incomplete lysis of cells during PCR leading to reduced amounts of template 
DNA or inhibition of Taq DNA polymerase or T7 exonuclease by the fungal 
cell debris could also account for the difference in signal.  These findings may 
explain why it was not possible to obtain a PCR product from 10 C. albicans 
cells added directly to PCR (see chapter 6). 
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7.5 Conclusions 
 There are many factors which contribute to the current produced in a 
given assay.  Some of these, particularly the factors pertaining to the PCR 
stage of the assay, are relatively well understood and the reasons for their 
effect on the assay can usually be explained thanks to the body of knowledge 
that underpins such a well-used and well-studied methodology.  However, the 
electrochemical portion of the assay is much less well understood as it is a 
novel methodology with only a handful of people involved in its study.  The 
basic model of the assay, hybridisation of a labelled probe which is then 
digested to release a labelled mononucleotide, was introduced in chapter 3 
and is a fairly well known concept as it is frequently used with fluorescent 
detection procedures but it is the method of detection by electrochemical 
means that makes the system unique and less easily understood. 
 
The findings discussed here and in chapter 3 shed some light on some of 
these less well understood areas and offer refinements to the basic model of 
electrochemical detection by ferrocene-labelled probes.  Unfortunately since 
the experiments were never part of a focused project to elucidate how 
different features of the assay work, the results are far from conclusive but 
amount to a small, but significant, body of evidence in support of these 
refinements.  Of particular interest were the results of the experiments into the 
various factors relating to the probes as this type of labelled probe is unique to 
Atlas Genetics and has not been exhaustively studied.  The conclusion that 
diffusion is a highly important factor in the production of current demonstrates 
further how the assay differs from conventional fluorescence based assays 
where the presence of a released fluorescent molecule in a reaction mix is 
sufficient to contribute to the signal as opposed to the electrochemical assay 
in which the released label must also make its way to an electrode surface to 
contribute to the output. 
 
The major drawback to the above conclusions is that there is nothing 
fundamental that supports and validates them - they were all produced using 
the assay which they then make predictions about.  It would be informative to 
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perform further experiments into diffusion of electroactive molecules, for 
example, using an unrelated system to validate the conclusions made here. 
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Chapter 8 – Discussion & Conclusions 
8.1 Discussion. 
 Using the electrochemical detection method established by Atlas 
Genetics a suite of six probes, capable of detecting DNA from fungi and of 
identifying five of the most clinically relevant species, was developed.  Using 
an improved PCR protocol, all of the probes were demonstrated to be able to 
detect DNA from target species to a level of ~1 genome present in a 50µl 
reaction volume and give zero background signal.  The specificity of the 
probes was confirmed experimentally against a test panel of nine non-target 
Candida species and against these nine species plus a further 27 fungal 
species when examined in silico.  A strategy of rapidly screening probe 
sequences against a matrix of fungal ITS2 sequences using the BLAST 
algorithm was also developed and was used to screen newly designed probes 
for specificity, as well as support the panfungal nature of the PanF PR probe.   
The robustness of the species-specific probes was also confirmed in tests 
with wild strains of the relevant species.   
 
The pan-fungal probe was designed to be able to detect a wide range of fungi 
including emerging opportunistic fungi, such as Rhizomucor, Absidia, 
Fusarium and Penicillium species, as well as the more commonly occurring 
Cryptococcus, Aspergillus and Candida species. It successfully detected 14 
species of opportunistic fungal pathogens including several infrequently 
encountered species, and one non-pathogenic fungal species, Cr. victoriae. 
The probe was also shown to be highly likely to be able to detect DNA from a 
total of 26 fungal species examined in silico, including some of the emerging 
pathogenic fungi.   
 
Finally, the C. albicans specific probe was shown to be capable of detection of 
~1 genome of extracted DNA spiked into a 1ml blood sample or 10 c.f.u. of C. 
albicans spiked into the same volume of blood following the application of a 
relatively straightforward total DNA extraction procedure which was developed 
for the purpose. 
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The probe set was designed to detect DNA from any fungal pathogen, as well 
as to achieve species-specific detection of the most common species involved 
in invasive fungal infections including C. glabrata and C. krusei which are 
associated with decreased susceptibility to fluconazole.  Detection methods 
that permit species-specific detection of the most common fungal pathogens, 
including fluconazole resistant species, are generally unsatisfactory as they 
cannot detect infecting species outside the test panel and the majority of 
methods of detecting invasive fungal infections have concentrated on a few 
common fungi, usually Candida species (Shin et al., 1999; Maaroufi et al., 
2003; Basková et al., 2007; Innings et al., 2007; Metwally et al., 2007).  Only a 
few methods have attempted to achieve detection (but not identification) of a 
range of fungal species (e.g. Vollmer et al., 2008) and very few have tried to 
design a probe capable of detecting all pathogenic fungi (e.g. Zhao et al., 
2009).  The inclusion of a pan-fungal probe in this suite means that early 
detection of an invasive infection caused by any fungal pathogen could be 
achieved enabling a patient to be monitored and treated more successfully.  A 
potential drawback to the use of a highly sensitive panfungal probe is that it 
necessitates extremely careful handling of samples since detection of even 
very low amounts (10 cells) of contaminating fungi from the environment may 
be detected by the assay. 
 
The limit of detection of the assay in blood was within a diagnostic range but 
was not as good as that achieved by other molecular detection methods (e.g. 
White et al., 2003; Klingspor & Jalal, 2006; Basková et al., 2007).  The limit of 
detection may have been negatively affected by the relatively unsophisticated 
method of total DNA extraction from spiked blood -  there were many 
opportunities for sample loss due to multiple centrifugation steps and the 
inability to use 100% of the lysate since the dregs could not be removed from 
the original vial and added to the spin column.  A study by Metwally et al. 
(2008) demonstrated that the choice of DNA extraction procedure can make a 
significant difference to the sensitivity of a diagnostic assay and it is likely that 
had the extraction procedure been improved further it would have resulted in 
increased signals at low cell densities and an improved sensitivity with the 
electrochemical assay.  The same study also suggested that contamination of 
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PCR by human rRNA may act to sequester primers.  This was pertinent since 
the human 5.8S and 26S rRNA genes have target sites which are similar to 
the binding sites of the ITS3.3/4.2 primers used with the electrochemical 
assay.  These rRNA target sites could only produce short, ssDNA molecules 
but in doing so could have depleted the primers which would have had a 
detrimental effect on the assay sensitivity.  The presence of human DNA in 
PCR may also have had an effect of the efficacy of amplification of the fungal 
ITS2 target due to random sequestration of the primers to non-specific target 
sites, as well as the genes coding for rRNA. 
 
As the work on the limit of detection in blood was begun with only a few 
months until the end of the project the limit of detection could only be 
ascertained for the C. albicans specific probe.  Since this was the best 
performing probe in the initial limit of detection work it would not be 
appropriate to assume that the other probes would behave similarly and so it 
is not known if the other probes would have been able to achieve the same 
limit of detection of Candida DNA or cells in blood samples.  The C. krusei 
specific probe in its current form would almost certainly not be capable of 
detection of 10 cells ml-1 blood and so it is likely that a redesign of this probe 
and further optimisation of the DNA extraction procedure would be required to 
achieve a satisfactory LOD for the remaining probes. 
 
Detection of Candida from clinical samples is the truest validation of a 
diagnostic assay but unfortunately such samples could not be obtained in 
time.  Following confirmation of the LOD of all of the members of the probe 
suite, successful testing of the assay using clinical samples containing cells of 
the appropriate species must be performed to show that the method is 
suitable for such a purpose. 
 
A further problem that affected the limit of detection work in PCR reactions 
and from blood was that of contamination.  There were two likely sources of 
the contamination observed in the work: the first was the environment - fungi 
are ubiquitous organisms and the lab in which the work was conducted is 
situated in close proximity to woodland with much decaying material.  The lab 
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also featured an air conditioning system which would have allowed access to 
the lab environment for airborne cells and spores.  The other source was 
amplified target DNA released into the lab environment following post-PCR 
manipulation of reaction products.  The presence of contaminating material 
was made more problematic by the fact that fungal universal primers were 
used which meant that DNA from any species of fungi was likely to be 
amplified.  The problem was somewhat alleviated by setting up reactions in a 
class 2 biological safety cabinet which was routinely sterilised by UV 
irradiation, however the contamination issue could not be completely 
removed.  Methods for prevention of PCR amplicon contamination exist (e.g. 
Longo et al., 1990; Rueckert & Morgan, 2007) and implementation of 
contamination control is necessary for work involving repeated amplification of 
the same PCR target, particularly when detection of low number of target 
molecules is being attempted. 
 
The capability of multiplex detection would be an extremely useful feature of 
the probe suite and the probes have been designed with this in mind.  The 
use of a single pair of fungal universal primers means that the likelihood of 
primer dimerisation is reduced and there is no chance of non-target 
amplification due to ‘unassociated’ primers binding to non-specific target sites 
by chance.  Furthermore, fungal universal primers allow the amplification of 
any fungal DNA present and specific detection can then be made by the 
species-specific probes.  This feature allows the easy incorporation of further 
species-specific probes to the suite.  Multiplex detection would be achieved by 
the use of ferrocene labels with different oxidation potentials.  In a similar way 
to fluorescent labels which emit light at different wavelengths, ferrocene 
molecules can be designed which are oxidised at different voltages and this 
would allow differentiation between which probes are producing a signal.  
Work performed by J. A. Olds with Atlas Genetics demonstrated that multiplex 
detection utilising three probes labelled with different ferrocene molecules was 
possible (unpublished data).  However, to date the potential for multiplex has 
been limited by unavailability of robust ferrocene probes with different 
oxidation potentials.  Work is ongoing within the Dept of Chemistry at the 
University of Bath to synthesise these molecules reproducibly. 
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8.2 Conclusions.  
 The assay which was developed in this work has the potential to be 
developed to provide frontline rapid diagnosis of invasive fungal infections.  
No single technique is flawless in its ability to diagnose invasive fungal 
infections since traditional culture-based methods are slow and not always 
specific while rapid molecular methods require trained personnel, specialised 
equipment and do not necessarily prove invasive fungal infection since they 
detect nucleic acid.  Therefore, a synergistic approach to detection and 
identification of fungal pathogens would offer many advantages over reliance 
on a single ‘gold standard’ method.  The rapid molecular techniques offer an 
early warning system for suspected fungal infections and can also indicate 
potentially drug resistant species so that appropriate therapy can be initiated 
at once.  Further confirmation of the presence of a fungal pathogen can then 
be obtained by tests for fungal antigens and culture of fungi from patient 
samples.  This approach would ensure that patients receive optimum 
antifungal therapy and the costs of treatment are minimised as there is less 
chance of inappropriate therapy being administered.   
 
A major problem with this approach is that not all hospitals have access to the 
same equipment and expertise, particularly where rapid molecular tests are 
concerned.  The Atlas Genetics proposed at-or-near point-of-care device aims 
to resolve this issue by providing a generic platform for detection of pathogens 
from patient samples with minimal user input thus providing a method of rapid 
molecular detection of pathogens to all hospitals. 
 
The results obtained show that the described methodology and probes have 
the required specificity, and could obtain the necessary limit of detection, to 
detect fungal DNA from samples and identify to species level the most 
clinically relevant fungi.  This key work advances the position of the fungal 
detection suite so that it is closer to being adapted and miniaturised for use in 
Atlas Genetics’ proposed at-or-near point-of-care format, and would be an 
excellent early detection system for fungal pathogens requiring minimal user 
expertise and facilities. 
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